Identifying genetic susceptibilities underlying

familial haematological malignancies in a

Tasmanian family resource by Blackburn, NB
Identifying genetic susceptibilities underlying 
familial haematological malignancies in a 
Tasmanian family resource 
by 
Nicholas Bayden Blackburn, BSc (Hons) 
Submitted in fulfilment of the requirements for the Degree of 
Doctor of Philosophy 
University of Tasmania 
August 2015 
ii 
Declaration of Originality 
This thesis contains no material which has been accepted for a degree or diploma by 
the University or any other institution, except by way of background information and 
duly acknowledged in the thesis, and to the best of the my knowledge and belief no 
material previously published or written by another person except where due 
acknowledgement is made in the text of the thesis, nor does the thesis contain any 
material that infringes copyright. 
Nicholas Bayden Blackburn 
iii 
Authority of Access Statement 
This thesis may be made available for loan and limited copying and communication in 
accordance with the Copyright Act 1968.  
Nicholas Bayden Blackburn 
iv 
Statement of Ethical Conduct 
The research associated with this thesis abides by the international and Australian 
codes on human and animal experimentation, the guidelines by the Australian 
Government's Office of the Gene Technology Regulator and the rulings of the Safety, 
Ethics and Institutional Biosafety Committees of the University. 
Nicholas Bayden Blackburn 
v 
Statement of Co-Authorship 
Nicholas B. Blackburn has incorporated a version of the published open access paper 
Blackburn et al.1 into Chapter 5 of his dissertation. The article is included in 
Appendix 5.1.  
This work was co-authored with: Dr Jac C. Charlesworth, Mr James R. Marthick, Dr 
Elizabeth M. Tegg, Dr. Katherine A. Marsden, A/Prof Velandai Srikanth, Prof John 
Blangero, Prof Ray M. Lowenthal, Prof Simon J. Foote and A/Prof Joanne L. 
Dickinson, with the majority of the research, analyses, text and figures generated and 
prepared by Nicholas himself.  
Blackburn, N. B. et al. A retrospective examination of mean relative telomere length 
in the Tasmanian Familial Hematological Malignancies Study. Oncology Reports 33, 
25–32 (2015).  
The contribution of the authors to the publication is as follows: 
N.B.B. was the primary author, conducted data analysis, was involved in laboratory 
experiments and study design and wrote the manuscript; J.C.C. (co-first author) 
design and performance of statistical analyses, manuscript preparation; J.R.M. design 
and performance of telomere length assay, data analysis and DNA extractions; V.S. 
scientific input and permission for use of control samples; J.B. scientific advice and 
design of statistical methods; K.A.M., R.M.L. provided clinical expertise. E.M.T. 
provided clinical expertise and scientific input. S.J.F. assisted with overall scientific 
direction and provided input into study design. J.L.D. conceived and designed 
experiments and contributed to data analysis and manuscript preparation; and all 
authors contributed to the final manuscript preparation. 
Signed: _______________________ ___________________________ 
A/Prof Joanne Dickinson Prof Tom Marwick 
Supervisor  Director 
Menzies Institute for Medical Research Menzies Institute for Medical Research 
University of Tasmania University of Tasmania 
Date: _________________________  ___________________________$XJXVW
vi 
Acknowledgements 
When I, rather naïvely, began this project four years ago I could never have imagined 
the opportunities that would grow from it, both personally and professionally. I am 
indebted to my supervisors, A/Prof Joanne Dickinson and Dr Jac Charlesworth, who 
together, both in complement and independently, have been amazing role models for 
me. Under their mentorship my fascination for genetics, and the dark-arts of 
bioinformatics, was encouraged and given the room it needed to grow. Thank you for 
all that you have taught me and for supporting me unwaveringly through various life 
and PhD-life challenges that have arisen. Thank you also to Prof Simon Foote for 
your initial supervision and involvement in this project. 
I’m very grateful to my fellow Team-Y member (and Captain), Mr James Marthick, 
for your guidance, hands-on support and humour in relation to all lab related 
activities. I like to think we successfully proved in the early days that the combination 
of two Ys was best for southern blotting – others will of course beg to differ. Thank 
you especially for your work and dedication to establishing the telomere length assay 
which was pivotal to a body of work that saw me through many lab meetings, 
conferences and talks. 
Mrs Annette Banks, your knowledge of all things related to Tasmanian family 
genealogy is second to none. Thank you for your genealogical support, patience in 
handling my oft complex queries about specific families and for being a smiling and 
encouraging face that has greeted me on many mornings (even if I did bribe you with 
lollies at various points in time). 
A warm ‘thank you’ to the other members of the Cancer, Genetics and Gene 
Regulation Groups, both past and present, particularly Dr Kate Brettingham-Moore 
for your frequent coffee excursions, exchange of ideas, celebrations and woes. As 
well as A/Prof Kathryn Burdon for bringing fresh light to many aspects of my 
research and Dr Joy Rathjen for guidance when I needed it and tea-related 
sympathies. And a special note of gratitude to my fellow PhD students and 
colleagues, Naseem Ali, David Ward, Marie Buscot, Emma Cazaly and Ciarán 
O’Mara, for your friendship and support during both the fun and the difficult times. 
My friendships with each of you have been one of the major highlights of this PhD. 
Naseem and David, I look forward to wearing the appropriate attire with you when we 
are indoctrinated together.  
I owe much to my Texan based colleagues. Particularly to Prof John Blangero for 
inviting me to train in the intricacies of NGS in his laboratory. Dr Joanne Curran, Dr 
Matthew Johnson and Dr Tom Dyer for your support, friendship and hospitality 
before, during and after my visit. And especially to Mr Juan Peralta – without your 
generous support, patience, friendship, extreme bioinformatics skills and instructions 
to ‘gts’, I’d still be finger painting. Thank you for being an ear of support and 
sympathy for many frustrations, sinceramente gracias amigo.  
A personal thank you to my friends and family. Particularly Gustaf, Ella and Jess, you 
have each been a source of strength in each challenge that has arisen in the past four 
years and sounding boards for so many problems. Finally, Mum and Dad, thank you 
vii 
for your constant support across four years of varying levels of grumpiness. Without 
you this would not have been possible. It is to each of you I dedicate this work. 
More specifically, particular acknowledgement needs to be made to the following 
people who have contributed to this project. 
The TFHMS clinicians, Prof Ray Lowenthal, Dr Katherine Marsden and Dr Elizabeth 
Tegg, for their assistance and input with the interpretation of the clinical aspects of, 
and records of patients in, this project. 
The TFHMS genealogist, Mrs Annette Banks for her ongoing work with this familial 
resource. 
Research Assistant James Marthick for his assistance across the laboratory aspects of 
this project. 
A/Prof Kathryn Burdon and Sionne Lucas for their contributions to the amplicon 
based sequencing experiment. 
The Australian Antarctic Division for access to and use of their ABI 3100 sequencer. 
Mr Alistair Chilcott for IT support. 
A/Prof Velandai Srikanth for his contributions to the telomere length work. 
Prof John Blangero, Dr Tom Dyer and Mr Juan Peralta for their bioinformatics advice 
and support with this project 
Prof Simon Foote for his initial involvement and supervision in this project. 
The Australian Government for my Australian Postgraduate Award scholarship, and 
the University of Tasmania and Menzies Institute for Medical Research for additional 
scholarship and travel funding. 
The participants of the Tasmanian Familial Haematological Malignancies Study. 
Finally, A/Prof Joanne Dickinson and Dr Jac Charlesworth for their supervision 
throughout this project. 
This project was supported by funding from the National Health and Medical 
Research Council, Australian Research Council, Australian Cancer Research 
Foundation, David Collins Leukaemia Foundation, Leukaemia Foundation of 
Australia and the Cancer Council Tasmania.  
viii 
Abstract
Haematological malignancies (cancers of the haematopoietic and lymphoid tissues) 
are collectively one of the most frequently diagnosed cancers in Australia. Family 
history is one of the strongest risk factors for disease. Evidence for this derives from 
large population-based studies that have identified an increased risk of haematological 
malignancies in first degree relatives of cases, as well as studies of individual families 
where analyses have identified genes where family specific germline mutations 
predispose to these malignancies. Despite intensive research into the genetic 
predisposition to these cancers, the known genes account for only a small portion of 
the overall inherited component of haematological malignancies, leaving a significant 
gap in our understanding of the genetic basis of disease. Earlier studies used candidate 
gene approaches or sparse sets of genome wide markers to identify predisposition 
genes. Such approaches have a limited capacity for disease gene identification. Now, 
application of innovative technologies, such as next generation sequencing, to familial 
datasets with multiple cases of haematological malignancies presents an ideal 
opportunity to identify new predisposing germline mutations and other genetic factors 
contributing to disease development. 
The aim of this study was to identify the genetic architecture of disease susceptibility 
in large families affected by multiple subtypes of haematological malignancies. This 
study takes advantage of a collection of extended Tasmanian haematological 
malignancy pedigrees comprising 48 families, as well as 84 additional Tasmanian 
haematological malignancy cases with no known family history of disease. This 
resource is particularly valuable due to the recognised stability and relative genetic 
homogeneity of the island population of Tasmania. 
Next generation sequencing approaches were employed to identify novel, rare and 
shared predisposing mutations in affected family members. This was achieved 
through a combination of whole exome and whole genome sequencing in five 
prioritised families. Genome and exome alignment and variant calling were conducted 
using BWA and SAMtools. High-quality single nucleotide and small insertion / 
deletion variants identified were then annotated with information from public data 
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sources using ANNOVAR. Variants were filtered to focus in on rare variants (with 
population frequency estimates of 1% or less) using frequencies in Caucasian 
population data from the 1000 Genomes Project and the UK10K consortia dataset. A 
large number of rare shared genetic mutations were identified between related 
haematological malignancy cases in these families. A tiered prioritisation strategy was 
developed and employed to identify the top preferred candidates for further follow-
up. This strategy incorporated variant-based prioritisation, using in silico predictions 
of variant effect, and gene-based prioritisation using known gene biology. For gene-
based prioritisation a literature curated network analysis tool (Ingenuity Pathway 
Analysis) and an ontology-based tool (Phevor) as well as publically available tissue 
expression profiles of the mutated genes were used. Genes prioritised for further 
follow-up include examples such as TNFSF9, TDP2, MMP8, and NOTCH1. These 
genes have not been previously implicated in the familial risk for haematological 
malignancies, although some have previously established roles in malignancy. For 
example, TNFSF9 is a gene with clear connections to both T-cell and B-cell biology 
and there is evidence from a mouse knockout model that disruption to this gene can 
contribute to malignancy development. 
A subsequent aim of this study was to explore the role of telomere biology in familial 
haematological malignancies. Telomere biology has a well-characterised role in 
cancer development. Disruption of key telomere biology genes has been shown to 
lead to a spectrum of syndromes of which haematological malignancies are a feature 
such as dyskeratosis congentia and aplastic anaemia. To examine whether disrupted 
telomere biology was detectable in haematological malignancies, an analysis of 
telomere length was conducted using a PCR-based assay measuring across the 
familial resource, non-familial cases and population controls. Telomere length was 
analysed as a quantitative trait using variance components modelling, adjusting for 
age, sex and importantly kinship. The key finding from this analysis was that telomere 
length was highly heritable at 62.5% (P=4.7×10-5) indicating a strong genetic effect 
driving variation in telomere length and that both familial and non-familial 
haematological malignancy cases had shorter telomeres (P=2.2×10-4 and 2.2×10-5 
respectively). These results indicate that telomere length contributes broadly to 
haematological malignancies. Genetic variation in some of the known telomere 
  x 
biology genes was examined, however the underlying genetic contribution to the 
observed shortened telomere length remains to be determined. 
 
This thesis describes the genetic analysis of a rare resource, providing evidence for 
several novel genes with possible roles in the development of haematological 
malignancies. As expected next generation sequencing of these families has further 
highlighted the multigenic contribution to risk in this complex disease.   
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Chapter 1 - Introduction 
 
1.1 Haematological malignancies 
Haematological malignancies (HMs) are cancers of the haematopoietic and lymphoid 
tissues and collectively are the third most diagnosed cancer in Australia and an 
important worldwide contributor to cancer related mortality2,3. An area of intense 
research is to identify why HMs occur, as this will lead to new mechanisms by which 
to prevent or treat disease. HMs, as for other types of cancers, are multifactorial 
diseases consisting of a complex interplay of genetic, environmental and lifestyle-
based risk factors. One understanding of how cancers including HMs develop likens 
the process to evolution4,5. Normal cells become malignant through a multi-step 
process, whereby several genetic mutations are acquired over time that change the 
cells such that they acquire or evolve the ‘hallmarks’ of cancer cells4,5. These 
hallmarks and characteristics, as proposed by Hanahan and Weinberg6,7, are 
summarised in Table 1.1. Together these hallmarks describe the complex barriers 
cells must overcome, by acquiring genetic mutations, to progress to malignancy. Cells 
evolve into a malignant state through development of several mutations in key genes 
that in sum result in acquisition of the hallmarks described in Table 1.1.  
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Table 1.1 Summary of the ‘Hallmarks of Cancer’ paradigm proposed by 
Hanahan and Weinberg, adapted from Hanahan et al.7 
 
Established cancer hallmarks Mechanism 
Sustaining proliferative signalling Recruit extra or increase sensitivity to growth 
factors 
Evading growth suppressors Inactivate tumour suppressor genes such as 
RB1 (retinoblastoma 1) and TP53 (tumour 
protein p53) 
Enabling replicative immortality Upregulated expression of telomerase, or 
alternate lengthening of telomeres, which 
prevents the triggering of cellular senescence 
or cellular crisis (and the subsequent cell 
death) 
Activating invasion and metastasis Loss of cell-to-cell adhesions, inactivation of 
E-cadherin, upregulation of N-cadherin, 
activation of EMT (epithelial-mesenchymal 
transition) 
Inducing angiogenesis Upregulated proangiogenic signals such as 
VEGFs (vascular endothelial growth factors) 
and FGFs (fibroblast growth factors) to form 
new vascularisation into the tumour site 
Resisting cell death Limit or prevent apoptosis by loss of TP53 
function, increasing expression of anti-
apoptotic factors (e.g. Bcl-2), decreasing 
expression of pro-apoptotic factors (Bax, Bim, 
Puma) 
Emerging hallmarks Mechanism 
Avoiding immune destruction Suppression of immune system, production of 
cancer cells that do not trigger an immune 
response 
Deregulating cellular energetics Limit energy supply of cancer cells to aerobic 
glycolysis, enhancing proliferative capacity 
Enabling characteristics Mechanism 
Tumour-promoting inflammation Inflammation provides bioactive molecules 
such as growth factors and proangiogenic 
factors to the developing tumour 
Genome instability and mutation Acquisition of successive genetic alterations 
(acquired mutations) for further hallmarks to 
develop, deregulation of DNA repair 
mechanisms 
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1.2 Deregulation of haematopoiesis leads to malignancy 
HMs arise as a result of deregulated haematopoiesis. Haematopoiesis is the biological 
process by which the mature cells of the haematopoietic and lymphoid tissues are 
formed. In healthy individuals haematopoiesis occurs in the bone marrow, where 
niches of long-term haematopoietic stem cells form short-term haematopoietic stem 
cells, from which the common myeloid and common lymphoid progenitors derive8,9. 
These progenitors can differentiate via a number of pathways to form the cellular 
components of blood as shown in a simplified model in Figure 1.1. Briefly, the 
common myeloid progenitors form two branches, the megakaryocyte / erythroid 
progenitors, which in turn form mature red blood cells and platelets, and the 
granulocyte / macrophage progenitors, which form mast cells, neutrophils, monocytes 
and macrophages, dendritic cells, eosinophils and basophils8,9. The common 
lymphoid progenitors form B-cells and plasma cells, T helper cells, cytotoxic T-cells 
and natural killer (NK) cells8,9.  
 
Haematopoiesis is not solely a linear process and it has been suggested that the 
simplified haematopoiesis hierarchical model as depicted in Figure 1.1 should be 
interpreted as an illustration of the differentiation possibilities8,10. There is also in 
vitro evidence showing that differentiation lineages can be reprogrammed (by forced 
expression of targeted transcription factors) from one lineage to another. But whether 
this can occur in vivo has yet to be determined11-13. Figure 1.2 adapted from Ceredig 
et al.10 illustrates an alternate model of haematopoiesis supporting the concept of a 
non-linear process whereby multiple different types of progenitors can differentiate to 
form the same terminally differentiated mature cells.  
 
Further underlining the idea that haematopoiesis is a system of differentiation 
possibilities is the observation of age related differences in haematopoietic stem cells. 
Studies have shown that with age, haematopoietic stem cells change, and become 
unstable and biased towards myeloid lineages over lymphoid lineages, and that this is 
in parallel with changes in gene expression with increased expression of malignancy-
related genes and decreased expression of DNA damage repair genes14-17. Indeed the 
specific transcription factor requirements of the different lineages in haematopoiesis 
are intimately linked with the potential for disruption to occur and HMs to form, with 
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the type of HM developing depending upon where and in which lineage disruption 
occurs.  
 
Key regulatory genes that are essential for haematopoiesis have been shown to be 
involved in the development of HMs8. An example is RUNX1 which is an essential 
transcription factor for haematopoiesis and haematopoietic stem cell formation8,18, 
and is regularly disrupted often by chromosomal translocations in a range of 
leukaemias19-21. Another example is the transcription factor GATA1 which is required 
in the myeloid lineage in haematopoiesis and is also causally involved in the HMs 
associated with Down syndrome22,23. These and many other genes essential for 
haematopoiesis can contribute to HM development when aberrantly regulated. What 
subtype of HM develops is dependent upon where in haematopoiesis and specifically 
what lineage is affected.  
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Figure 1.1 A simplified hierarchical model of haematopoiesis.  
Self-renewing haematopoietic stem cells differentiate into mature cells of either the lymphoid or myeloid lineage. Figure constructed using 
images adapted under the creative commons license from http://commons.wikimedia.org/wiki/File:Haematopoiesis_(human)_diagram.png by A. 
Rad and by adaptation of information in Orkin et al.8, Ceredig et al.10 and Hatton et al.9.  
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Figure 1.2 An alternate model of haematopoiesis from Ceredig et al.10 
This model, as proposed in Ceredig et al.10, shows haematopoiesis as a continuum of 
differentiation with progenitor cells having flexibility to move between related 
differentiation lineages, in contrast to the hierarchical commitment in Figure 1.1. As 
described10 this model makes no assumptions as to the hierarchical structure of 
differentiation instead showing arcs that indicate known oligopotent progenitor cells, 
e.g. the Megakaryocyte-erythrocyte arc shows the potential of these progenitors to 
form both megakaryocytes and erythrocytes. DC, dendritic cell; EPLM, early 
progenitor with lymphoid and myeloid potential; FLT3, FMS-related tyrosine kinase; 
LMPP, lymphoid-primed multipotent progenitor; NK cell, natural killer cell.  
 
be because there is a difference between 
what occurs in vivo and what HSCs can be 
‘persuaded’ to do in vitro. We think that the 
traditional hierarchical tree may not be the 
best way to illustrate haematopoiesis. Hence, 
we explore an alternative view to explain 
how intermediate progenitors can give rise 
to certain combinations of cell fates while 
excluding others.
A simple pairwise relationships model for 
the specification of haematopoietic cell fates. 
Using the ‘sequential determination’ model46 
as a starting point, we have developed a 
revised model to depict the developmental 
relationships between haematopoietic cell 
lineages (FIG. 2). This involves grouping 
the pairwise relationships between lineage 
fates around a broken circle. The pattern of 
relationships seems to be determined by a 
cell-intrinsic programme that operates in 
HSCs and in the various progenitors that 
are derived from them.
In the model, an HSC developing into an 
immune cell moves towards a specific cell 
fate as it progresses from having the poten-
tial to become any cell (as shown within 
the inner, broken circle) towards having the 
potential to become one of several contigu-
ous cell types (as shown by outer arcs) and 
finally committing to a differentiated 
cell fate (as shown by the outermost arc). 
Throughout development, each cell fate 
potential varies between being dominant 
(that is, the most likely outcome adopted), 
being available (but less available than the 
potential to differentiate into a cell type 
that is contiguous in the spectrum) and 
already having been lost (that is, latent 
and not irretrievable). Rather than as step 
transitions between one fate and the next, 
each transition between a pair of lineage 
fates is shown as a continuum. When a cell 
becomes committed to an individual fate, 
the last cell fate potentials to be lost are 
those that are immediately adjacent in  
the spectrum of relationships.
FIGURE 2 also depicts the development 
potentials of known progenitors as segments 
of the central circle. Each arc encompasses 
a contiguous set of cell fates that have 
been shown experimentally to be closely 
related18,36,37,47,48. Moreover, the arrangement 
of lineage fates into pairwise relationships is 
consistent with findings of studies of LMPPs, 
suggesting that HSCs progress from having 
megakaryocytic and erythroid potential to a 
myeloid potential and are finally restricted 
to the lymphoid differentiation pathways9. 
In LMPPs, a gradual increase in transcrip-
tional priming for lymphoid differentiation 
coincides with a gradual reduction in their 
capacity to differentiate into granulocytes 
and monocytes49. In the model proposed by 
Ye and Graf44 (FIG. 1a), development proceeds 
first past branches for the erythroid and 
myeloid lineages and then past branches  
for the lymphoid lineages.
In the pairwise relationships model 
there are no assumptions about any under-
lying strict branching pattern that might 
seem to dictate a preferred route for HSCs 
to a particular cell fate. In other words, 
HSCs can reach a specific cell fate through 
more than one type of intermediate pro-
genitor. In this regard, subsets of DCs can 
be derived from cells purified as either CLPs 
or common myeloid progenitors (CMPs), 
suggesting that DCs can have both lym-
phoid and myeloid origins50. However, the 
cell surface phenotypes and transcriptional 
profiles of DC subsets derived from differ-
ent progenitors appear to be identical, so it 
seems that the developmental programme 
of DCs is independent from that of lym-
phoid and myeloid cells47. Cells that have 
the potential to become DCs often also 
have the potential to become B, T and NK 
cells. A subpopulation of progenitors that 
expresses FLT3 generates DCs, B, T and NK 
cells in vitro and lacks myeloid potential18. 
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Figure 2 | A pairwise relationships model of haematopoiesis. This model depicts haemato-
poiesis as a continuum of lineage relationships between haematopoietic stem cells (HSCs) and their 
oligopotent progeny. Instead f a classical tree depiction of haematopo esis, we propose that there 
is a series of invariant pairwise developmental relationships between the various haematopoietic 
lineages. This model makes no assumptions about underlying branching patterns that might seem 
to dictate a preferred route to a particular cell fate. Arcs indicate the known oligopotent progenitor 
cells. Some of the arcs overlap: in particular, the arrowheads on two of the arcs indicate that den-
dritic cells (DCs) can be derived from both megakaryocyte–monocyte progenitors and B-cell–T-cell 
progenitors. This reflects the idea that a final cell fate may be reached through more than one type 
of intermediate progenitor. There may be several different progenitors that have the potential to 
become cells that are contiguous in the sequence. These considerations take into account the devel-
pmental po ential of the v rious progenitor cells that have been describ  so far and those that 
may remain to be discov red. The c ncept of pairwise relationships is supported by previous descrip-
tions of progenitors that have the following combined developmental potentials: megakaryocyte–
erythrocyte37; B cell–T cell–monocyte–DC18,47; megakaryocyte–monocyte–DC18,47; neutrophil–monocyte36; 
and megakaryocyte–basophil or mast cell48. In addition, this model explains how myeloid- and erythroid-
cell development can proceed through multiple routes (as depicted in previous models; see FIG. 1). 
EPLM, early progenitor with lymphoid and myeloid potential; FLT3, FMS-related tyrosine kinase 3; 
LMPP, lymphoid-primed multipotent progenitor. NK cell, natural killer cell.
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1.3 Population and clinical aspects of haematological malignancies  
Broadly HMs can be stratified into three major groups: leukaemias, lymphomas, and 
myelomas. Within these the World Health Organization (WHO) has classified over 
100 different specific subtypes of HMs on the basis of morphology, 
immunophenotype, genetic features and clinical features24. Subtypes vary widely in 
their diagnosis, treatment and clinical outcomes24. What HM subtypes do share in 
common is that they arise from genetic abnormalities that affect haematopoiesis. 
Myeloid malignancies such as acute myeloid leukaemia (AML), chronic myeloid 
leukaemia (CML) and myeloproliferative neoplasms (MPNs) arise from deregulation 
of the myeloid lineage24. In the same way, lymphoid malignancies such as acute 
lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), multiple 
myeloma (MM) and Hodgkin lymphoma (HL) arise from deregulation of the 
lymphoid lineage24.  
 
1.3.1 Population impact of haematological malignancies  
The Australian Institute of Health and Welfare (AIHW) has shown consistently from 
2003 to 2010 that the number of HMs diagnosed yearly in Australia exceeds 10,000 
people25. According to 2010 AIHW data, HMs, with 11,559 cases nationally, were the 
third most common cancer after prostate and breast cancers25. HMs are reported 
across 16 different classes in AIHW statistics. Table 1.2 shows the AIHW 2010 
cancer incidence data for the top six most frequently diagnosed cancers, with the 16 
classes of HMs combined to show the total incidence and then with the specific class 
breakdown. Figure 1.3 shows the incidence relationships of these cancers in Australia 
using AIHW data from 1982 to 2010. 
 
  8 
 
Table 1.2 AIHW 2010 data for the top 5 cancers diagnosed nationally, with 
haematological malignancies consisting of 16 separate AIHW classification 
classes25. 
 
AIHW Cancer Classification Male Female Total 
C61 Prostate 19,821 0 19,821 
C50 Breast 127 14,181 14,308 
Haematological malignancies 6,662 4,897 11,559 
C81 Hodgkin lymphomas 324 248 572 
C82 Follicular non-Hodgkin lymphoma 542 446 988 
C83 Diffuse non-Hodgkin lymphomas 1,229 848 2,077 
C84 Peripheral and cutaneous T-cell lymphomas 168 95 263 
C85 Other and unspecified non-Hodgkin lymphomas 605 529 1,134 
C88 Immunoproliferative cancers 53 38 91 
C90 Multiple myeloma and other plasma cell cancers 826 641 1,467 
C91 Lymphoid leukaemias 952 600 1,551 
C92 Myeloid leukaemias 792 609 1,402 
C93 Monocytic leukaemias 36 25 61 
C94 Other leukaemias of specified cell type 15 16 30 
C95 Leukaemias of unspecified cell type 35 31 65 
C96 Other and unspecified cancers of lymphoid, 
haematopoietic and related tissue 
17 20 37 
D45 Polycythaemia vera 101 90 191 
D46 Myelodysplastic syndromes 764 476 1,241 
D47 Other cancers of lymphoid, haematopoietic and 
related tissue 
204 185 389 
C43 Skin - Melanoma 6,700 4,705 11,405 
C34 Bronchus and lung 6,241 4,042 10,283 
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Figure 1.3 Incidence of major cancer types in Australia from 1982 to 2010 using data from the Australian Institute of Health and 
Welfare25. 
This figure shows that consistently, HMs are one of the most frequently diagnosed cancers in Australia. 
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GLOBOCAN 20123 is the most recent comprehensive worldwide study of cancer in 
the adult population (ages 15 and over). GLOBOCAN reports that the estimated 5-
year population prevalence of HMs worldwide (categorised as leukaemia, multiple 
myeloma, Hodgkin lymphoma and non-Hodgkin lymphoma) is 33.7 per 100,000 
people26. GLOBOCAN 2012 estimates the 5-year population prevalence of HMs in 
Australia is 134.9 per 100,000 people. This is similar to other ‘Western’ countries 
such as the United States of America and the United Kingdom with 5-year population 
prevalence estimated at 134.3 and 120.1 per 100,000 people respectively. These 
country specific figures are much greater than GLOBOCAN’s estimated worldwide 
prevalence of 33.7 per 100,000, as there are countries with much lower prevalence 
estimates.  
 
The difference in prevalence between the worldwide figure and the 
Australian/USA/UK figures is due to the much lower 5-year prevalence of HMs in 
regions such as Africa (15.8), Asia (17.2) and South America (28.3). This is 
illustrated in Figure 1.4, four world maps generated from GLOBOCAN 2012 with the 
prevalence of HMs across the world described as heat maps. As can be seen in Figure 
1.4 there is a trend that Caucasian countries, predominantly the UK, USA and 
Australia, have a much higher 5-year prevalence of HMs in comparison to African 
and Asian countries. As HMs are multifactorial complex diseases this immediately 
questions whether region specific environmental risk factors contribute to the higher 
prevalence of HMs within particular countries or whether genetic ancestry drives this 
prevalence disparity. GLOBOCAN worldwide data may also be influenced by 
incomplete reporting rates and low quality data from non-Western country regions. 
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Figure 1.4 GLOBOCAN 2012 worldwide prevalence of HMs per 100,000 people.  
A) Leukaemia, B) multiple myeloma, C) non-Hodgkin lymphoma, D) Hodgkin lymphoma. Obtained from http://globocan.iarc.fr3. 
 
A B 
C D 
  12 
1.3.2 Clinical aspects of haematological malignancies  
Haematological malignancies recapitulate Hanahan and Weinberg’s ‘hallmarks of 
cancer’ listed in Table 1.17. Through acquisition of genetic mutations, the normal 
process of haematopoiesis becomes a source of malignancy as cells obtain replicative 
immortality with sustained proliferation and avoidance of the immune system and 
apoptosis. HMs may present as primarily a circulating disease within the blood, such 
as observed in CLL, or in other subtypes solid tumours are the primary feature of 
disease, for example HL24. Some HMs are asymptomatic in early stages of disease, 
and may be first detected as a result of standard general practice medical 
examinations, presenting as abnormal blood cell counts24.  
 
1.3.3 Challenges of therapies in haematological malignancies 
One of the major goals of HM therapies is to reduce toxicity and increase survival. 
For younger patients, for example childhood ALL, therapeutic strategies must weigh 
disease eradication against the potential for long-term side effects of therapy, such as 
therapy related malignancies27,28. In older patients, many suffer from additional 
comorbidities that reduce fitness for intensive therapy, which also influences therapy 
choice. For many HMs prognostic genetic factors that assist in stratifying patients into 
treatment groups have been identified. For example in CLL a recurring genetic factor 
is deletions of the p arm of chromosome 17 (encompassing the tumour suppressor 
gene TP53). Patients with del(17p) do not respond as well as other CLL subgroups to 
combination chemotherapy with fludarabine and rituximab, so other treatment options 
such as allogeneic stem cell transplant are used29,30.  
 
HMs have a high burden across the population, so identifying ways to improve 
treatment results and minimise later complications arising from therapy is a priority 
research area. One aspect of this is identifying factors that can be used to predict 
disease risk, progression or treatment response.  
 
1.4 Risk factors for haematological malignancies 
As a multifactorial disease, a number of risk factors have been associated with the 
development of HMs. A strong risk factor for HMs is a family history of disease and 
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accordingly the primary topic of this thesis is understanding the genetic basis of 
disease. However it is also important that genetic risk factors are considered in light 
of known non-familial and environmental risk factors.  
 
1.4.1 Non-familial risk factors 
1.4.1.1 Age 
Increased age is a well-known risk factor for cancer and increasing age is associated 
with cancer risk31. This is reflected in HMs where data from the AIHW show that the 
mean age of disease incidence is above 60 years across different HM subtypes2. The 
exception is HL where the mean age of disease incidence is 402. Even so, some 
subtypes of HMs are considered clinically to be childhood diseases. AML, for 
example, is typically a childhood cancer, but can also be seen in adults24. Whereas 
subtypes such as CLL and the MDS are rare in children and are seen more commonly 
in adults24.  
 
The risk of developing HMs increases with age with risk magnitudes differing 
between subtypes. For example in Australia the lifetime risk of developing CLL to 
age 75 is one in 304 people with this risk almost doubling to one in 161 if the age 
range is extended to age 852. For HL the mean age of incidence is around 20 years 
younger than CLL however the overall risk is lower being one in 549 to age 75 and 
one in 463 to age 852. Therefore age as a risk factor is important in HMs but the risk 
effect varies considerably from subtype to subtype.  
 
Further, the increased risk of cancer with age has been attributed to the accumulation 
of acquired genetic mutations over time. However the logic of this axiom has been 
challenged recently by DeGregori who makes a compelling argument that as the rate 
of acquired genetic mutations peaks in ontogeny, why then does the incidence of 
cancer peak much later in life and not concurrently with mutation rate?32 Thus 
genetics may be involved in the age-related increase in the incidence of HMs but 
whether this is solely due to the acquisition of genetic mutations over time remains to 
be determined.  
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1.4.1.2 Sex 
Sex is another well-characterised risk factor for cancer, where broadly, the incidence 
of non-sex specific cancers is greater in men than women2,31,33-35. In Australians the 
incidence and mortality of HMs is greater in men than women across the age and 
subtype spectrum2. The exception is again HL where incidence changes with age, and 
is higher for women than men from around age 20 to 30 and again at around ages 50 
and 752. This age and sex interaction on risk occurs in other HM subtypes36. 
Speculation on the biological causes underlying the sex difference in cancers such as 
HMs has suggested factors such as differences due to hormones, genetics, epigenetics 
and immune surveillance, however the causes remain uncharacterised37,38.  
 
1.4.1.3 Environmental and lifestyle factors 
A range of environmental and lifestyle factors also contribute to cancer development5. 
Factors such as smoking, occupational exposure to carcinogens, chronic infections 
and ionizing radiation, can cause additional damage to haematopoietic cells that 
additively contributes to a transformation to malignancy5,39. A US study of population 
birth cohorts showed that the incidence of leukaemia varied significantly across birth 
years and per generation40. In this study the incidence of AML and ALL was seen to 
increase across the temporal cohort spectrum, while CML and CLL declined. This 
could indicate a change in environmental exposures and lifestyle factors resulting in 
increased incidence of AML and ALL and decreased incidence of CML and CLL. 
These incidence differences between birth cohorts support the hypothesis that adult 
leukaemia is modulated by environmental and lifestyle exposures and that these 
exposures change over time across cohorts.   
 
In the World Cancer Report 2008, the International Agency for Research on Cancer 
listed a range of industries where occupational exposure to particular carcinogens was 
attributed to increasing the incidence of leukaemias and lymphomas in workers of 
those industries (as summarised in Table 1.3, data drawn from39). One occupational 
carcinogen example is the solvent benzene, which is also present in cigarette smoke. 
Studies have shown an association between benzene exposure from smoking and the 
incidence of myeloid leukaemias41 and exposure due to occupation and CLL and MM 
incidence42,43. Even though there is a clear involvement between benzene and HM 
  15 
incidence the association has differing levels of evidence between different subtypes 
and is compounded by other co-occurring occupational exposures44. Identifying what 
is and what is not an occupational risk factor for HMs is challenging due to 
compounding factors, difficulties with sample size and quantifying exposures but is 
still crucial for disease management and prevention.  
 
Table 1.3 Occupational exposures to environmental risk factors believed to 
contribute to the development of HMs. Data from the World Cancer Report 
200839. 
 
Carcinogen Industry / Industrial use HM type 
Benzene Solvents, fuel Leukaemia 
1,3-Butadiene Plastics and rubber industries Leukaemia 
Non-arsenical insecticides Agriculture Leukaemia 
Polychlorinated biphenyls Electrical components Lymphoma 
Tetrachloroethylene Solvent Lymphoma 
Trichloroethylene Solvent, dry cleaning Lymphoma 
 Boot and shoe manufacture and repair Leukaemia 
 Petroleum refining Leukaemia 
 
Ionizing radiation is a well-established carcinogen that contributes to the risk of HM 
development. Exposure can occur occupationally, medically or due to close proximity 
to events and locations such as Chernobyl and the atomic bombings of Japan. It has 
been proposed that ionizing radiation can act directly on stem cells in the body, 
including haematopoietic stem cells, inducing changes that increase the risk of 
malignancy development45. Nakamura suggests that ionizing radiation could be acting 
on pre-malignant cells randomly adding additional genetic mutations which in turn 
trigger cellular progression to malignancy46. This is particularly in line with early 
research that showed that pre-natal exposure to X-ray irradiation during obstetric 
examination raised childhood cancer rates, including leukaemia47,48.  
 
Retrospective studies of Japan’s atomic bomb survivor cohort have also drawn the 
link between ionizing radiation and the increased occurrence of HMs, particularly 
AML49,50, but also MDS51 with risk of developing some subtypes persisting up to five 
decades after the initial exposure. However, an increased risk of CLL, HL and MM 
were not detected in this cohort50. Other studies of CLL and other leukaemias outside 
of Japan have reported conflicting results as to whether there is an association 
between disease risk and ionizing radiation exposure. For example, studies of cohorts 
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in Ukraine52 and Russia, Belarus and the Baltic countries53 show that exposure to 
ionizing radiation is associated with an increased risk of HMs including CLL. 
Whereas other cohort studies have shown that there is an increased risk for leukaemia 
development in those exposed to radiation, except for CLL54,55.  
 
Virus infection is another environmental / lifestyle factor that has been shown to 
contribute to the development of HMs. Adult T-cell leukaemia is strongly related to 
infection by human T-cell leukaemia virus type-1, particularly in Japan where there is 
an endemic cluster of this HM subtype56-58. Patients infected with human 
immunodeficiency virus (HIV) have an increased risk of lymphoma development due 
to progressive immune system suppression, particularly in the later stages of acquired 
immunodeficiency syndrome (AIDS)59-61. Epstein-Barr virus (EBV), as well as being 
an additional factor in the development of HIV/AIDS related lymphoma, has been 
shown to independently related to the development of HL, Burkitt lymphoma (BL) 
and non-Hodgkin lymphoma (NHL), as reviewed in Kutok et al.62.  
 
1.4.1.4 Ancestry / ethnicity 
As discussed in section 1.3, there are significant differences globally in the prevalence 
of HMs when looking at data from GLOBOCAN 20123. Asian, African, Russian and 
Baltic countries have a lower prevalence of HMs than ‘Western countries’ including 
Northern and Western Europe, Northern America (excluding Mexico) and Australia 
as illustrated globally in Figure 1.4. One possible explanation is that the differences 
between high and low prevalence countries are due to environmental and lifestyle 
factors. There is evidence to support this in specific subtypes of HMs such as BL 
resulting from EBV infection in Africa63, however research also points to ethnicity 
and genetic ancestry as the main driver of these differences. It is also possible that 
limited data collection and diagnoses from developing Asian and African countries 
drives these geographical differences. Studies assessing migrant populations in 
countries with high incidences of HMs can overcome the data collection problem, 
allowing a focus on differences between ethnicities. For example, studies of migrant 
Asians in America have shown that the migrant groups retain the low HM prevalence 
of their ethnic background64. This lower prevalence is maintained across subsequent 
generations born in the high incidence country64. Similar findings came from a data-
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linkage study in the UK where HM prevalence in British Caucasians was compared to 
multiple UK migrant ethnic groups65. These studies support a role for genetics in the 
ethnicity differences in HM prevalence and are evidence against ethnicity specific 
environmental and lifestyle factors being the primary difference.  
 
It is also possible that the same HM subtype is fundamentally different in different 
ethnic groups. However a recent study compared the molecular profiles of Asian and 
Caucasian CLL cases66, finding the profiles to be much the same. This shows that at 
least for CLL there is not a fundamental difference in the cancer genomes between 
Asian and Caucasian disease, yet it does not explain why CLL is more prevalent in 
Caucasians. This study did not compare the germline genome of the cases. It is likely 
that the differences in HM prevalence between ethnicities is due to the underlying 
genetic differences between groups and points to an inherited basis of disease. 
Therefore ethnicity and ancestry have an important role in the development of HMs 
but our understanding remains limited with further work required to tease out specific 
ethnicity risk factors for HMs.  
 
Moving away from the global population level consideration of HMs, what these 
findings from ethnicity studies do suggest is that there are inherited risk factors that 
have an important role in HM development. Different types of studies can address 
components of these ethnicity and inheritance-based questions.  
 
1.4.2 Familial risk in haematological malignancies 
1.4.2.1 Population-based studies of familial HMs 
One of the earliest reports providing population-based evidence of a familial risk for 
HMs is from 1947 when Videbæk published his pioneering work comparing 
Scandinavian families of 209 leukaemia probands to the families of 200 unaffected 
individuals67. This publication was one of the first to signal a change in the field away 
from an environmental or contagious cause of HMs towards a genetic basis for 
disease. Videbæk’s work revealed that in a series of 209 patients with leukaemia, 17 
had evidence of familial leukaemia whereas in the relatives of the 200 unaffected 
control individuals there was only one case of leukaemia. At the time this was the 
most extensive and comprehensive study of familial HMs that went beyond single 
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case reports. It was also one of the first suggestions that multiple subtypes of HMs, as 
well as other cancers, could occur in the same family and may have a genetic 
connection. 
 
In more recent years, large studies have repeatedly shown that HMs aggregate in 
families and that a family history of disease is a significant risk factor for HMs. A 
familial risk for HMs is supported by the results of large epidemiological studies that 
link data in the Swedish Cancer Registry68 and the Swedish Multigenerational 
Registry69. Together these registries provide information on cancer patients and their 
relatives in Sweden back to 1958. As summarised in Table 1.4 and Figure 1.5 most 
studies have shown that first-degree relatives have a statistically significant increased 
risk of developing the same HM subtype as the related case. Additionally, most 
studies have shown that first-degree relatives of HM cases have a statistically 
significant increased risk of developing other subtypes of HMs. For example one 
study has shown that first degree relatives of CLL cases have an 8.5 fold increased 
risk of developing CLL and increased risks for other subtypes of NHLs including B-
cell NHL, hairy cell leukaemia (HCL), and lymphoplasmacytic lymphoma / 
Waldenström macroglobulinemia (LPL/WM)70. By identifying an increased risk in 
first-degree relatives of HM cases these epidemiological studies provide compelling 
evidence of an inherited genetic risk for HMs. Similar studies across a number of 
centres, using the Danish Cancer Registry71, Swedish Cancer Registry72-74 and studies 
from the United Kingdom75, Utah76 and a multi-centre consortium study77 support 
these findings.  
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Table 1.4 Summary of the findings from population based studies of familial HMs.  
  
Proband Disease LPL/WM78 MPN79 CLL70 DLBCL80 FL80 HL80 MM81 MGUS82 AML83 MDS83 
Study Details                     
Cases 2144 11039 9717 2517 2668 6963 13896 4458 6962 1388 
# 1st degree case relatives 6177 24577 26947 8974 10188 24053 37838 14621 20579 3994 
Controls 8279 43550 38159 9932 10468 28371 54365 17505 27872 5312 
# 1st degree control relatives 24609 99542 107223 35310 40384 108180 151068 58387 90406 15818 
Period 1958-2005 1958-2005 1958-2004 1958-2004 1958-2004 1958-2004 1958 - 2005 1967-2005 1958-2004 1993-2004 
Relative Risk in First Degree Relatives RR (95% C.I.) with * signifying statistical significance in that study, NR = not reported  
MM 1.6 (0.8–3.2)   1.2 (0.85–1.8)       2.1 (1.6–2.9)* 2.9 (1.9–4.3)* 1.0 (0.6–1.5) 0.7 (0.2–2.0) 
MGUS 5.0 (1.3–18.9)*   1.4 (0.88–1.8)       2.1 (1.5–3.1)* 2.8 (1.4–5.6)*     
ALL             2.1 (1.0–4.2)*   1.2 (0.5–2.7) 2.0 (0.2–21.3) 
NHL 3.0 (2.0–4.4)*   1.9 (1.5–2.3)*       1.1 (0.8–1.7) 1.1 (0.8–1.5) 1.0 (0.8–1.3) 0.7 (0.3–1.4) 
B-cell NHL     1.8 (1.3–2.5)* 1.63 (NR) 1.81 (NR) 1.54* (NR)         
T-cell NHL     1.3 (0.36-4.9)               
Indolent B-cell NHL     2.2 (1.5–3.2)* 1.66 (NR) 2.11 (1.1–3.9)* 1.26 (NR)         
Aggressive B-cell NHL     1.0 (0.41–2.5)               
DLBCL       9.85 (3.1–31)*   2.45* (NR)         
Mantle Cell Lymphoma     1.1 (0.24–5.5)               
Hairy Cell Leukaemia     3.3 (1.0-10.9)*               
FL     1.6 (0.87–2.8)   4.0 (1.6–9.5)* 1.35 (NR)         
CLL 3.4 (1.7–6.6)* 1.6 (1.1–2.5)* 8.5 (6.1–11.7)*   1.8 (1.0–3.3)*   1.1 (0.8–1.7) 2.0 (1.2–2.3)* 1.6 (1.0–2.5)* 0.5 (0.1–2.1) 
LPL/WM 20.0 (4.1–98.4)*   4.0 (2.0–8.2)*       1.4 (0.7–2.8) 4.0 (1.5–11)*     
HL 0.8 (0.3–2.2)   1.5 (0.96–2.3) 2.04 (1.05–4.0)* 1.42 (NR) 3.93* (NR) 0.9 (0.6–1.4) <45yo 1.3 (0.6–
2.9), >45yo 0.2 
(0.0–1.7) 
1.3 (0.8–2.2) 0.8 (0.2–3.6) 
Any LP (NHL, HL, CLL, MM)     2.6 (2.2–3.0)*           1.1 (0.9–1.4) 0.7 (0.4–1.1) 
AML/MDS             0.8 (0.5–1.2)   1.0 (0.6–1.9) 1.5 (0.5–4.8) 
AML   1.3 (0.9–1.9)             0.9 (0.5–1.9) 1.1 (0.30–3.8) 
MDS   1.6 (0.6–4.4)             1.8 (0.6–5.7) 4.0 (0.4–43.1) 
CML   1.9 (0.9–3.8)         0.5 (0.2–1.2)   1.3 (0.6–2.9) 2.0 (0.2–21.6) 
Any myeloid malignancy                 1.1 (0.7–1.8) 1.6 (0.6–4.5) 
MPD             1.1 (0.7–1.6)       
PV   5.7 (3.5–9.1)*             2.3 (1.2–4.5)* 0.8 (0.1–6.7) 
ET   7.4 (3.7–14.8)*             1.0 (0.4–2.6)   
MF   0.9 (0.2–4.2)             1.0 (0.4–3.1) 1.3 (0.1–12.6) 
MPN unclassifed   7.5 (2.7–20.8)*             1.1 (0.3–3.9)   
Any MPN (PV, ET, MF, MPD)   5.6 (3.8–8.2)*             1.5 (0.9–2.3) 1.6 (0.50–5.0) 
Any myeloid or MPN                 1.3 (0.9–1.8) 1.6 (0.7–3.6) 
Any HM                 1.2 (1.0–1.4)* 0.9 (0.6–1.3) 
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Figure 1.5 Summary of the findings from population based studies of familial HMs. 
Relative risks for each study reported in Table 1.4 are graphed for comparison. Due to variation between studies in HM subtypes investigated, not all subtypes have a relative risk score. One study reported relative risk 
values without confidence intervals (DLBCL, FL and HL80). The relatives of MGUS patients82 who were diagnosed with HL have two relative risk points corresponding to risk calculations in two age groups < 45 years 
old: 1.3 (0.6-2.9) and > 49 years old 0.2 (0.0-1.7). Statistically significant relative risks (P < 0.05) are indicated in red in the plots for each study. Each study is plotted on a different x-axis scale as indicated.  
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1.4.2.2 Evidence of familial risk from single family studies of familial HMs 
A key omission in the population-based studies of familial HM risk is that they only 
examine whether first-degree relatives of HM cases are at an increased risk of disease, 
without extending to more distant relationships. Reports of individual families where 
HMs occur across multiple generations and multiple individuals indicate that the 
increased risk extends beyond that of first-degree relatives. Such families include 
those for which inherited syndromes are responsible for the HM predisposition, 
including Bloom syndrome84,85, and dyskeratosis congenita86-88, as well as HMs 
occurring in non-syndrome HM families89-92. Further evidence for the familial risk of 
HMs includes twin studies that have shown in monozygotic twins that if one twin 
develops a HM the second is also at an increased risk of developing a HM93,94.  
 
Typically more recent studies of familial HMs have focused on families with one 
subtype of HM with incidental recruitment of other subtypes whereas the early reports 
of familial HMs by Videæk and Gunz, show the occurrence of multiple subtypes in 
the same family67,95. Recent studies have recruited families without a subtype bias and 
report families with multiple subtypes of HMs92,96,97. Such reports, together with the 
large population studies of familial HMs support the hypothesis that there is an 
inherited risk of HM development across a range of HM subtypes and that the familial 
risk for HMs extends beyond first-degree relatives. Biologically this multiple subtype 
predisposition is intuitive in the context of Figures 1.1 and 1.2 where early 
haematopoietic progenitor cells can give rise to multiple mature cell lineages. Thus an 
inherited susceptibility may affect multiple related haematopoietic lineages giving rise 
to different HM subtypes in the same family. 
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1.5 Identifying the mechanism of familial risk in HMs 
The underlying mechanisms behind the occurrence of HMs in families remain largely 
uncharacterised. Segel and Lichtman98 proposed that the occurrence of HMs in 
families, and the increased familial risk for HMs, results from either chance, or the 
inheritance of predisposing genetic variants that increase the likelihood of developing 
cancer. Given the breadth of familial studies in this area, at both the population and 
individual family levels, it is unlikely that the observed aggregation of HMs in 
families is due to chance. Familial studies strongly support the idea that germline 
inheritance, be it through single mutations in cancer susceptibility genes or multiple 
predisposing mutations, has an important role in the development of familial HMs. 
Therefore genetic studies of families with clusters of HM subtypes will assist in the 
elucidation of mechanisms underlying the familial aggregation. Such an approach has 
proven successful previously for studies of other familial cancers such as breast 
cancer and Lynch syndrome99-106.  
 
For many cancers there exists a genetic predisposition to disease that precedes, and 
sometimes underpins, the acquired somatic mutations cancers develop during 
malignancy progression. While in recent years the focus of cancer genetics has been 
primarily on identifying somatic mutations, as evidenced by large scale projects such 
as The Cancer Genome Atlas (TCGA)107 and the International Cancer Genome 
Consortium as databased in the Catalogue Of Somatic Mutations In Cancer 
(COSMIC)108-110,377, an area of equal importance has been the identification of 
germline mutations in genes that predispose to cancer development. Such cancer 
predisposition genes, as defined in111, are genes where rare mutations confer an 
increased risk of cancer in mutation carriers. Functionally we categorise these genes 
into two categories: tumour suppressor genes and oncogenes.  
 
Tumour suppressor genes have an active role in preventing malignancy from 
developing. A classic example is RB1 which acts as a negative regulator of the cell 
cycle preventing uncontrolled cellular growth and malignancy112. Mutational 
inactivation of tumour suppressor genes, such as RB1, can be one of the initiating 
events that contributes to cancer development and acquisition of a number of the 
‘hallmarks of cancer’7. Oncogenes, in contrast, are activated by mutation. A classic 
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example of an oncogene is MYC. Many oncogenes like MYC are transcription factors 
so deregulation by mutation can lead to flow on effects to multiple genes113. MYC and 
a number of genes it interacts with are frequently deregulated in cancer. For example, 
the translocation t(8;14)(q24;q32), affecting MYC, is a hallmark of Burkitt lymphoma 
(BL)63. Together, mutations of tumour suppressor genes and oncogenes are the base 
upon which cancer develops. Mutations of tumour suppressor genes and oncogenes 
can be inherited, predisposing to cancer development, or acquired somatically as 
cancer develops, further driving malignancy.  
 
There are now at least 114 clinically confirmed cancer predisposition genes, in a 
range of cancers, most of which have been identified through studies of families with 
unusual clustering of cancer occurrences111. Identification of genes in other familial 
cancers has facilitated the development of screening programs for relatives of cases. 
Through these programs relatives can assess their risk of developing disease allowing 
increased clinical monitoring and the option of prophylactic treatment, where 
applicable, for those relatives identified as having a greater genetic risk of cancer114. 
Importantly this approach has identified key targets for therapeutic research into these 
cancers. It is possible that genetic studies of family HMs will also identify cancer 
predisposition genes allowing development of HM screening programs and targeted 
therapies. A range of approaches has been taken in this area with a number of 
successful studies identifying HM predisposition genes. Figure 1.6, a Circos plot115, 
summarises the findings of these varied approaches, discussed below. 
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Figure 1.6 Circos plot graphical representation of currently implicated genes and loci in the germline susceptibility to HMs. 
  
As detailed in Tables 1.5, 1.6, 1.9 and Appendix 1.1. Outermost track shows an ordered chromosome ideogram as per numbering; sex 
chromosomes are not shown, as there are no known associations. The second track shows a scatter plot of the odds ratios of the 
significant genome-wide association study (GWAS) findings, with green track background being odds ratios (ORs) > 1 and blue < 1, 
with OR = 1 shown by the thicker black axis, an axis scale is shown for this track at the 12’oclock position. The innermost track shows 
the known familial HM genes, labelled, identified through constitutional chromosome studies, genome-wide linkage studies, candidate 
gene studies and next generation sequencing studies.   
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1.5.1 Constitutional chromosome abnormalities in familial HMs 
The first attempts to characterise the genetic factors contributing to familial HMs 
were cytogenetically-based. A study from 1969 identified a recurring abnormal 
karyotype present in both bone marrow and skin fibroblasts from a family with three 
CLL cases116. Other unaffected relatives also carried the abnormal karyotype but were 
unaffected by CLL. It is possible that carriers of the abnormal karyotype were at an 
increased lifetime risk of CLL, or that other genetic factors present in the three cases 
were contributing to disease. The specific genetic factors underlying the abnormal 
karyotype were not able to be determined with the technology at the time. Whether 
this abnormal karyotype contributes to HM development is unknown. A more recent 
study has investigated the occurrence of constitutional chromosome abnormalities in 
bone marrow from 5633 HM patients compared to non-disease tissue such as skin or 
remission samples117. Whilst this study was not family-based, it does show that 50 
patients had constitutional chromosomal abnormalities that were germline or de novo 
in origin.  
 
A recent study of a family with HL118, identified a constitutional chromosomal 
breakpoint, involving chromosomes 2 and 3 and the disruption KLHDC8B. In this a 
family several individuals with the chromosome abnormality have also had HL. This 
study added further supportive evidence that constitutional chromosomal 
abnormalities may contribute to HM predisposition. KLHDC8B on chromosome 3 
encodes the protein kelch domain containing 8B which is translated only during 
mitosis and has a role in cytokinesis118. Salipante and colleagues determined that a 
decrease in the expression of KLHDC8B during cytokinesis results in the binucleated 
Reed-Sternberg cells that are a pathological hallmark of classical HL. A study seeking 
to validate the findings of germline mutations in KLHDC8B in familial NLPHL did 
not find any disease associated mutations119, which is consistent with Reed-Sternberg 
cells not being a feature of most NLPHL patient samples24. For KLHDC8B further 
studies are required to determine whether this gene contributes more widely to disease 
in other HM families.  
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1.5.2 Microsatellite and SNP-based genome-wide linkage studies of familial HMs 
The development of Genome-Wide Linkage Studies (GWLS) using microsatellite 
repeat polymorphisms to identify genome linkage regions within disease families 
provided an increase to the resolution of genetic studies for detecting germline 
predispositions to disease. Researchers applied the GWLS technology to genome-
wide investigations of families with multiple HM cases. Typically studies focused on 
families with one subtype of HM with GWLS conducted in families with CLL, HL, 
WM and AML. Table 1.5 summarises the findings from GWLS that have led to 
identification of genes contributing to familial HMs. 
 
Table 1.5 Summary of genes identified by GWLS in familial HMs. 
 
HM 
Subtype 
Chromosome 
Band 
Gene 
implicated 
Method Reference 
FPD/AML 21q22.12 RUNX1 Microsatellite 120,121 
CLL 9q21.33 DAPK1 Microsatellite 122 
CLL 2q21.1 CXCR4 SNP 123,124 
 
1.5.2.1 RUNX1 in familial platelet disorder with AML predisposition 
The most influential finding from GWLS in HMs came from studying families with 
familial platelet disorder (FPD) and a predisposition to develop AML. This lead to the 
identification of germline mutations in RUNX1120,121. RUNX1 encodes a transcription 
factor located on chromosome 21q22, that has a key role in haematopoiesis in the 
regulation of both myeloid and lymphoid lineages8,125. Additionally, Down syndrome 
or trisomy 21 has also been shown to have an increased predisposition to the 
development of HMs23,126 for which the extra copy of RUNX1 may be contributing. 
RUNX1 mutations have since been consistently identified in FPD with predisposition 
to develop AML127,128 and sporadic de novo AML, particularly as somatic mutations 
involving chromosomal translocations that create RUNX1 gene fusion products such 
as RUNX1-ETO129-132. It is interesting to note here that the identification of germline 
mutations in RUNX1 in a syndrome with a predisposition to develop AML has also 
been relevant in non-syndrome sporadic AML. 
 
Current studies show that RUNX1 is a tumour suppressor gene and that germline 
mutations act as a cancer initiating event, increasing the risk of AML, with further 
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somatic mutations required to fully develop AML133. There is also evidence 
implicating RUNX1 in the development of ALL133.  
 
1.5.2.2 SNP array-based GWLS in familial CLL 
With the development of SNP genotyping arrays, GWLS increased in resolution from 
hundreds of microsatellite markers to early SNP-based studies using around 10,000 
polymorphic markers across the genome. This higher resolution of GWLS was 
applied in a number of studies of familial CLL. In 2005, Sellick and colleagues, using 
115 CLL families found suggestive linkage at chromosome 11p11134. In an effort to 
increase the linkage detection power in their studies the two main groups studying 
familial CLL, one in the UK the other in the US, combined their familial resources for 
a SNP-based GWLS of 206 CLL families (155 CLL only and 51 families with CLL 
and other HMs), superseding all previous familial CLL GWLS123. Genome-wide 
significant linkage regions were detected on chromosome 5q23.2, 6p22.1, 11q12.1, 
18q21.1 and 2q21.1. A follow up study of a SNP nearby the chromosome 18q21.1 
region in 18q24 in 984 cases and 4831 controls did not replicate the association135. 
The 2q21.1 region was also followed up in a study that sequenced the CXCR4 gene in 
this region in 188 familial CLL cases and 213 controls. The study identified three 
CXCR4 germline mutations in CLL cases not present in controls, suggesting that rare 
CXCR4 mutations may contribute to CLL susceptibility124. Despite these potential 
regions of interest in familial CLL, a GWLS of a single large multigenerational CLL 
family using SNP arrays did not find new or confirm previous linkage regions136.  
 
1.5.3 Genome-wide association studies of HM disease susceptibility 
Even with the increase in resolution with SNP array technology, familial studies 
largely failed to find statistically significant evidence of linkage to loci associated 
with HM occurrence136. This may have been due to inadequate power from studies 
using only a few small families, or inadequate resolution with the small microsatellite 
marker numbers and the early lower resolution SNP arrays. With the increasing 
resolution of SNP-based arrays a new type of study emerged, the genome-wide 
association study (GWAS). A GWAS in concept is similar to a GWLS, looking for 
genetic variation more common across multiple cases than controls to implicate 
genomic regions in disease susceptibility. However a GWAS is fundamentally 
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different to a GWLS in that it’s design is population-based instead of family-based, 
requiring large numbers of cases and controls for adequate power and specifically 
targets common variation, SNPs, contributing to disease susceptibility. 
 
The first GWAS in HMs was conducted in a CLL cohort consisting of 517 CLL 
cases, 155 of whom had a family history of disease137. Initial associations identified 
were validated in two further cohorts identifying seven SNPs in six genomic regions 
associated with CLL risk. Associations were found with loci at 2p13, 2q37.1 (SP140), 
6p25.3 (IRF4), 11q24.1, 15q23 and 19q13.32 (PRKD2) with odds ratios ranging from 
1.39 to 1.46, providing the first evidence of low risk common variants predisposing to 
HMs. Since this first study, several other GWASs have been conducted, particularly 
in CLL but also other subtypes of HMs. Appendix 1.1 presents a summary of the loci 
identified to date associated with HMs, with significant associations and their odds 
ratios plotted on the radial axes of the Circos plot115 in Figure 1.5.  
 
1.5.3.1 CLL GWAS findings 
CLL has been the most frequently examined HM using the GWAS approach. As at 
October 2014 there are 42 reported CLL GWAS associations with odds ratios ranging 
from 1.18 to 1.64 (Table 1.5) with estimations that the known associations account for 
around 19% of the familial risk of CLL138. Most of these CLL associations are to 
SNPs in intergenic, intronic or regulatory regions with as yet unknown effect on 
function. A coding variant has been reported as associated with CLL located in 
MYNN with an odds ratio of 1.26 (Appendix 1.1)138, however the SNP has no clear 
functional effect on the MYNN gene.  
 
Many of the CLL GWASs have suggested, in one syntax or another, that as the 
associated loci are common variants within the Caucasian population they must 
therefore contribute significantly to the risk of developing CLL with those having 
more variants also having a corresponding greater risk. This logic seems flawed. Even 
though CLL accounts for a large portion of HMs in western countries it is still a 
relatively rare disease in the general population. It is likely, given their frequency in 
the population, that the common variants identified as associated with CLL have a 
very small influence on disease risk. Indeed GWASs as a whole have been 
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disappointing as there has been little clinical impact achieved as a result of the GWAS 
identified association signals. For CLL rigorous studies have yet to be conducted 
which demonstrate the clinical relevance of the 42 associated loci.  
 
It is likely that genes with germline variations identified as contributing to HM 
development will also be mutated somatically in HMs. Examining genes implicated 
by CLL GWAS loci in the 378 CLL cancer genomes contained within COSMIC 
reveals that genes at the CLL GWAS loci, with the exception of POT1 with 12 
samples (3.2%) containing mutations, are not recurrently somatically mutated in 
CLL108-110. It is however possible that these CLL GWAS loci, and those identified in 
future studies, may be used as variables in prediction models together with age, sex, 
ethnicity and family history of disease to determine the likelihood of an individual 
developing disease. Further studies are required to determine their clinical utility 
given that these are common mutations with small effect sizes that also occur in the 
general population.  
 
1.5.3.2 ALL GWAS findings 
Childhood ALL is another HM subtype that has been studied by many GWASs with 
42 associations identified as potential disease susceptibility sites (Appendix 1.1). 
Many of these sites show associations across multiple ethnicities. This is best 
demonstrated by a study conducted in a childhood onset ALL cohort containing 
European, African, Asian and Native American genetic ancestries139. This study 
validated previous European ethnicity-based findings of associations at IKZF1, 
PIP4K2A, ARID5B and CEBPE across multiple ethnicities139. Of the genes linked to 
ALL susceptibility by GWAS two genes, IKZF1 and CDKN2A, show evidence for 
recurrent somatic mutations in ALL in COSMIC108-110.  
 
Across all HM GWASs, studies of ALL have identified the largest odds ratio risks 
associated with disease, for example one SNP rs17079534 upstream of MYRIP has an 
OR of 4.07, however the biological significance of this association to ALL 
development has not been identified. 
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1.5.3.3 Criticism of HM GWAS findings 
The underlying basis of GWASs is the ‘common disease, common variant’ 
hypothesis, whereby common diseases are due in part to common variants present in 
> 5% of the general population140. By virtue of their design GWASs will identify 
common variants that individually or in combination confer an increased risk of 
disease140. They are not designed to detect all genetic variation contributing to disease 
and are significantly biased specifically to common variation. The associated loci for 
HMs account for little of the heritability of disease, indicating that there are other 
important heritable factors contributing to disease risk. This remaining unexplained 
heritability has been termed the ‘missing heritability’ of disease and is repeatedly 
described for many complex diseases140. It has been suggested that the ‘missing 
heritability’ of complex diseases such as HMs may include genetic factors that are not 
detectable by GWAS such as rare germline variants, structural variants, crosstalk 
between genes, epigenetic factors, or interactions between genes and environmental 
factors141.  
 
It has been suggested that GWAS variants that have been identified across multiple 
diseases actually represent synthetic associations, particularly as GWAS variants are 
generally in genomic regions with no functional indication such as intronic and 
intergenic regions. First proposed in 2010 a synthetic association is when a rare 
variant or variants, that are the actual genetic factors contributing to disease 
susceptibility and not detectable by GWASs, occur by chance more often with one 
allele at a SNP, or sets of SNPs, than another thus driving the association at this 
loci142. Until recently synthetic associations only existed theoretically and have been a 
source of debate in the field143. However a recent study in prostate cancer has found 
that for the HOXB locus at 17q21 there is a synthetic association detected through 
common GWAS variants. However this is caused by an underlying partially 
correlated rare coding variant in HOXB13; the first identified synthetic association in 
cancer144. This is early evidence that supports the idea that the common GWAS 
variants associated with disease susceptibility in other diseases, such as HMs, may be 
due to synthetic associations. This does not make the findings of GWAS irrelevant 
but instead indicates genetic studies with greater resolution, such as is afforded by 
next generation sequencing, are the next step to identifying disease susceptibilities. In 
line with this there has been a shift in the GWASs of HMs away from attributing 
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disease susceptibility and causation to associations with common variants137 towards 
using the results of GWASs to indicate genome localisations where the true 
susceptibility loci or candidate genes may be in close proximity145. 
 
1.5.4 Candidate gene approach to familial HMs 
Genome-wide approaches, such as GWLSs, are an unbiased approach to identify HM 
predisposition genes. An alternate approach is the candidate gene approach which is a 
biased approach focusing on genomic regions or genes that have evidence implicating 
their involvement in disease. The candidate gene approach has resulted in 
identification of several familial HM genes, as summarised in Table 1.6. Particularly 
interesting is the identification of mutations in the telomere biology genes TERT and 
TERC and the haematopoietic transcription factor GATA2 in familial MDS/AML.  
 
Table 1.6 Summary of findings from candidate gene approaches to familial HMs. 
 
HM Subtype Gene  Reference 
AML CEBPA 146 
MDS/AML TERT 147 
 TERC 147 
 GATA2 148 
CLL ARLTS1 149 
 miR-16-1 150 
 ATM 151 
T-cell NHL MSH2 152 
JMML CBL 153 
 
1.5.4.1 TERT and TERC mutations in familial MDS/AML 
Germline mutations in TERT, the gene encoding telomerase, and TERC, the gene 
encoding the RNA component of telomerase, have been identified in 4 families with 
multiple cases of MDS/AML147. Telomeres are hexameric nucleotide repeats found at 
the ends of chromosomes. They are several kilobases in length and have an important 
role in protecting chromosomal DNA from the end replication problem during DNA 
replication. Telomeres and mutations in telomerase-associated genes have also been 
implicated as a mechanism of disease anticipation in the bone marrow failure disorder 
dyskeratosis congenita154,155 and other diseases156,157. Further, patients with 
dyskeratosis congenita are at an increased risk of developing MDS/AML88 and 
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germline mutations in TERT had also been identified in sporadic cases of AML158 
thus prompting the investigation of TERT and TERC in familial MDS/AML. In the 
four families described by Kirwan and colleagues, two families have germline 
mutations in TERC and two families have germline mutations in TERT. Not all 
mutation carriers in these families are affected with MDS/AML and there seems to be 
some diversity in the disease status of those carrying the mutations including the 
occurrence of aplastic anaemia. Given this diversity and the occurrence of similar 
mutations in dyskeratosis congenita it is likely that mutations in TERT and TERC 
predispose to a range of diseases with a strong predisposition to the development of 
MDS/AML. The mutations to TERT and TERC alter the activity levels of the 
telomerase protein, which in turn reduces the maintenance of telomeres, providing an 
opportunity for aberrant chromosomal interactions to occur and malignancies to 
develop. Germline mutations in TERT and TERC have yet to be confirmed as a 
recurring feature of familial HMs, however Kirwan and colleagues show evidence 
supporting a role for telomere biology in the development of HMs that warrants 
further investigation. 
 
1.5.4.2 GATA2 mutations in familial MDS/AML 
Together with RUNX1120,121 and CEBPA146, germline mutations in GATA2 have been 
identified in affected individuals of families with MDS and AML148. By screening 50 
candidate genes for variants, Hahn and colleagues found 4 families with novel 
germline GATA2 variants. Three MDS/AML families were identified with the amino 
acid substitution Thr354Met and the fourth family consisting of a father-son pair, both 
affected by MDS, had a 3 base pair deletion in GATA2 resulting in the amino acid 
deletion Thr355del. All family members affected with AML or MDS had a variant in 
GATA2 but unaffected family members were also variant carriers. GATA2 variants 
were not detected in 35 other families with HMs or 695 normal controls in this study. 
GATA2 encodes a zinc-finger transcription factor located on chromosome 3. The two 
germline variants reported disrupt the zinc finger 2 domain of GATA2 resulting in a 
reduced ability for DNA binding and thus reduced transactivation ability on GATA2 
responsive enhancers148. GATA2 has been shown to have important roles in the 
myeloid cell pathway of haematopoiesis159 which aids in our understanding of how 
mutations in GATA2 contribute to myeloid malignancies including somatic mutations 
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in sporadic AML and CML160,161. The presence of GATA2 variants in unaffected 
relatives of patients with HMs suggests that it is a predisposing germline variant not 
sufficient for malignancy development. Additionally, germline GATA2 variants have 
also been identified in Emberger syndrome162, MonoMAC syndrome163 and an 
immunodeficiency syndrome characterised by a dendritic cell, monocyte, B and NK 
lymphoid deficiency164 each of which predisposes patients towards the development 
of MDS and myeloid leukaemias. GATA2 variants have been validated in other 
families with MDS/AML165 as well as MDS/AML families that exhibit multiple 
GATA2 related phenotypes including MonoMAC and primary lymphedema166. 
Identification of GATA2 as a gene involved in familial HMs has contributed 
significantly to the understanding of how HMs develop but is yet to reveal new 
therapeutic avenues for treatment of HMs. The finding of multiple disease phenotypes 
resulting from GATA2 variants has raised the possibility of a GATA2 syndrome with 
one of the main features being a predisposition to HMs, dependent upon other genetic 
factors167. An example of one of these other genetic factors are somatic variants in 
ASXL1 which are recurrently acquired in GATA2 mutation carriers, possibly 
contributing to HM development168.   
 
1.5.4.3 Bias in candidate gene studies 
In the context of familial cancers, including HMs, the use of candidate gene studies is 
inherently biased by a gene list selected by the investigators. Only mutations in genes 
in that list are considered, with varying degrees of evidence to support selection of 
those genes for study. Given that these studies screen for mutations in candidate genes 
in related cases it is not unreasonable to expect rare or even private mutations to occur 
by chance in at least one of the selected genes in the family. This means that results 
from biased approaches must be validated in multiple ways as they only provide the 
first indicative evidence that a gene is implicated in the familial risk of HMs. In the 
case of CEBPA, ATM, TERT/TERC, MSH2, CBL, and GATA2 there is evidence from 
somatic studies of HMs and other cancers as well as functional studies that support 
the role of these genes in HM development. However, for the HM families that these 
genes were identified in, an additional unbiased analysis of their genomes may 
identify multiple other variants that may be involved in the familial predisposition to 
HM development.  
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HMs, and cancer more broadly, are not single gene diseases. Mutations in multiple 
genes will contribute to the familial predisposition. The degree of uncertainty from 
candidate gene approaches, and the resolution challenges with genome-wide linkage 
and association approaches are clear indicators that identification of familial HM 
predisposition genes will require a new approach. The advent of next generation 
sequencing (NGS) technologies such as whole genome sequencing (WGS) and whole 
exome sequencing (WES) presents a new and unbiased approach to identifying cancer 
predisposition genes in familial HMs.  
 
1.5.5 HM predisposition as part of cancer predisposition syndromes  
Within a number of inherited cancer predisposition syndromes such as Li Fraumeni 
syndrome there is an increased risk of HM development169. HM families have been 
described carrying mutations in genes which are more typically implicated in a cancer 
predisposition syndrome (such as TP53 discussed in section 1.10.3.3) thus there is an 
overlap between the genes identified as causal in both HMs connected to a syndrome 
and familial HMs without a known underlying syndrome. Rahman111 has curated and 
reported a set of 114 cancer predisposition genes, many of which are associated with a 
cancer syndrome. Of the genes reported by Rahman, 19 have a HM as a major 
associated tumour type, as shown in Table 1.7. It is important to be aware of these 
syndrome associated HM genes as evidence suggests that the genes predisposing to 
HMs associated with cancer predisposition syndromes may also be implicated in non-
syndrome familial HMs, as has been seen for TERT/TERC147 and GATA2148.  
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Table 1.7 Cancer predisposition genes with HM as major associated subtype, 
adapted from Rahman111. 
 
Gene Syndrome/s 
HM subtypes as reported 
by Rahman 
ATM Ataxia-telangiectasia Lymphoid HMs, lymphoma 
BLM Bloom syndrome Lymphoma, ALL, myeloid 
HMs 
BRCA2 Hereditary breast-ovarian cancer syndrome and 
Fanconi anaemia (D1) 
Myeloid HMs 
BRIP1 Fanconi anaemia (J) Myeloid HMs 
BUB1B Mosaic variegated aneuploidy syndrome Myeloid HMs 
CBL Noonan syndrome JMML 
DKC1 Dyskeratosis congenita AML 
DOCK8 Hyper-immunoglobulin E syndrome Lymphoma 
ELANE Severe congenital neutropenia Leukaemia 
FANCA Fanconi anaemia (A) Myeloid HMs 
FANCC Fanconi anaemia (C) Myeloid HMs 
FANCG Fanconi anaemia (G) Myeloid HMs 
GATA2 Emberger MonoMAC syndrome Myeloid HMs 
GBA Gauchers type 1 Myeloma, myeloid HMs 
ITK Lymphoproliferative syndrome 1 Hodgkin lymphoma 
MLH1 MMR deficiency syndrome (biallelic mutations) 
Lynch syndrome / Hereditary non-polyposis colon 
cancer    (monoallelic mutations) 
HMs 
MSH2 MMR deficiency syndrome (biallelic mutations) 
Lynch syndrome / Hereditary non-polyposis colon 
cancer  (monoallelic mutations) 
HMs 
MSH6 MMR deficiency syndrome (biallelic mutations) 
Lynch syndrome / Hereditary non-polyposis colon 
cancer    (monoallelic mutations) 
HMs 
NBN Nijmegen breakage syndrome Lymphoma 
PALB2 Fanconi anaemia (N) Myeloid HMs 
PMS2 MMR deficiency syndrome (biallelic mutations) 
Lynch syndrome / Hereditary non-polyposis colon 
cancer    (monoallelic mutations) 
HMs 
PTPN11 Noonan syndrome JMML 
RMRP Cartilage-hair hypoplasia syndrome NHL, leukaemia 
RUNX1 Familial platelet disorder Myeloid HMs 
SBDS Schwachman-Diamond syndrome Myeloid HMs 
SH2D1A Lymphoproliferative disease Lymphoma 
STAT3 Hyper-immunoglobulin E syndrome Lymphoma 
TERT Dyskeratosis congenitia AML 
TNFRSF6 Autoimmune lymphoproliferative syndrome Lymphoma 
WAS Wiskott-Aldrich syndrome Lymphoma 
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1.6 Next generation sequencing in HMs 
Next generation sequencing (NGS) includes the technologies of whole genome 
sequencing (WGS), whole exome sequencing (WES) and RNA sequencing for whole-
transcriptome sequencing. NGS affords a significant advancement upon previous 
Sanger sequencing capabilities with regard to throughput, cost and applications. NGS 
has facilitated a number of new approaches to study familial diseases such as HMs. It 
is now possible to obtain full coverage of the genome for multiple affected and 
unaffected members of a HM family and use this information to identify inherited 
mutations that may be contributing to disease.  
 
Another NGS approach that has been applied to HM genetics is the paired tumour-
normal sequencing approach where the tumour genome and germline genome for an 
individual are both sequenced from appropriate source tissues. In HMs this is 
typically DNA from circulating blood malignant cells or solid-tumour biopsies for the 
tumour genome and DNA from a skin biopsy for the germline genome. The variants 
identified in the germline genome are filtered from the tumour genome leaving only 
somatic mutations. Both the familial study and ‘tumour-normal’ study approaches are 
revealing important new insights into the genetics of HMs and both have considerable 
potential to have a clinical impact on patient treatment and diagnosis. The primary 
focus of NGS in HMs to date has been to identify somatic mutations with much less 
focus given to germline mutations.  
 
1.6.1 Identifying recurrent somatic mutations in HMs using NGS 
The paired tumour-normal approach has been successful in revealing a number of 
recurrently mutated genes across specific HM subtypes with significant clinical 
impact and large potential for targeted disease treatment. Indeed the first WGS report 
of a human cancer was the tumour-normal sequencing of a single AML patient 
identifying ten genes with somatic mutations of which eight were previously 
undescribed in HMs170. Since this first report in 2008 many other HM subtypes have 
been studied using WGS or WES identifying a range of genes that are frequently 
mutated, with some common patterns between HM subtypes171, and even between 
HMs and other cancers172. What has become clear from this type of study is that the 
tumour profile for each HM diagnosed is unique but when large enough numbers of 
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tumours are sequenced mutation patterns are revealed with some subtype specific and 
cross-subtype recurring gene and pathway mutations. Table 1.8, adapted from171 
summarizes the major somatic mutation findings of WGS/WES studies in HMs. 
There are over 20 published genome and exome sequencing studies of somatic 
mutations in HMs. Contained within the whole genome section of the COSMIC is 
information for over 1003 HM tumour genomes in 19 different HM subtypes108-110. 
The most common recurring gene mutated is TP53 in 9% of genomes, followed by 
NPM1 in 5% of genomes108-110, with many more genes mutated in lower sample 
percentages. 
 
Table 1.8 Major findings from WGS/WES studies of HMs, adapted from Watson 
et al.171. 
 
HM 
subtype Method 
Sample 
size 
Highlighted or novel 
somatically mutated genes* References 
AML WGS 24 TP53, KRAS, SMAD4, MLL3, 
ROBO2, RNF43, PEG3, GNAS 
173 
 WGS 50 SMC3, SMC1A, STAG2, RAD21 174 
 WES 150 FLT3, NPM1, DNMT3A, IDH1, 
IDH2, TET2, RUNX1, TP53, 
NRAS, CEBPA, WT1, PTPN11, 
KIT, U2AF1*, KRAS, SMC1A, 
SMC3, PHF6, STAG2, RAD21, 
FAM5C, EZH2, HNRNPK 
174 
MDS WES 29 SF3B1*, SRSF2, U2AF1*, 
ZRSR2, SF3A1, PRPF40B, 
U2AF2, SF1 
175 
 WES 9 SF3B1* 176 
CLL WES 5 NOTCH1 177 
 WGS 4 NOTCH1, MYD88, XPO1, 
KLHL6 
178 
 WES / WGS 88 SF3B1* 179 
 WES 105 SF3B1* 180 
DLBCL WES 6 MLL2, CREBBP, EP300 181,182 
 WES / WGS 13 MLL2, MEF2B 183 
 WES 55 MEF2B, MLL2, BTG1, GNA13, 
ACTB, P2RY8, PCLO, 
TNFRSF14, BCL2 
184 
MM WES / WGS 38 DIS3, FAM46C, LRRK2, BRAF, 
IRF4, BTRC, CARD11, CYLD, 
IKBIP, IKBKB, MAP3K1, 
MAP3K14, RIPK4, TLR4, 
TNFRSF1A, TRAF3 
185 
*indicates that genes are mutated across multiple HMs. 
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1.6.2 Application of NGS to familial HMs and germline mutations 
Despite the repeated identification of a family history of disease as a risk factor for 
HMs and reports of individual families with multiple HM cases the NGS approach to 
identify germline susceptibilities has not been widely applied in HMs. Familial NGS 
studies involve the selection and sequencing of families with multiple related affected 
family members. Analysis then focuses on identifying shared mutations between 
related affected family members which are ideally not present in unaffected family 
members. In cancers such as HMs and other complex diseases, penetrance and 
susceptibility issues further complicate the study design. Not all mutation carriers 
develop a HM, nor will they develop HMs in the future.  
 
The primary benefit of conducting a familial HM study over a population-based one is 
that studying families increases the chance of detecting rare mutations contributing to 
disease186. In a population study of cases it is likely that each case has different 
genetic factors contributing to their disease development and for each rare 
susceptibility mutation there will be only one copy present in the population. In a 
family study cases have a shared genetic background, which increases the likelihood 
of finding multiple copies of the disease susceptibility mutations. These mutations 
may be extremely rare in the population with minor allele frequencies less than 1%, or 
private mutations present only in the study family.  
 
To date a small number of familial HM studies have used the NGS approach to 
identify susceptibility genes through exome sequencing in related cases and follow up 
in the rest of the family. This approach has identified six genes with germline 
mutations in specific HM subtypes as summarised in Table 1.9. Three of these genes, 
TP53187, SH2B3188 and PAX5189 were identified in familial ALL studies. While 
mutations in the remaining three genes, SRP72, NPAT and KMT2A, were identified in 
family studies of MDS190, nodular lymphocyte predominant Hodgkin lymphoma 
(NLPHL)191 and primary mediastinal large B-cell lymphoma (PMBCL)192 
respectively. Of particular interest is the PAX5 ALL study which identified the same 
mutation in both a Puerto Rican family and an African-American family189. The same 
gene has also been identified as mutated in an Ashkenazi Jewish family with ALL193, 
highlighting that mutations in a single gene can cause HMs across three different 
ethnicity groups. PAX5 is a transcription factor that has a key role in haematopoiesis, 
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specifically B-cell development, and has been shown to have diverse roles in 
malignancy development, as reviewed in194. It is known to be a recurrent acquired 
mutation in ALL108,109,195,196 and in these families it appears that loss or inactivation of 
the second copy of PAX5 is required for ALL to develop. The identification that an 
inherited PAX5 mutation contributes to ALL in these families means that unaffected 
mutation carriers can undergo regular cancer surveillance to detect the early onset of 
ALL. This means that ALL in PAX5 mutation carriers can be treated early and 
potentially with therapies specifically targeted at PAX5 related haematopoietic 
differentiation pathways. Additionally other families with clustering of ALL can be 
screened for mutations in PAX5 informing therapy options when mutations are 
identified, particularly in regards to selection of related bone marrow donors without 
the mutation as has occurred in another NGS study of familial ALL for TP53187.   
 
Table 1.9 Summary of findings from NGS approaches to familial HMs. 
 
HM Subtype Gene  Reference 
ALL TP53 187 
 SH2B3 188 
 PAX5 189 
MDS SRP72 190 
NLPHL NPAT 191 
PMBCL KMT2A 192 
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1.7 Family studies are most likely to identify HM genetic susceptibilities  
The genetic architecture of HM susceptibility has yet to be fully characterised. A 
range of different methods ranging from candidate gene studies, to GWAS and now, 
NGS, has identified several susceptibility genes. With the power and resolution 
provided by NGS, GWAS and candidate gene studies while potentially still 
informative have been superseded. As discussed, there are two very clear branches of 
previous work in the field of HM genetics using NGS. One branch has focused on 
studies of somatic or acquired cancer mutations while the second branch has focused 
on studies of germline or inherited cancer susceptibility mutations. In the context of 
familial studies somatic mutations in cancer are of secondary interest to the primary 
study goal of germline mutations. The focus of this dissertation is the latter but it must 
also be recognised that one can inform the other; germline genetic factors in familial 
HMs may recapitulate the somatic cancer mutations of HMs and vice versa. 
Ultimately the successful treatment of HMs will lie in a combined assessment of the 
patient’s germline genetic background, which could contain targetable factors driving 
tumour development, as well as an assessment of the complexity of their somatic 
tumour genome. Together these will provide the necessary information crucial for 
targeted genetic therapies and personalised medicine.  
 
Identification of germline susceptibility mutations in HM families will enhance our 
understanding of HM development by describing the early genetic factors that 
contribute to the progression to malignancy. This will indicate pathways that can be 
targeted early in disease development for effective treatment before malignancy and 
multi-clonality of disease is established. It will provide the opportunity to screen 
individuals, particularly those with a family history of disease, for susceptibility 
mutations. A positive screening result can then lead the individual into a cancer 
surveillance strategy to catch any development of HMs early, which depending upon 
the subtype may inform a targeted treatment regimen with an increase in positive 
treatment outcomes. Finally, for HM families, identification of germline mutations 
will provide opportunities for genetic counselling of HM risk and informed lifestyle 
choices.   
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It is also important to consider the risks associated with identifying new genetic 
susceptibilities underling predispositions to HMs, or indeed other types of cancer. 
While having significant research application and long-term clinical potential, there 
may be of no immediate clinical utility for families identified to carry the mutation/s. 
Indeed the identified germline mutations may be only one part of a larger genetic profile 
requiring multiple additional somatic genetic changes to occur for cancer to develop. 
Further, screening of unaffected relatives of familial HM cases in a genetic counselling 
context, when no preventative treatments are available, could unnecessarily increase 
anxiety and stress within the family. It has been suggested that population based cancer 
screening strategies are not resulting in the expected improved health outcomes from 
early disease detection. Evidence supporting this is derived from population-based 
screening studies conducted in ovarian cancer197 and breast cancer198. For those 
individuals with a known family history of cancer, the benefits of screening include 
both the management of anxiety arising in those concerned about a history of disease 
in their families, as well as the possible improved health outcomes from early cancer 
detection. Population screening and early detection of the onset of HMs is currently of 
limited clinical value, however there may be clinical relevance in families with an 
increased risk of disease. Encouragingly in other cancers, at least for carriers of 
mutations predisposing to Lynch syndrome (i.e. individuals with a family history of 
disease) there is a demonstrated benefit for decreasing colon cancer occurrence by using 
aspirin as a chemoprevention treatment199.  
 
The short-term benefits and risks of identifying HM predisposing mutations should not 
be overstated. Instead the focus of research in this area, after mutation identification, 
should be the potential long-term clinical benefits for identifying a recurring mutation, 
or mutated gene that affects multiple families, with demonstrable disease causality, for 
which targeted therapies can be generated. 
 
1.8 Hypothesis and aims of the study 
This study explores the area of the genetic susceptibility of HMs using HM families. 
To date, mutations in several genes have been identified that contribute to the genetic 
predisposition to HMs (Figure 1.6). Many of these genes are also somatically mutated 
in HM tumour genomes. Known genes account for only a small portion of the overall 
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inherited component of HMs leaving a significant gap in our understanding of the 
genetic basis of disease. Application of innovative NGS technologies presents an 
ideal opportunity to generate new findings in this area. To date, familial HM studies 
have generally focused on families with single subtypes of HMs while evidence 
shows that in relatives of HM patients there is an increased risk of multiple HM 
subtypes (see Table 1.4, Figure 1.5). Therefore this study hypothesises that: 
 
Studies of families with multiple HM subtypes will identify genetic factors 
contributing to disease predisposition.  
 
Two specific aims were developed to test this hypothesis:  
 
Aim 1: Explore the use of a NGS approach in the genetic analysis of familial HMs, 
using extended pedigrees from the Tasmanian population, to identify candidate 
variants that are likely to predispose to disease. The familial dataset used for this 
study, including pedigree structure and clinical information for families that were 
sequenced, is described in Chapter 2. Chapter 3 details the NGS assembly and variant 
calling pipeline developed and used, and describes the prioritisation strategies used to 
identify variants for the laboratory-based follow-up analyses in Chapter 4.  
 
Aim 2: Use data from a quantitative trait, telomere length, due to its relevance to 
cancer development, in variance components modelling to identify whether variation 
in telomere length as a trait is related to HM status in this resource. These analyses are 
described in Chapter 5. 
 
Chapter 6 draws together the findings of this dissertation linking them to the broader 
clinical sphere for HMs and makes recommendations as to the future use of 
susceptibility information in clinical practice for treatment of HMs.  
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Chapter 2 - The Tasmanian Familial Haematological 
Malignancies Study 
2.1 Background 
2.1.1 Genetic studies in Tasmania 
Tasmania is the island state of Australia and had a population of over 513,400 at 
September 2013200. Tasmanians are predominantly of Caucasian descent with an 
estimated 87% of Tasmanian residents born in Australia201, the highest of all 
Australian states and territories. In the 2011 Australian Census the top ancestries 
reported by Tasmanians were Australian (33.9% responders), English (33.7%), Irish 
(7.8%) and Scottish (6.7%)202.  
 
Indigenous people first inhabited Tasmania prior to European contact with an 
estimated population of 5000-10000. The British colonised Van Diemen’s Land, as 
Tasmania was then known, in 1803. Initially Tasmania was established as a penal 
colony, with a small number of free settlers and military personnel sent to develop an 
agricultural industry. Convict transportation to Tasmania ceased in 1853 with around 
75,000 convicts transported203. With Australian federation the colony of Tasmania 
became the state of Tasmania in 1901. Over this time the population grew to become 
a mixture of immigrating British free settlers and released convicts203.  
 
The result of this is that Tasmania is unusual in comparison to other states of 
Australia due to its largely homogenous population of residents with British ancestry. 
An estimated 65% can trace their heritage back to around 10000 founder families 
from the mid-19th century. This together with Tasmania’s historically low migrant 
rates created a closed population with little movement between Tasmania and the 
Australian mainland. Today, of course, immigration into and out of Tasmania is much 
higher but overall Tasmania still has the lowest migration rates in Australia201.   
 
The early history of the Tasmanian population, including convict transportation, free-
settler land ownership, and early British immigration, is well documented. This 
together with the establishment in 1838 of an Act requiring civil registration of all 
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births, deaths and marriages, means early generations of the Tasmanian population are 
very accessible for genealogical research. This facilitates the identification of large 
multigenerational families with many individuals from the current generations still 
living in Tasmania.  
 
Such genealogical potential has facilitated past and present familial genetics research 
programs in Tasmania. Indeed for a number of conditions a founder effect has been 
observed in specific Tasmanian families. An early prominent example of this includes 
a large Tasmanian family with Huntington’s disease. All Huntington’s disease in 
Tasmania can be traced back to a female immigrant who migrated to Tasmania in 
1843 with her husband and seven children204. Another example is the ‘Tasman 1’ 
multiple endocrine neoplasia (MEN1) family that can be traced back to a single 
English immigrant and his descendants, of which there were around 2000 in the 
original publication, with other independent MEN1 families identified in Tasmania205. 
Importantly, the genealogical knowledge of these families has allowed the tracing of 
disease inheritance through the generations.  
 
Huntington’s disease and multiple endocrine neoplasia are both examples of single-
gene ‘Mendelian’ diseases with mutations in the HTT and MEN1 genes respectively. 
Tasmania also has a history of familial studies of complex, multi-genic diseases such 
as prostate cancer206, primary open angled glaucoma207, and multiple sclerosis208. 
Another complex familial disease studied in Tasmania is haematological 
malignancies, on which this dissertation is based92,97,209-212. 
 
2.1.2 The Tasmanian Familial Haematological Malignancies Study 
The Tasmanian Familial Haematological Malignancies Study (TFHMS) is a 
collection of large Tasmanian families with multiple generations affected by a range 
of HMs. The TFHMS owes its origins to a population-based study of HMs in 
Tasmania conducted by the University of Tasmania and the Royal Hobart Hospital 
between 1972 and 1980209-211. The original study identified some occupational and 
demographic exposures as disease risk factors. For example farmers, miners and 
hairdressers as well as people who lived in rural areas were at a heightened risk of 
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disease. An additional finding was the clustering of disease in small family units 
which was at that time attributed to shared environmental factors209,211.  
 
Researchers involved in the earlier study, particularly the research assistant Jean 
Panton, observed that a number of the HM patients presenting for treatment were 
related and accordingly began to informally collect together large pedigrees with 
clusters of HM cases. In 2006 this resource became part of the Menzies Institute for 
Medical Research and formally became the Tasmanian Familial Haematological 
Malignancies Study. Using a genealogical database at the Menzies Institute for 
Medical Research the original 866 participants from the population-based study were 
linked to both current generations and disease records from the Tasmanian Cancer 
Registry, which has documented cases of HMs since 1978. A public recruitment 
campaign was conducted and many of the original study families as well as new 
families volunteered or were invited to join the TFHMS. Family members provided 
further information through questionnaires and personal interviews. The result is a 
statewide resource of multigenerational families with multiple cases of HMs as well 
as a collection of HM cases with no reported family history of disease. Historical 
information from clinical records, patient self-report and Jean Panton’s records, was 
available in some instances allowing data for deceased cases to be included.  
 
Previously the TFHMS resource has been used to identify whether particular subtypes 
of HMs cluster together in families92. Analyses showed that CLL cases in particular 
clustered together in families but did not cluster with other B-cell malignancies. 
Additionally evidence suggesting a shared genetic predisposition to both lymphoid, 
and myeloid malignancies, was found on the basis that families were not enriched 
solely for a single type of HM. Previous research using this resource also identified 
evidence for the genetic phenomenon of anticipation whereby the age of disease 
diagnosis is earlier with each subsequent affected generation in the family97. These 
findings strengthen the argument that in these families there is a genetic basis to HM 
occurrence.  
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2.1.3 Definition of affection status 
In this study HM cases are defined according to the 2008 World Health Organisation 
classification system for tumours of haematopoietic and lymphoid tissues24. Initial 
diagnoses were obtained from reports from the Tasmanian Cancer Registry. For cases 
predating the registry (pre-1978) diagnosis was obtained from family records, death 
certificates, or archived medical records and where possible diagnostic criteria were 
matched to current WHO guidelines. For more recent and living cases for whom we 
have DNA samples, diagnosis was confirmed where possible by review of patient 
medical records by clinical pathologists (Dr. Katherine Marsden and Dr. Elizabeth 
Tegg) and a clinical oncologist (Prof. Ray Lowenthal).   
 
2.2 Methods  
2.2.1 Ethics approval 
Ethics approval for this study was obtained from the Human Research Ethics 
Committee Tasmania Network and has been continuously in place since its inception 
in 2005 (HREC reference number H8551). This study was conducted in accordance 
with the Australian National Statement on Ethical Conduct in Human Research 2007 
(updated March 2014)213, and the Australian Code for the Responsible Conduct of 
Research214. Written informed consent was obtained from all study participants. 
 
2.2.2 The TFHMS Resource 
The TFHMS resource consists of 48 multigenerational families with diverse subtypes 
of HMs from whom we have obtained DNA samples, where possible, from HM cases 
and their unaffected relatives, predominantly first-degree relatives. We also have a 
collection of 84 non-familial HM cases that have no self-reported family history of 
disease and after extensive genealogical evaluation are not part of any known 
Tasmanian HM families. Table 2.1 summarises this resource. Families selected for 
intensive analysis in this dissertation include LK0051, LK0139, LK0124, LK0153 
and LK2042 as indicated in Table 2.1. 
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Table 2.1 Summary of TFHMS Families. 
 
Family 
Known HM 
cases 
Generations 
with HM 
cases 
HM Cases 
with DNA 
Unaffected relatives 
with DNA 
LK0001 14 4 4 18 
LK0002 15 3 2 12 
LK0004 7 2 3 11 
LK0016 18 5 10 31 
LK0024 3 2 1 0 
LK0026 6 2 1 6 
LK0040 7 4 2 2 
LK0051* 21 5 9 29 
LK0054 9 3 0 4 
LK0065 8 2 1 8 
LK0124* 24 5 13 40 
LK0132 5 2 0 8 
LK0139* 7 2 2 2 
LK0153* 9 2 4 8 
LK0511 2 2 1 0 
LK0512 2 1 1 0 
LK0537 2 1 2 0 
LK0546 2 2 1 0 
LK0560 2 2 1 0 
LK0561 2 2 1 0 
LK0580 2 2 2 0 
LK0600 5 3 3 2 
LK0625 4 2 2 1 
LK0647 2 2 1 0 
LK0672 3 3 1 0 
LK0710 3 2 0 1 
LK0823 2 1 2 0 
LK0836 6 3 2 6 
LK1155 2 1 1 3 
LK2042* 32 5 15 48 
LK2447 3 2 1 2 
LK6000 6 2 3 0 
LK7739 2 1 1 0 
LK7740 2 2 2 0 
LK7743 3 2 2 0 
LK7744 2 2 0 1 
LK7748 2 2 1 0 
LK7749 3 2 1 0 
LK7750 4 2 2 0 
LK7751 9 3 1 0 
LK7754 3 1 1 0 
LK7755 2 2 2 2 
LK7756 2 1 1 1 
LK7766 2 2 1 0 
LK7768 2 1 1 0 
LK7772 4 2 1 0 
LK7773 2 1 2 0 
Total  - - 112 246 
Non-familial cases - - 84 1 
 
*Indicates families selected for analysis by NGS in this dissertation  
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2.2.3 Population controls  
Tasmanian population controls used in this study were recruited randomly from the 
Tasmanian electoral role (n = 758), through the Tasmanian Study of Cognition and 
Gait (TASCOG) study (HREC reference number H9785)215 and from population 
controls in the prostate cancer familial (HREC reference number H6914) and case-
control (HREC reference number H7740) studies206. Table 2.2 summarises the 
characteristics of this population control set. In this study, different subsets of the 
population controls were used depending upon the analysis conducted.  
 
Table 2.2 Summary of population controls. 
 
Control Group Number Mean age (range) % Male 
TASCOG 393 73.2 (61.4 - 87.9) 57.5% 
Case-control 
prostate cancer 
study controls 
232 61.0 (45.1 - 71.3) 100% 
Familial prostate 
cancer  controls 
133 61.9 (30.7 - 80.9) 90.2% 
All 758 67.5 (30.7 - 87.9) 76.3% 
 
2.2.4 Genetic material 
For participants in the TFHMS genetic material for DNA was obtained primarily from 
peripheral blood samples but also from saliva samples using Oragene collection kits. 
Similarly for the population controls, DNA was obtained from peripheral blood 
samples.  
 
HM patients who received an allogeneic bone marrow transplant prior to recruitment 
into the study or HM patients who may have circulating tumour cells within the 
sample obtained were noted. For these patients an Oragene saliva DNA sample was 
obtained, where possible, as an alternative, recognising that saliva DNA is known to 
be a mixture of both epithelial and white blood cells.  
 
DNA from peripheral blood samples was extracted using Nucleon BACC3 Genomic 
DNA Extraction Kits (GE Healthcare Life Sciences) according to standard kit 
protocols. The Nucleon BACC3 system is a resin-based method of DNA extraction. 
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Saliva samples for DNA collected using Oragene 2 mL collection kits (DNA 
Genotek) were extracted according to standard kit protocols.  
 
2.2.5 HM patient clinical information 
Clinical Pathologist Dr Katherine Marsden and Clinical Oncologist Prof. Ray 
Lowenthal conducted a detailed clinical review of available medical records for HM 
cases in the TFHMS. Where available, clinical information included details of patient 
treatment and disease course, pathology reports and clinical notes. This meant that 
confirmation of HM diagnosis was possible and facilitated an assessment of whether 
patients had circulating disease at the time of blood sample collection.  
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2.3 Description of TFHMS extended pedigrees used in this study 
2.3.1 Section overview 
This section describes the TFHMS extended pedigrees and describes the available 
clinical information for those cases selected in these families for whole genome 
sequencing or whole exome sequencing. Each family is accompanied by a pedigree 
figure containing only the relevant parts of the family. From 1978 onwards, 
confirmation of case status is available for all participants. The disease status for 
earlier generations is generally unknown unless this information was obtained from 
clinical records and these individuals have been marked as unaffected in pedigree 
diagrams. Figure 2.1 describes the generic symbol representations used across the 
family pedigree drawings with pedigree specific information described on the relevant 
figures.  
 
 
Figure 2.1 Generic pedigree symbol key explaining the symbols used throughout 
pedigree figures. 
?"
Consanguineous union!
Male!
Female!
Deceased!
Twins, zygosity unknown!
+"+"
DNA sample available!
Unrelated union!
Indicates repeated instances of same 
individual in pedigree, as a result of 
consanguineous relationship!
A! A!
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2.3.2 Family LK0051 
LK0051 (shown in Figure 2.2) is a family affected by HMs in five generations. 
Nineteen HM cases have been identified along with one other cancer. There are seven 
different HM case subtypes in this family. Members of this family were ascertained 
from the original 1970s study209-211. Five people in this family were sequenced 
including three WGS cases and two WES unaffected relatives, as shown in Table 2.3 
and Figure 2.2. 
 
Table 2.3 Characteristics of sequenced family members in LK0051. 
 
Sample ID HM Diagnosis Sex 
Age at 
diagnosis 
Age at 
sample 
collection 
Sample 
types 
available* 
Sample 
type 
for 
NGS 
Evidence of 
circulating 
disease in 
sample 
WGS 
or 
WES 
LK0051-001 T-cell NHL M 30 40 PB / O PB No WGS 
LK0051-007 Unaffected F -- 46 PB PB -- WES 
LK0051-128 BL M 6 13 PB PB No WGS 
LK0051-159 DLBCL F 58 69 PB / O PB No WGS 
LK0051-165 Unaffected M -- 65 PB PB -- WES 
 
* PB = genetic sample available from peripheral blood, O = genetic sample available 
from saliva collected in an Oragene kit.  
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Figure 2.2 Extended pedigree of TFHMS family LK0051.  
For the current study three HM cases were genome sequenced (LK0051-001, LK0051-128 and LK0051-159) and two unaffected relatives were exome sequenced, one as an informative control (LK0051-165) and the 
other as an obligate carrier (LK0051-007). Two of the genome sequenced cases (LK0051-001 and LK0051-128) have an avuncular relationship, connected by their mother/sister (LK0051-007). The remaining genome 
sequenced case (LK0051-159) and her unaffected exome sequenced brother (LK0051-165) are distant relatives to this trio, separated by nine meioses. Diagnosis abbreviations: AML = acute myeloid leukaemia, BL = 
Burkitt lymphoma, CML = chronic myeloid leukaemia, DLBCL = diffuse large B-cell lymphoma, HL = Hodgkin lymphoma, MM = multiple myeloma, MPN = myeloproliferative neoplasm, NHL = non-Hodgkin 
lymphoma, N/A = specific diagnosis unavailable. 
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2.3.3 Family LK0124 
LK0124 (shown in Figure 2.3) is a large HM family with five generations affected by 
HMs. Members of this family were ascertained from the original 1970s study209-211. A 
total of 24 cases with several different subtypes of HMs occur in this family. This 
family has five consanguineous loops as a result of five cousin-cousin marriages. An 
unusual feature of this family, noted by haematologist Dr. Elizabeth Tegg, is that 
there are seven known cases of DLBCL including multiple atypical site presentations 
such CNS presentations in LK0124-179 (spinal presentation) and LK0124-187 (brain 
presentation). Three HM cases were genome sequenced in this family, as shown in 
Table 2.4 and Figure 2.3.  
 
Table 2.4 Characteristics of sequenced family members in LK0124. 
 
Sample ID HM Diagnosis Sex 
Age at 
diagnosis 
Age at 
sample 
collection 
Sample 
types 
available* 
Sample 
type 
for 
NGS 
Evidence of 
circulating 
disease in 
sample 
WGS 
or 
WES 
LK0124-117 AML M 24 36 PB / O PB No WGS 
LK0124-179 DLBCL (CNS) M 84 87 PB PB No WGS 
LK0124-202 APML M 30 35 PB / O PB No WGS 
 
* PB = genetic sample available from peripheral blood, O = genetic sample available 
from saliva collected in an Oragene kit. 
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Figure 2.3 Extended pedigree of TFHMS family LK0124.  
The focus in this family for the current study has been on three HM cases, LK0124-117, LK0124-202 and LK0124-179. These three cases are distant cousins. All were genome sequenced. Diagnosis abbreviations: 
APML = acute promyelocytic leukaemia, AML =  acute myeloid leukaemia, CLL = chronic lymphocytic leukaemia, DLBCL = diffuse large B-cell lymphoma, HL = Hodgkin lymphoma, MM = multiple myeloma, 
ML* = myeloid leukaemia specific subtype unspecified, MPD* = myeloproliferative disease specific subtype unspecified, NHL = non-Hodgkin lymphoma. 
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2.3.4 Family LK0139 
LK0139 (shown in Figure 2.4) comprises a small family with two generations 
affected by HMs including an affected father-daughter pair, LK0139-001 and 
LK0139-005, both of whom have plasma cell disorders. A sibling (LK0139-003) of 
LK0139-005 was diagnosed with cervical cancer. Nieces of LK0139-001 are reported 
to have a HM and a brain tumour respectively. As shown in Table 2.5 and Figure 2.4 
the father-daughter affected HM pair were genome sequenced and an unaffected 
daughter exome sequenced in this family. 
 
Table 2.5 Characteristics of sequenced family members in LK0139. 
 
Sample ID HM Diagnosis Sex 
Age at 
diagnosis 
Age at 
sample 
collection 
Sample 
types 
available* 
Sample 
type 
for 
NGS 
Evidence of 
circulating 
disease in 
sample 
WGS 
or 
WES 
LK0139-001 PCT M 57 81 PB PB No WGS 
LK0139-004 Unaffected F -- 58 PB PB  WES 
LK0139-005 MM F 52 53 PB / O PB No WGS 
 
* PB = genetic sample available from peripheral blood, O = genetic sample available 
from saliva collected in an Oragene kit.  
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Figure 2.4 Extended pedigree of TFHMS family LK0139 
For the current study both LK0139-001 and LK0139-005 were genome sequenced and LK0139-001’s third unaffected daughter, LK0139-004, 
was exome sequenced as an informative control. Diagnosis abbreviations: ALL = acute lymphoblastic leukaemia, MM = multiple myeloma, 
NHL = non-Hodgkin lymphoma, N/A = diagnosis unavailable, PCT = plasmacytoma. 
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2.3.5 Family LK0153 
LK0153 (shown in Figure 2.5) is a large TFHMS family that was ascertained from the 
original 1970s study209-211. There are ten HM cases across two generations with 
several different HM subtypes occurring including siblings, LK0153-003 and 
LK0153-004, who had mucosa-associated lymphoid tissue lymphoma (MALT 
lymphoma) and Waldenström macroglobulinemia (WM) respectively. As shown in 
Table 2.6 and Figure 2.5 the affected sibling pair and their father were genome 
sequenced. A separate but informative branch of the family without evidence of HM 
occurrence, were genome and exome sequenced as per Table 2.6 and Figure 2.5.  
 
Table 2.6 Characteristics of sequenced family members in LK0153. 
 
Sample ID HM Diagnosis Sex 
Age at 
diagnosis 
Age at 
sample 
collection 
Sample 
types 
available* 
Sample 
type 
for 
NGS 
Evidence of 
circulating 
disease in 
sample 
WGS 
or 
WES 
LK0153-003 MALT F 58 63 PB PB No WGS 
LK0153-004 WM / MDS / AML M 55 61 PB / O PB Yes WGS 
LK0153-029 Unaffected M -- 85 PB PB -- WGS 
LK0153-086 Unaffected M -- 70 PB PB -- WGS 
LK0153-078 Unaffected M -- 78 PB PB -- WGS 
LK0153-079 Unaffected F -- 73 PB PB -- WES 
LK0153-084 Unaffected M -- 46 PB PB -- WES 
LK0153-080 Unaffected M -- 49 PB PB -- WGS 
 
* PB = genetic sample available from peripheral blood, O = genetic sample available 
from saliva collected in an Oragene kit.  
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Figure 2.3 Extended pedigree of TFHMS family LK0124.  
The focus in this family for the current study has been on three HM cases, LK0124-117, LK0124-202 and LK0124-179. These three cases are distant cousins. All were genome sequenced. Diagnosis abbreviations: 
APML = acute promyelocytic leukaemia, AML =  acute myeloid leukaemia, CLL = chronic lymphocytic leukaemia, DLBCL = diffuse large B-cell lymphoma, HL = Hodgkin lymphoma, MM = multiple myeloma, 
ML* = myeloid leukaemia specific subtype unspecified, MPD* = myeloproliferative disease specific subtype unspecified, NHL = non-Hodgkin lymphoma. 
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2.3.6 Family LK2042 
LK2042 (shown in Figure 2.6) is one of the largest HM families in the TFHMS. 
Members of this family were not ascertained from the original 1970s study. This 
family has five known generations affected by HMs totalling 33 cases with several 
different subtypes dispersed across the family. Additionally this family contains three 
consanguineous loops as a result of three cousin-cousin marriages, two of which were 
between first cousin pairs in the late 1800s and early 1900s. As shown in Table 2.7 
and Figure 2.6 across this family six HM case were genome sequenced and two were 
exome sequenced. One unaffected relative was genome sequenced and three were 
exome sequenced.  
 
Table 2.7 Characteristics of sequenced family members in LK2042. 
 
Sample ID HM Diagnosis Sex 
Age at 
diagnosis 
Age at 
sample 
collection 
Sample 
types 
available* 
Sample 
type 
for 
NGS 
Evidence of 
circulating 
disease in 
sample 
WGS 
or 
WES 
LK2042-003 T-cell ALL M 7 26 PB / O PB No WGS 
LK2042-005 B-cell ALL M 2 26 O O No WES 
LK2042-006 HL M 29 37 PB / O PB No WGS 
LK2042-018 Unaffected F -- 67 PB PB -- WGS 
LK2042-231 DLBCL M 58 66 PB PB No WGS 
LK2042-232 Unaffected F -- 63 PB PB -- WES 
LK2042-257 HL M 66 67 PB / O PB No WGS 
LK2042-258 Unaffected M -- 69 PB PB -- WES 
LK2042-259 Unaffected M -- 63 PB PB -- WES 
LK2042-281 MCL M 73 75 PB / O PB No WGS 
LK2042-290 ET F 52 59 PB / O PB Unknown WGS 
LK2042-300 HL M 61 64 PB / O PB No WES 
 
* PB = genetic sample available from peripheral blood, O = genetic sample available 
from saliva collected in an Oragene kit.  
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Figure 2.6 Extended pedigree of TFHMS family LK2042.  
The focus in this family for the current study has been on eight HM cases, seven of which are still living, and four unaffected relatives who were selected as informative controls. The HM cases that were genome 
sequenced are LK2042-003, LK2042-006, LK2042-231, LK2042-257, LK2042-281 and LK2042-290. Two HM cases were exome sequenced, LK2042-005 and LK2042-300. Two unaffected siblings of LK2042-257, 
LK2042-258 and LK2042-259, and an unaffected sibling of LK2042-231, LK2042-232, were exome sequenced as informative controls. LK2042-018 who is the daughter of a HM case and the grandmother of another 
HM case was genome sequenced as a suspected obligate carrier. Diagnosis abbreviations: ALL = acute lymphoblastic leukaemia, BL = Burkitt lymphoma, CLL = chronic lymphocytic leukaemia, CML = chronic 
myeloid leukaemia, DLBCL = diffuse large B-cell lymphoma, ET = essential thrombocythaemia, HL = Hodgkin lymphoma, MCL = mantle cell lymphoma, MDS = myelodysplastic syndrome, MM = multiple 
myeloma, MPN = myeloproliferative neoplasm, NHL = non-Hodgkin lymphoma, ML* = myeloid leukaemia specific subtype unspecified, PV = polycythaemia vera. 
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2.4 Discussion 
A comprehensive clinical review was conducted for all TFHMS HM cases. As HMs 
can present as a circulating tumour or a solid tumour-based malignancy, depending 
upon the subtype, clinical review permitted the identification of those with circulating 
tumour cells. It is likely that genomes extracted from samples largely comprising 
malignant cells will contain somatically acquired variations that would impact on the 
ability to identify true germline variants. However, the possibility that there are a 
significant population of circulating HM disease cells within collected samples is less 
important in light of this study’s approach of identifying shared predisposing genetic 
variants. Finding shared genetic variants between multiple related HM cases provides 
support that these variants are germline and not somatically acquired. 
 
Nevertheless, for sixteen of the eighteen sequenced cases it is unlikely that the 
collected blood samples contained a significant population of malignant cells. For the 
remaining two individuals the sample collected from LK2042-290 does contain 
circulating disease cells as a feature of her indolent HM subtype (essential 
thrombocythaemia) and for LK0153-004 it cannot be confirmed to the same level as 
other individuals whether malignant cells are present or not in the sample obtained.  
 
This chapter also detailed the pedigree structures of the study families. The sequenced 
cases and unaffected relatives from these five TFHMS families were selected to 
permit a number of different analysis strategies aimed at identifying shared variants 
predisposing to HMs. This is inline with the study hypothesis, as discussed in Chapter 
1, that familial cases will be enriched for shared variants predisposing them to HMs. 
The caveat of predisposition is that unaffected relatives may also carry these variants 
without developing disease. Reduced penetrance of complex diseases such as HMs 
must be taken into consideration, as not all mutation carriers will develop disease216.   
 
It is important to note that the TFHMS families studied here are multigenerational 
Tasmanian families that can be genealogically traced back to the approximately 
10000 Tasmanian founder families as discussed in section 2.1.1. As has been seen in 
other known founder populations, such as Finland, there can be a high frequency of 
rare and/or novel variation present within the general population, due to the 
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bottleneck effect several generations earlier when the population began from a smaller 
number of individuals or due to limited regional population movements217. When the 
frequency of genetic variants identified in these populations is compared to broader 
population resources such as the 1000 genomes project, the presence of variants that 
occur at low frequencies in broader resource (i.e. are rare) are seen at higher 
frequencies in the founder population (i.e. are common). The more frequent 
occurrence of such rare variants in founder population necessitates an analysis design 
that utilises founder population matched controls. The historically documented 
population bottle necks in Tasmania are not as pronounced as other isolated 
populations such as Finland217, so while the ‘common rare variant’ issue is an 
important consideration it should not be a major confounder in this study. 
 
In comparison to other published familial HM studies the TFHMS has similarities to 
but also important differences to other resources. Recent publications that have used 
NGS in HM families have concentrated on using families with single related subtypes 
of HMs to identify susceptibility variants, for example GATA2 variants in familial 
MDS/AML148 and PAX5 variants in familial ALL189. Instead, the TFHMS families 
have multiple subtypes of disease, such as in family LK0051 where a T-cell and two 
differing B-cell HMs were genome sequenced, or in the LK0153 family where two 
different B-cell malignancy subtypes were genome sequenced. These families provide 
opportunities to question whether there is a common genetic predisposition to 
multiple subtypes. Similar to other familial HM studies, TFHMS families include 
examples of first-degree relative case pairs, such as in families LK0153 and LK0139, 
however the extensive genealogical research conducted using this resource and the 
benefit of using an isolated population has allowed identification of larger HM 
affected families, such as in families LK0124 and LK2042. NGS of large HM 
families with cases more genealogically distant than first or second cousins have not 
been reported, whereas here three of the five families studied have more distant 
affected relatives. This provides a novel opportunity to identify predisposing genetic 
variants shared between distant relatives. 
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Chapter 3 - Genome and exome sequencing, variant 
identification and prioritisation 
3.1 Introduction 
Since the development of NGS, an area of ongoing change has been the 
bioinformatics techniques used for sequence alignment to the reference genome and 
subsequent identification and analysis of sequence variation. A recent report 
comparing five different alignment and variant calling pipelines showed low 
concordance between pipelines for single nucleotide variant (SNV) and insertion / 
deletion (indel) variant identification218. It is apparent from this study that the use of 
an established bioinformatics pipeline for alignment and variant identification is 
crucial. With several comparable options available, this dissertation has used, 
primarily for speed and computing RAM requirements219, the Burrows-Wheeler 
alignment (BWA) method220, with additional post alignment processing using the 
Genome Analysis Tool Kit (GATK)221. SAMtools222 was chosen for SNV and indel 
identification because of the ability to identify variants across multiple samples 
simultaneously.  
 
A strength of this project lies in the family-based study design providing the ability to 
construct sharing-based analyses within families to identify variants segregating with 
disease. However studying a disease by NGS in related individuals will identify many 
shared variants by virtue of kinship that are not related to the disease. Accordingly a 
methodology to identify the variants that are most likely to contribute to disease 
susceptibility in affected individuals must be established. As it is not yet feasible to 
examine or validate the occurrence of hundreds of likely susceptibility variants, a 
prioritisation strategy must be used to reduce and focus analyses on a specific variant 
set. In this study variant analysis to prioritise those likely to be contributing to disease 
was conducted using two approaches. One approach applied was a probabilistic 
approach using statistical prediction algorithms to prioritise the most likely candidate 
variants contributing to disease. The primary approach used however, was a heuristic 
approach using manual filtering of annotated variants with a series of targeted 
assumptions to narrow down variants to a small number for further follow-up.  
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An example of a probabilistic tool is pVAAST223 (developed by the Huff Lab at the 
MD Anderson Cancer Center), a variant prioritisation tool that builds upon 
VAAST224,225 (from the Yandell Lab at the University of Utah), the probabilistic 
disease gene finder tool. By incorporating pedigree information pVAAST conducts a 
linkage-based analysis, together with VAAST’s rare variant association test, 
searching for rare, functional variants inherited in the family that could be 
contributing to disease. pVAAST was chosen because it is able to identify disease 
causing variants in family-based studies of conditions that have recessive or dominant 
inheritance patterns as well as being able to handle challenges such as incomplete 
penetrance and locus heterogeneity223. Such an unbiased approach is very favourable 
when analysing a complex disease. Here the use of pVAAST was explored in an 
analysis of the LK0051 family. 
 
One widely used tool for facilitating heuristic-based variant filtering is 
ANNOVAR226, originally designed by Dr Kai Wang. A heuristic-based strategy for 
variant prioritisation requires development of specific analysis hypotheses. An 
example would be to identify variants shared between all cases in the family but not 
present in related controls. Such hypotheses then rely on the annotation of variants 
from the wealth of publically available data such as population frequencies from large 
NGS consortia projects, predictions of variant effect and locations of the variant 
within potentially functional genomic regions. Then, based on the specific hypothesis 
the annotated variants are filtered and reduced to a smaller set of variants. 
ANNOVAR facilitates this annotation and filtering, forming the foundations of the 
tiered prioritisation strategy that was used in this project to identify variants likely to 
contribute to disease in the five families sequenced.  
 
Once a filtered set of variants, conforming to the specific hypothesis, has been 
identified the analyses can move from a variant-based to a gene-based approach. 
Gene-based analyses are directed at prioritising variants based upon what is known 
about the gene in which the identified deleterious variant occurs. This information can 
include gene expression profiles in normal tissues or cancer cells, known literature 
interactions with other molecules, as well as the known function of the gene and its 
potential to have a biological relationship with HM disease when that function is 
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altered. The gene-based analyses presented here have relied specifically on two 
complementary tools: the publically accessible Phevor227 (from the Yandell Lab at the 
University of Utah), which is a phenotype driven ontology-based gene ranking tool; 
and a commercial tool, QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity), which is a tool that builds interaction 
networks between molecules based on a curated literature database of interactions.  
 
Specifically, Phevor uses a set of defined phenotype terms related to the disease of 
interest to combine outputs from multiple biomedical ontologies including the Human 
Phenotype Ontology, the Mammalian Phenotype Ontology, the Disease Ontology and 
the Gene Ontology227. Phevor connects these outputs together, creating a framework 
built around the defined phenotype. The queried gene list is then reprioritised in light 
of this knowledge, the gene’s connections into the ontologies and the corresponding 
phenotype defined. Complementary to this is QIAGEN’s IPA®, which is a 
commercial resource of curated literature-based molecular interactions. Using IPA® 
the queried gene list can be searched for direct molecule-to-molecule interactions 
within and between other lists of known HM related genes. Using Phevor and IPA® to 
connect genes with deleterious variants identified in the prioritisation analysis to 
genes known to be involved in HM development, or to the HM phenotype, increases 
the evidence implicating the identified variants in disease development.  
 
The final stage of a heuristic-based analysis of variants is to assess the variants more 
closely to predict their direct effects on gene function, at the transcript or protein 
level, to identify those most likely to contribute to HM development.  
 
3.2 Aims 
The objective of these analyses was to establish a method for identifying 
susceptibility variants in the five TFHMS families examined employing either a 
probabilistic or heuristic approach.  
 
A probabilistic strategy, using pVAAST223, was trialled using the sequence data in 
family LK0051. However, this was found to have a number of limitations in 
application to this data, so instead, a heuristic-based filtering approach with a tiered 
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family-by-family strategy was used. This approach, initially based at the variant level, 
focuses on variants that are likely to be deleterious and in gene regions where in silico 
tools can be used to predict the variant effect. Then the approach moves to the gene 
level. At the gene level prioritisation is based on the known biology of the gene, its 
expression patterns, protein functions and interactions. Variants in genes that have a 
biological indication that if functionally disrupted could contribute to HM 
development are prioritised for further analysis. An additional analysis for each 
family was to examine non-shared variants specific to each HM case.  
 
3.3 Methods 
3.3.1 Generating the WGS and WES data 
Due to the availability of resources and the schedule of grant funding, WGS and WES 
were performed over a four-year period. All samples were sequenced on the Illumina 
platform.  
 
Prior to sequencing, the selected DNA samples were quantitated using the Qubit 2.0 
fluorometer system with both broad range and high sensitivity kits where required, 
according to the manufacturer’s protocols. Purity was determined by measurement on 
the NanoDrop 1000 using the A260/280 ratio. Samples with purity outside a 1.7 - 1.9 
range were processed by phenol chloroform extraction and ethanol precipitation 
(Appendix 3.1) prior to NGS analysis. DNA for NGS analysis was also visually 
examined by agarose gel electrophoresis to assess for sample degradation. 
 
For WGS 3 - 5 µg of DNA (100µL at 30 - 50 ng/µL) with A260/280 ratio in range 1.7 - 
1.9 was used for 100 bp paired end genome sequencing to a mean coverage of 30× or 
greater. For WES 30 ng of DNA (20 µL at 1.5 ng/µL) with A260/280 ratio in range 1.7 - 
1.9 was sequenced in-house using the Nextera Exome Enrichment System and the 
Illumina TruSeq paired-end cluster kit v2 for 100 bp paired end exome sequencing to 
a mean coverage of 30× or greater. 
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3.3.2 Genome and exome sequencing alignment 
An analysis pipeline, outlined in Figure 3.1, was established for consistent alignment 
and variant calling of the genomes and exomes on the 8000 processor compute cluster 
MEDUSA housed at Texas Biomedical Research Institute, San Antonio, Texas, USA 
with the assistance of their lead NGS bioinformatician Mr Juan Peralta.  
 
WGS data was obtained from Illumina in BAM file format. Each BAM file was 
converted to FASTQ format to obtain de-multiplexed paired end sequencing reads of 
100 bp in length. For WES data, bases were called from HiSeq 2500 raw intensity 
files using Illumina’s CASAVA 1.8+ suite228 and emitted in FASTQ format of 100 bp 
paired-end sequencing reads.  
 
A custom mapping pipeline built with GNU Make229 was applied to both genomes 
and exomes, as shown in Figure 3.1. Use of GNU Make facilitates the scaling of 
analysis pipelines from one to multiple samples, using one to thousands of processors 
on the MEDUSA compute cluster. To facilitate parallelisation across the cluster 
FASTQ files were split into fragments containing 4,000,000 sequencing reads. Reads 
were aligned to the hg19 (GRCh37, February 2009) version of the human reference 
genome using BWA (v0.6.1)220. BWA was chosen over other aligners primarily for its 
speed. Fragmenting the alignment into smaller tasks results in many tasks with fewer 
reads to align, leading to shorter overall run times instead of a few tasks with many 
reads to align and longer run times. Aligned reads were then processed with a custom 
awk script (by Mr. Juan Peralta, Appendix 3.2) to ensure consistency of the mapped 
metadata and compliance with the SAM/BAM standard. The resulting alignments 
were converted to BAM format using SAMtools222. BAM fragments were merged and 
pooled on a per sample basis and SAMtools (v0.1.18)222was used to mark likely PCR 
duplicates. The IndelRealigner method from GATK (v1.6)221 was used for 
realignment around indels and GATK’s BaseRecalibration method was used for base 
quality score recalibration. This generated realigned, recalibrated and sorted BAM 
files for each genome and exome. 
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Figure 3.1 Pipeline schematic for WGS and WES alignment to hg19 reference 
genome. 
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3.3.3 WGS and WES quality assessment 
For quality assessment the final aligned genome BAM files were assessed using 
FASTQC (v0.10.0)230 and additionally for exomes, Qualimap (v2.0)231. Mean WGS 
coverage was calculated using SAMtools idxstats (v0.1.18)222 and mean WES 
coverage depth was calculated using Qualimap (v2.0)231. Plots of genome and exome 
coverage were calculated using BEDTools genomeCoverageBed (v2.17.0)232 and 
plotted using R (v3.1.0)233.  
 
Exomes were assessed in all instances using the relevant TruSeq Exome Enrichment 
Kit targeted regions from Illumina from: 
http://support.illumina.com/downloads/truseq_exome_targeted_regions_bed_file.html  
 
3.3.4 Single nucleotide and indel variant calling 
SAMtools mpileup (v0.1.18)222 was used for variant calling of single nucleotide 
variants and indels. To parallelise variant calling across the compute cluster the 
genome was fragmented into 1,125 × 3,000,000 base pair regions. Using BEDTools 
subtractBed232 the 1,125 regions were intersected with 457 regions from UCSC’s gap 
track234 and a set of 411 blacklist regions from the Broad Institute235 to remove 
genomic regions with low mappability, unusually high mappability, or telomeric and 
centromeric regions. This resulted in 1,737 genomic regions to call variants across 
using SAMtools mpileup. The resulting VCF files generated were further processed 
by GATK (v1.4.37) to add quality filter tags to each sample’s variants to facilitate 
filtering of variants on quality at a later analysis stage. Variants with coverage depth ≥ 
10 and quality scores ≥ 20 were called high quality variants. Variants meeting one but 
not the other quality criterion were called medium quality variants. Variants failing to 
meet either quality criteria were called low quality variants. Any variant that was 
tagged as a high quality variant in at least one sample was carried forward into the 
final VCF files. These variants were used in the probabilistic pVAAST analyses 
described below. Example SAMtools mpileup and GATK commands for one region 
are shown in Appendix 3.3. 
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3.3.5 ANNOVAR SNV and indel filtering and annotation 
SNV and indel variants in VCF file format were converted into ANNOVAR226 input 
format using a custom script (Appendix 3.4). Using the variants_reduction.pl script of 
ANNOVAR and the allele frequencies from the 1000 Genomes Project (1000GP) 
Caucasian population (Phase 1 v3 April 2012 release)236, common variants with an 
alternate allele frequency in 1000GP of >1% were removed from further analysis. 
Variants were then annotated with human genome RefSeq237 designations (as at 
12/07/2014) which provided gene and gene region-based annotations, Table 3.1 
describes the designation priority order as used by ANNOVAR. Annotated variants 
located within intronic or intergenic regions were removed from further analysis 
leaving variants present in exonic, splicing, 3’ and 5’ untranslated regions (UTR), 
upstream, downstream and within non-coding RNA (ncRNA).  
 
Table 3.1 ANNOVAR RefSeq genomic region annotation definitions226. 
 
Annotation Definition Precedence 
Exonic Variant is within gene coding exon 1 
Splicing Variant is within 2-bp of exon / intron boundary 1 
ncRNA Variant is within a known transcript that is non-
coding 
2 
5’UTR Variant is within 5’UTR gene region 3 
3’UTR Variant is within 3’UTR gene region 3 
Intronic Variant is within a gene intron 4 
Upstream Variant is within a 1000 base pair region upstream of 
transcription start site 
5 
Downstream Variant is within a 1000 base pair region downstream 
of transcription end site 
5 
Intergenic  Variant is in an intergenic region 6 
 
These variants (exonic, splicing, 3’ and 5’ UTR, upstream, downstream and within 
ncRNA) were then annotated with information contained within the databases listed 
in Table 3.2. Most were built and sourced from ANNOVAR, where the 
table_annovar.pl script was used, but a number are custom annotations or accessed 
through specific web-based tools as described in Table 3.2. Specifically the Caucasian 
data from the most recent 1000 Genomes Project data release (September 2014, Phase 
3 v5), together with allele frequency data from the UK10K consortia238 was applied to 
the variants to again remove those with alternate allele frequencies ≥ 1% in these 
large scale resources. This resulted in variants with alternate allele frequencies < 1% 
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for the next stage of analysis. These variants were used in family specific analyses 
using the heuristic filtering approach to prioritise variants for follow-up using a tiered 
strategy. 
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Table 3.2 Databases accessed for variant-based annotations.  
 
 
Database Name Database Source When variant is identified in database annotates variant: Database 
Reference 
RefGene 
 
ANNOVAR With RefSeq gene ID, genomic region, exonic function (synonymous, nonsynonymous, 
frameshift, stop loss, stop gain), amino acid changes 
237 
UCSC CpG Islands UCSC When located in a CpG island 234 
UCSC cytoBand 
 
UCSC / ANNOVAR With macroscopic chromosome metaphase cytoband location 234 
TargetScanS UCSC / ANNOVAR With TargetScanHuman 5.1 generated prediction of whether variant is located within a 
miRNA binding site in 3’UTR of genes 
239 
encode_tfbs 
 
UCSC / ANNOVAR With location of transcription factor binding sites that are determined from the 
ENCODE project ChIP-Seq experiments  
240 
COSMIC 70 COSMIC / ANNOVAR With information from COSMIC when variant is previously observed in cancer 
genomes, what tissue and frequency 
109,241 
ljb23_all dbNSFP / ANNOVAR Annotates variants with a variety of functional prediction and conservation scores from 
the following tools: whole-exome SIFT scores, PolyPhen2 HDIV scores, PolyPhen2 
HVAR scores, LRT scores, MutationTaster scores, MutationAssessor score, FATHMM 
scores, MetaSVM scores, MetaLR scores, GERP++ scores, PhyloP scores and SiPhy 
scores. 
242 
dbSNP 138 NCBI / ANNOVAR With dbSNP RS identifiers  243 
CADD http://cadd.gs.washington.edu With CADD scores and Phred-scale like conversion of CADD scores, a deleteriousness 
score for SNVs and indels 
244 
SilVA http://compbio.cs.toronto.edu/silva With a functional prediction score and a prediction label (for exonic synonymous SNVs 
only) 
245 
ucscGenePfam UCSC With manually curated protein domain information from the Pfam (Protein family) 
database (for exonic SNVs and exonic indels) 
246 
1000 Genomes Project Caucasian 
allele frequencies (Phase 3v5 
September 2014 release) 
1000GP / ANNOVAR With alternate allele frequencies for 507 Caucasian samples in 1000GP cohort 236 
UK10K consortia Caucasian 
allele frequencies from whole 
genome cohorts 
UK10K With alternate allele frequencies from 4000 whole genomes in the UK10K ALSPAC 
and TWINSUK cohorts 
238 
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3.3.6 A probabilistic approach to disease gene identification using pVAAST 
The pVAAST223 software is the pedigree-based adaptation of the VAAST224,225 
software, a probabilistic disease gene finder. For each family pVAAST takes as input 
a pedigree structure and disease information about family members, a target set of 
variants from the family being analysed, a background set of variants from population 
and bioinformatics methods matched controls, a configuration file detailing specific 
settings for the analysis (Appendix 3.5) and a file defining gene features; 
refGene_hg19_with_introns.gff3 sourced from the VAAST server was used.  
 
To trial pVAAST the LK0051 family (target) was analysed together with three 
background control sets. The first was the default VAAST background sourced from 
the VAAST server. This is a background generated from all genome data from all 
available populations in the 1000GP dataset as at December 2011. The specific file 
used was: 1KG_refGene_Dec2011_CGDiv_NHLBI_NoCall.cdr. The second was a 
background constructed from 100 Caucasian samples from the 1000GP. For this 
background 70 Caucasian exomes and 30 Caucasian genomes from the 1000GP data 
set were downloaded and variants were multi-sample called as per 3.3.4. The third 
background was constructed from the remainder of the TFHMS samples used in this 
study (N=26, excluding the LK0051 samples as they were used as the target). 
 
Then pVAAST was run using the following command settings: 
 
VAAST -m pvaast -e --indel --rate 0.01 -o output_name -pv_control 
ConfigurationFile.ctl -p 55 -gw 1e6 refGene_hg19_with_introns.gff3 
BackgroundFile.cdr 
 
This command calls the VAAST program and specifies that the method (-m) to use is 
the pvaast analysis, to score all variants both coding and non-coding and indels (-e -
-indel), with the expected maximum disease allele frequency observed in the 
background set at 1% (--rate), to use the specific configuration file (-pv_control, 
as per Appendix 3.5) and to parallelise the run across 55 threads (-p) and to perform 
1×106 analysis permutations (-gw), meaning the minimum P-value that can be 
achieved is 1×10−6.  
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Multiple pVAAST analyses were completed using a full set of variants in the LK0051 
target and also an analysis with variants restricted to a minor allele frequency ≤1%, 
filtered based on the 1000GP and UK10K Caucasian population frequencies, 
excluding intergenic and intronic variants.  
 
The VAAST PDF reporter script (vaast_pdf_reporter.pl) was used to generate 
Manhattan and quantile-quantile plots.  
 
3.3.7 A tiered heuristic approach to disease variant and disease gene 
identification  
A tiered heuristic approach, following family-based analysis strategies, was 
developed and used to identify and prioritise candidate variants and genes that may 
have predisposed HM affected family members to disease development.  
 
3.3.7.1 Tier One: Family specific variants  
In the first step of this approach the initial filtered variants identified across the 31 
sequenced individuals were reduced to an analysis set by removing high quality 
variants (with coverage depth ≥ 10 and quality scores ≥ 20) variants present in 
relatives of HM cases who were unaffected and non-obligate carriers, across the five 
families. A limitation of this is that lower quality true variants in these control 
individuals may be retained in the analysis set, however removing variants that occur 
at lower qualities in control samples from the cases risks removing true causal 
variants. Then a tiered strategy was developed and applied to each family 
individually. Not all families carry each of the analysis set variants so a smaller 
number of variants are applicable in each family. 
 
3.3.7.2 Tier Two: Family specific sharing  
After removal of variants present in unaffected non-obligate carrier relatives, each 
family has different analysis opportunities. Sharing analyses were designed 
specifically for each family but were all based on identifying shared variants between 
related cases. 
 
  75 
3.3.7.3 Tier Three: Deleterious variants according to the CADD model 
To score variants based upon their predicted deleteriousness, i.e. the potential for a 
variant to have an effect on gene function, Combined Annotation-Dependent 
Depletion (CADD) phred-like scaled C scores244 (v1.1) were applied to identify 
variants likely to be damaging. CADD measures deleteriousness of single nucleotide 
and small insertion / deletion variants by combining in a single score 63 variant 
annotations related to variant function, including nucleotide and amino-acid 
conservation across species and epigenetic regulatory information from ENCODE244. 
A CADD phred-like scaled C score threshold of ≥ 10 was used to select for variants 
predicted to be deleterious. These are variants with the highest 10% of all scores, the 
top 10% predicted to be most deleterious of all possible variants under the CADD 
model. For variants in 5’UTRs or 3’UTRs a scaled C score of ≥ 20 was used to 
identify the most deleterious regulatory variants.  
 
3.3.7.4 Tier Four: Deleterious variants with the most interpretable impact upon gene 
function 
Interpreting the potential effects of a range of variants on the function of a gene is 
challenging. A variant can be predicted to be highly deleterious based on CADD 
scoring, but have no foreseeable effect on gene function. To this end, to prioritise 
variants that are able to have a biological prediction as to their effect on gene function 
variants were filtered to:  
- Nonsynonymous exonic variants located in known protein family domains, 
according to the Pfam database246 
- Synonymous exonic variants predicted to be deleterious by an additional tool, 
SilVA245 
- Variants located in splicing regions 
- Upstream and 5’UTR regulatory variants in a known transcription factor 
binding site based on ChIP-Seq data from ENCODE247, specifically the ‘Txn 
Fac ChIP V2’ data from the UCSC genome browser234 with CADD scaled C 
scores ≥ 20 
- Downstream or 3’UTR regulatory variants in predicted miRNA binding sites 
based on the TargetScanHuman 5.1 database239 
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3.3.7.5 Tier Five: Network-based prioritisation of genes 
To draw a stronger connection between the prioritised variants and HMs Tier Five 
moved from a variant-based analysis to a gene-based analysis to prioritise genes 
likely to be involved in HMs. Phevor227 and IPA® were used.  
 
In Phevor a HM related phenotype was defined using the terms: haematological 
neoplasm, hematopoietic or lymphoid organ development, hematopoietic stem cell 
differentiation, hematopoietic progenitor cell differentiation, hematopoietic stem cell 
proliferation, hematopoietic stem cell homeostasis, cancer, hematologic cancer, and 
hematopoietic system disease. Genes identified in Tier Four were queried against this 
phenotype through Phevor, with default filtering conditions enabled. Genes not 
filtered by Phevor were classified as having some evidence of relationship to the HM 
phenotype defined and were prioritised for further analysis.  
 
For gene prioritisation using IPA®, a background of HM related genes was manually 
curated from the literature. This included genes recurrently somatically mutated in 
HMs (as per Chapter 1 Table 1.8171) and genes identified as contributing to a germline 
predisposition to HMs (Chapter 1 Table 1.5, Table 1.6 Table 1.7111 and Table 1.9). 
This list of HM related genes was entered into IPA® to create a HM gene background 
network, as shown in Figure 3.2. Each of these interactions, shown with edges in 
Figure 5.2, is a direct molecule-to-molecule interaction that has been curated from the 
literature and is contained within the Ingenuity® Knowledge Base. Each interaction, 
including its direction, has been curated from the biomedical literature or third-party 
databases by trained curators248. There are approximately five million connections 
within the Knowledge Base and together this builds a network of approximately 
40,000 nodes (mammalian genes and their products) with approximately 1,480,000 
edges between them, representing experimentally observed relationships248.  The 
background network formed in this analysis was used to identify connections between 
the genes from each Tier Four prioritisation and this background network of genes 
known to contribute to HM development. Within IPA® the pathway ‘Connect’ tool 
was used, specifying ‘direct’ interactions only with ‘experimentally observed’ or 
‘high (predicted)’ confidence levels, other settings were used at default. The variants 
in genes that were connected into the HM background network by this tool could 
potentially have a role in HM predisposition and development.  
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An additional network-based analysis was conducted using the Network of Cancer 
Genes 4.0 (NCG 4.0) database249. The NCG 4.0 analysis was used to highlight genes 
that have been previously identified as mutated in cancer and to identify genes known 
to be false positives in NGS projects, such as TTN and OBSCN two of the largest 
coding genes in the genome, which due to their long length are more likely to have 
mutations than other genes. Genes in each analysis that were prioritised by Phevor 
and/or IPA®, and not predicted to be possible false positives by NCG 4.0, were 
carried forward to the next Tier analysis for each family. 
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Figure 3.2 Ingenuity Pathway Analysis network of HM background genes curated from the literature 
This network was formed from direct molecule-molecule interactions identified within the Ingenuity knowledge base, a curated database of 
interactions. Genes are shown as nodes and gene / gene product interactions as edge connections between nodes, as shown in the legend. 
Seventeen genes do not connect in with the larger network, as indicated to the right of the network diagram. Seven genes, indicated in magenta, 
have been shown to both contribute to an inherited predisposition to HMs and be recurrently mutated somatically in HMs. 
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3.3.7.6 Tier Six: Prioritisation based on analysis of known gene functions, expression 
and predicted effects of variant on protein function 
For shared, network prioritised variants identified in each family, Tier Six examines 
the predicted effects of each variant in the context of gene function and gene 
expression profiles. In Tier Four nonsynonymous exonic variants in Pfam domains 
were selected. Many Pfam domains have a solved protein crystal structure or a 
structure that can be modelled based on homology to other known protein structures 
from humans or other species. This allows for the specific amino acid change to be 
examined in the context of the protein itself.  
 
Project HOPE (Have yOur Protein Explained)250 was used to model effects of single 
amino acid changes on protein function. Particularly, conservation of the amino acid 
was used, as changes in highly conserved amino acids are more likely to be 
deleterious to protein function. When the amino acid was not conserved, and the exact 
variant amino acid or an amino acid with similar properties occurred in homologous 
protein sequences in other species, this variant was not prioritised further. Project 
HOPE is limited to modelling single amino acid changes from SNVs. Insertion and 
deletion variants, causing coding frameshift amino acid mutations in Pfam domains, 
were evaluated manually by examining amino acid conservation and involvement of 
affected amino acids in protein function (e.g. trimer interface residues, disulphide 
bond residues).  
 
Synonymous exonic variants that were predicted to be deleterious using SilVA were 
evaluated for potential effects on codon usage bias or proximity to splice sites. 
Variants in splicing regions were specifically assessed to examine their predicted 
effects on the key splice site nucleotides as described in Baralle and Baralle251. 
Regulatory variants upstream / 5’UTR in transcription factor binding sites based on 
ENCODE data and downstream / 3’UTR in miRNA binding sites based in 
TargetScanS predictions were carried forward without further assessment.  
 
Gene expression profiles were then examined for each gene using publically available 
microarray data presented in BioGPS252, in particular using the U133A gene atlas 
human gene expression data of 79 human tissues, including expression from 15 
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tissues and five cell lines relevant to HMs, that is described in Su et al.253. A finding 
of striking gene expression in haematopoietic or lymphoid tissues, or HM cell lines 
was additional evidence in gene prioritisation. Reported gene literature, and gene 
mutations recorded in COSMIC108-110, were also assessed to evaluate the functional 
potential of the gene in HM development.  
 
As the overarching hypothesis for this project is that shared variants contribute to 
disease in these individuals, non-shared variants were not prioritised at this stage for 
further follow-up.  
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3.4 Results 
3.4.1 Genome and exome sequence quality assessment 
All genomes and exomes passed quality and coverage assessment. Representative 
FASTQC reports for LK2042-003 (WGS) and LK2042-005 (WES) are located in 
Appendix 3.6. Mean WGS coverage results from analysis with SAMtools idxstats 
(v0.1.18)222 and mean WES coverage depth from analysis with Qualimap (v2.0)231 are 
shown in Table 3.3. A representative WES Qualimap report for LK2042-005 is 
located in Appendix 3.6. Plots of genome and exome coverage calculated using 
BEDTools genomeCoverageBed (v2.17.0)232 are shown in Figure 3.3.  
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Table 3.3 Mean coverage depth results for genomes (using SAMtools) and 
exomes (using Qualimap). 
 
Sample NGS method Mean coverage 
LK0051-001 WGS 39.56 
LK0051-007 WES 34.12 
LK0051-128 WGS 35.79 
LK0051-159 WGS 37.06 
LK0051-165 WES 27.05 
LK0124-117 WGS 54.20 
LK0124-179 WGS 47.43 
LK0124-202 WGS 48.70 
LK0139-001 WGS 46.81 
LK0139-004 WES 38.59 
LK0139-005 WGS 47.61 
LK0153-003 WGS 46.94 
LK0153-004 WGS 42.68 
LK0153-029 WGS 45.07 
LK0153-078 WGS 42.24 
LK0153-079 WES 46.72 
LK0153-080 WGS 43.95 
LK0153-084 WES 26.52 
LK0153-086 WGS 41.07 
LK2042-003 WGS 40.40 
LK2042-005 WES 34.17 
LK2042-006 WGS 38.83 
LK2042-018 WGS 36.96 
LK2042-231 WGS 39.42 
LK2042-232 WES 36.58 
LK2042-257 WGS 37.59 
LK2042-258 WES 44.79 
LK2042-259 WES 37.09 
LK2042-281 WGS 35.64 
LK2042-290 WGS 37.51 
LK2042-300 WES 39.82 
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Figure 3.3 Genome and exome coverage plot. 
Calculated in BEDTools and plotted in R this plot shows the fraction of bases (Y-
axis) at a coverage depth (X-axis). Genomes have high coverage across genome, with 
≥ 80% of genome with depth ≥ 20× read depth. Exomes have lower overall coverage 
of exome target regions with approximately 80% of exome coverage at ≥ 10× read 
depth. 
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3.4.2 Variant identification and initial filtering 
The total number of variants identified across the 31 individuals genome or exome 
sequenced, using SAMtools mpileup, was 12,183,143. Table 3.4 describes the step-
wise filtering of these variants to the 11,959,582 variants used in the pVAAST 
analysis and the 96,220 used in the heuristic filtering analysis.  
 
Table 3.4 Initial filtering of identified variants. 
 
Number of variants Step-wise filtering 
12,183,143 All variants identified 
11,959,582 Variants that are high quality in at least one sample 
(coverage depth ≥ 10, quality score ≥ 20), used for pVAAST 
analysis 
4,085,033 Variants with alternate allele frequencies ≤ 1% in 1000GP 
Caucasian data (Phase 1 v3 April 2012 release) 
134,370 Variants located in RefSeq (as at 12/07/2014) gene regions 
that were exonic, splicing, 3’ and 5’ untranslated regions, 
upstream, downstream and within ncRNA 
96,220 Variants with alternate allele frequencies ≤ 1% in 1000GP 
Caucasian data (September 2014, Phase 3 v5) and the 
UK10K consortia data, used for heuristic filtering analysis 
 
3.4.3 Analysis of LK0051 family using pVAAST 
3.4.3.1 LK0051 pVAAST analysis (11,959,582 variants) using the default VAAST 
background and the 1000GP background from 100 Caucasian samples 
In separate pVAAST analyses, the VAAST provided 1000GP cross-population based 
background and a self generated background from 100 Caucasian 1000GP samples 
were used with the LK0051 family target data, with three HM cases and two 
unaffected relatives, one of whom (LK0051-007) is an obligate carrier connecting two 
cases. Multiple genome-wide significant associations (VAAST genome-wide 
significance threshold: P ≤ 2.4×10−6) were identified as shown in the Manhattan plots 
(Figure 3.4 A and C) however the Q-Q plots (Figure 3.4 B and D) show that the 
pVAAST observed −log P-values are much greater than the expected −log P-values 
indicating a Type 1 error inflation. This means the identified associations should not 
be considered further. 
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Figure 3.4 LK0051 pVAAST analysis results from using the default VAAST 
background and the 1000GP background from 100 Caucasian samples. 
Manhattan plot (A, C) and Q-Q plot (B, D) results from the LK0051 pVAAST trial 
analysis using the VAAST developers sourced control background file (A and B) and 
a self generated control background file from 100 Caucasian samples from the 
1000GP (C and D) that underwent the same variant calling methods as the target 
samples. The x-axis of the Manhattan plots show gene-based results (with VAAST 
gene index) in sequential chromosomes from chromosome 1 to chromosome Y. 
VAAST genome-wide significance threshold: P ≤ 2.4×10−6 (dashed lines in figures 
A-D). Q-Q plot 95% confidence interval indicated by grey shading in B and D. 
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3.4.3.2 LK0051 target pVAAST analysis using a TFHMS sample background 
The Type 1 errors resulting from use of the default VAAST background and the 
1000GP background from 100 Caucasian samples in the pVAAST analysis with 
LK0051 indicated that a population, sequencing methodology, bioinformatics pipeline 
matched background with target and background samples variant called together was 
required, as per VAAST and pVAAST guidelines254. At the time of analysis to meet 
these guidelines with available data the decision was made to use the remainder of the 
TFHMS samples, N=26, combined together as a background control. Analysis with 
this background was run firstly with all 11,959,582 variants (Figure 3.5 A and B) and 
then with the 96,200 rare variants with 1000GP and UK10K Caucasian minor allele 
frequencies ≤1% (Figure 3.5 C and D). Both strategies reduced the inflated Type 1 
error originally observed with the previous backgrounds. However the Q-Q plot when 
all 11,959,582 variants (Figure 3.5 B) still shows abnormal inflation of the observed 
−log P-values. As described in254 VAAST-based analysis is a conservative test so the 
observed P-values are typically lower than the expected P-values when target and 
background are well matched (for population, sequencing methodology, 
bioinformatics pipeline) and sample sizes are small. The Q-Q plot when using 96,200 
rare variants only (Figure 3.5 D) is representative of the typical Q-Q plot described 
in254 so the results from this analysis can be considered further.  
  87 
 
       
Figure 3.5 LK0051 pVAAST analysis results from using a TFHMS sample 
background.  
Manhattan plot (A, C) and Q-Q plot (B, D) results from the LK0051 pVAAST trial 
analysis using the self generated control background file from the remaining 26 
TFHMS samples that are from the same population and underwent an identical 
sequencing methodology and bioinformatics pipeline to identify variants. The x-axis 
of the Manhattan plots show gene-based results (with VAAST gene index) in 
sequential chromosomes from chromosome 1 to chromosome Y. VAAST genome-
wide significance threshold: P ≤ 2.4×10−6 (dashed lines in figures A-D). Q-Q plot 
95% confidence interval indicated by grey shading in B and D. 
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From the pVAAST analysis restricted to rare variants, only one genome-wide 
significant result was obtained (Figure 3.4 C). The result of this analysis implicated 
the gene MAGEC1 (melanoma antigen family C, 1) with a P-value of 1×10−6 listing 
four variants as contributing to this association. These variants are shown in Table 
3.5. However all four variants are present in the unaffected non-obligate carrier 
family member LK0051-165 and there is no evidence of inheritance of this variant in 
the LK0051-001, LK0051-007 and LK0051-128 cluster as the unaffected obligate 
carrier, LK0051-007, is homozygous reference at all four variants. 
 
Table 3.5 LK0051 pVAAST analysis trial results using rare variants and 
TFHMS background. 
 
Location Variant LK0051-001 LK0051-007 LK0051-128 LK0051-159 LK0015-165 
chrX:140993745 T>A 0/0 0/0 0/1 0/1 0/1 
chrX:140993751 A>G 0/0 0/0 0/1 0/1 0/1 
chrX:140993755 C>A 0/0 0/0 0/1 0/1 0/1 
chrX:140993913 A>G 0/1 0/0 0/1 0/1 0/1 
0/0 = homozygous reference for variant, 0/1 = heterozygous for variant 
 
3.4.4 Analysis of TFHMS families using a heuristic tiered analysis strategy 
The step-wise heuristic tiered analysis as outlined in section 3.3.7 was applied by 
using multiple Tier Two sharing strategies across the study families. For each family 
the results presented below show in table format the tier-by-tier results for each 
sharing analysis and a table of the final resulting variants for each family. All 
prioritised variants were heterozygous. 
 
3.4.4.1 The final variant set for heuristic tiered analysis 
After removing variants present in unaffected, non-obligate carrier relatives of HM 
cases across the five study families 44,692 variants remain for analysis. As shown in 
the Venn diagram in Figure 3.6, not all families carry each of the 44,692 variants so a 
smaller number of variants are applicable in each family in the heuristic tiered 
analysis. 
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Figure 3.6 Venn diagram showing the sharing of 44,692 rare genetic variants 
across the five TFHMS families sequenced. 
 
LK0051 
LK0124 
LK0139 
LK0153 
LK2042 
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3.4.4.2 Heuristic tiered analysis of the LK0051 family 
Three family sharing Tier Two strategies were used in the analysis of the LK0051 
family as shown in Figure 3.7. 
 
The first strategy used was to identify variants shared between all three cases, 
LK0051-001, LK0051-128 and LK0051-159 and the obligate carrier, LK0051-007. 
This strategy hypothesises that the two closely related cases (LK0051-001, LK0051-
128) share susceptibility variants with the distantly related case (LK0051-159). 
LK0051-007 is considered an unaffected obligate carrier of the disease susceptibility 
variants shared between LK0051-001 and LK0051-128. 
 
The second strategy used was to identify variants shared between the closely related 
cases, LK0051-001 and LK0051-128 and the obligate carrier, LK0051-007. This 
strategy hypothesises that closely related cases will share susceptibility variants and 
that LK0051-159 does not carry the susceptibility variants due to their genetic 
distance (> 8 meioses). 
 
The third strategy used was to identify non-shared variants present individually in 
each HM case. This strategy hypothesises that each HM case has their own genetic 
variants that in addition to the shared genetic predisposition contributed to HM 
development. 
 
The results of these three strategies are shown in Table 3.6. From the tiered 
prioritisation analysis in LK0051 seven Tier Six variants were identified for 
laboratory-based follow-up as described in Table 3.7. 
 
 
  91 
 
 
Figure 3.7 Schematic of the prioritisation strategies used in the analysis of family 
LK0051.  
A reduced pedigree is shown for reference. The full pedigree is located in Figure 2.2 
on page 51. 
 
Tier Two Strategy 3!!
Non-shared variants 
individually in:!
LK0051-001 
LK0051-128 
LK0051-159
Tier One!
Variants in family
Tier Two!
Family sharing 
strategies
Tier Three!
CADD scaled C score ≥ 
10
Tier Four!
Most interpretable 
impact on gene function
Tier Five!
IPA® / Phevor / NCG 4.0 
prioritisation
Tier Six!
Specific gene / variant 
prioritisation
Tier Two Strategy 2!!
Variants shared in:!
LK0051-001 
LK0051-007 
LK0051-128
Tier Two Strategy 1!!
Variants shared in:!
LK0051-001 
LK0051-007 
LK0051-128 
LK0051-159
Overall Tiered 
prioritisation strategy
Family LK0051 Tier Two!
sharing strategies
LK0051-128!
Burkitt lymphoma 
Diagnosed age 6
LK0051-001!
T-cell non-Hodgkin!
lymphoma!
Diagnosed age 31
LK0051-007
WES WGS
WGS
WGS WES
LK0051-159!
Diffuse large !
B-cell lymphoma 
Diagnosed age 58
LK0051-165
(eight meioses)
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Table 3.6 LK0051 family heuristic-based analysis results. 
  
 LK0051 Tier Two Sharing Strategies 
Prioritisation tiers Strategy 1 Strategy 2 Strategy 3: LK0051-001 
Strategy 3: 
LK0051-128 
Strategy 3: 
LK0051-159 
Variants in family 11,432 
Sharing strategy  995 1,755 3,201 2,617 3,029 
CADD scaled C score ≥ 10 59 142 366 335 417 
Most interpretable impact 
on gene function 3 28 62 56 61 
IPA®/Phevor/NCG 4.0 
prioritisation 3 8 27 26 29 
Specific gene / variant 
prioritisation  2 5 -- -- -- 
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Table 3.7 LK0051 family prioritised variants. 
  
Family 
Strategy 
Gene Variant / dbSNP138 
ID if known 
Type Functional effect RefSeq Gene237 biological function summary 
S1 NOTCH1 chr9:139417464 T>G Exonic 
SNV 
T194P Has a role in a variety of developmental processes by 
controlling cell fate decisions.  
S1 NF1 chr17:29508805 T>G 
rs200962248 
Splicing 
SNV 
Changes the second intronic 
nucleotide immediately 3’ 
after exon 7, could affect 
splicing efficiency 
Negative regulation of Ras signal transduction pathway, 
mutations are  linked to neurofibromatosis type 1, Watson 
syndrome and JMML. 
S2 TNFSF9 chr19:6534728 G>C 
rs61750000 
Exonic 
SNV 
G139A Tumour necrosis factor (TNF) ligand family member 9, a 
costimulatory receptor molecule in T lymphocytes, also 
involved in antigen presentation process in B lymphocytes. 
S2 TDP2 chr6:24658126 C>T 
rs200729372 
Exonic 
SNV 
S144N Member of a superfamily of divalent cation-dependent 
phosphodiesterases. It associates with CD40, TNF 
receptor-75 and TNF receptor associated factors. It inhibits 
nuclear factor-kappa-B activation. Sequence and structural 
similarities to endonucleases involved in DNA repair and 
activation of transcription factors. 
S2 MMP8 chr11:102585288 T>G 
rs138686754 
Exonic 
SNV 
Synonymous variant, 
R397R changes codon bias 
Is involved in extracellular matrix breakdown, stored in 
secondary granules in neutrophils and is able to degrade 
type I, II and III collagens. 
 
S2 LRP5 chr11:68181292 C>A Exonic 
SNV 
T880N A lipoprotein receptor that binds and internalizes ligands in 
receptor-mediated endocytosis, transduces signals by Wnt 
proteins and plays a key role in skeletal homeostasis. 
S2 PEX6 chr6:42934551 G>A Exonic 
SNV 
R644W Has a direct role in peroxisomal protein import and is 
required for PTS1 (peroxisomal targeting signal 1) receptor 
activity.  
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3.4.4.3 Heuristic tiered analysis of the LK0124 family 
Two family sharing Tier Two strategies were used in the analysis of the LK0124 
family as shown in Figure 3.7. 
 
The first strategy used was to identify variants shared between at least two of the three 
cases LK0124-117, LK0124-179 and LK0124-202. With at least eight meioses 
separating each HM case, this strategy hypothesises that distantly related HM cases 
will share susceptibility variants. 
 
The second strategy used was to identify non-shared variants present individually in 
each HM case. This strategy hypothesises that each HM case has their own genetic 
variants that in addition to the shared genetic predisposition contributed to HM 
development. 
 
The results of these two strategies are shown in Table 3.8. From the tiered 
prioritisation analysis in LK0124 three Tier Six variants were identified for 
laboratory-based follow-up as described in Table 3.9. 
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Figure 3.8 Schematic of the prioritisation strategies used in the analysis of family 
LK0124.  
As the three individuals are distantly related a reduced pedigree is not an informative 
reference. The full pedigree is shown in Figure 2.3 on page 53. 
Tier Two Strategy 2!!
Non-shared variants 
individually in:!
LK0124-117 
LK0124-179 
LK0124-202
Tier One!
Variants in family
Tier Two!
Family sharing 
strategies
Tier Three!
CADD scaled C score ≥ 
10
Tier Four!
Most interpretable 
impact on gene function
Tier Five!
IPA® / Phevor / NCG 4.0 
prioritisation
Tier Six!
Specific gene / variant 
prioritisation
Tier Two Strategy 1!!
Variants shared in at 
least 2 of:!
LK0124-117!
LK0124-179!
LK0124-202
Overall Tiered 
prioritisation strategy
Family LK0124 Tier Two!
sharing strategies
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Table 3.8 LK0124 family heuristic-based analysis results. 
  
 LK0124 Tier Two Sharing Strategies 
Prioritisation Tiers Strategy 1 Strategy 2:  LK0124-117 
Strategy 2: 
 LK0124-179 
Strategy 2:  
LK0124-202 
Variants in family 13,115 
Sharing strategy  2,457 3,680 3,530 3,430 
CADD scaled C score 
≥ 10 
280 607 590 561 
Most interpretable 
impact on gene 
function 
40 85 111 89 
IPA®/Phevor/NCG 
4.0 prioritisation 
25 38 50 39 
Specific gene / 
variant prioritisation  
3 -- -- -- 
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Table 3.9 LK0124 family prioritised variants. 
  
Family 
Strategy 
Gene Variant / dbSNP138 
ID if known 
Type Functional effect RefSeq Gene237 biological function summary 
S1 NOTCH1 chr9:139417464 T>G Exonic 
SNV 
T194P Has a role in a variety of developmental processes by 
controlling cell fate decisions.  
S1 
 
NF1 chr17:29508805 T>G 
rs200962248 
Splicing 
SNV 
Changes the second intronic 
nucleotide immediately 3’ 
after exon 7, could affect 
splicing efficiency 
Negative regulation of Ras signal transduction pathway, 
mutations are  linked to neurofibromatosis type 1, Watson 
syndrome and JMML. 
S1 STT3B chr3:31659458 T>G 
rs199778452 
Exonic 
SNV 
F384V Is the catalytic subunit of a protein complex that transfers 
oligosaccharides onto asparagine residues. 
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3.4.4.4 Heuristic tiered analysis of the LK0139 family 
Two family sharing Tier Two strategies were used in the analysis of the LK0139 
family as shown in Figure 3.9.  
 
The first strategy used was to identify variants shared between the two cases, 
LK0139-001 and LK0139-005. This strategy hypothesises that the parent-offspring 
affected pair share disease susceptibility variants.  
 
The second strategy used was to identify non-shared variants present individually in 
each HM case. This strategy hypothesises that each HM case has their own genetic 
variants that in addition to the shared genetic predisposition contributed to HM 
development. 
 
The results of these two strategies are shown in Table 3.10. From the tiered 
prioritisation analysis in LK0139 five Tier Six variants were identified for laboratory-
based follow-up as described in Table 3.11. 
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Figure 3.9 Schematic of the prioritisation strategies used in the analysis of family 
LK0139. 
A reduced pedigree is shown for reference. The full pedigree is located in Figure 2.4 
on page 55. 
 
Tier Two Strategy 2!!
Non-shared variants 
individually in:!
LK0139-001 
LK0139-005
Tier One!
Variants in family
Tier Two!
Family sharing 
strategies
Tier Three!
CADD scaled C score ≥ 
10
Tier Four!
Most interpretable 
impact on gene function
Tier Five!
IPA® / Phevor / NCG 4.0 
prioritisation
Tier Six!
Specific gene / variant 
prioritisation
Tier Two Strategy 1!!
Variants shared in:!
LK0139-001!
LK0139-005!
Overall Tiered 
prioritisation strategy
Family LK0139 Tier Two!
sharing strategies
LK0139-005!
Multiple myeloma!
Diagnosed age 52
LK00139-004
WES WGS
LK0139-001!
Plasmacytoma!
Diagnosed age 57
WGS
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Table 3.10 LK0139 family heuristic-based analysis results. 
  
 LK0139 Tier Two Sharing Strategies 
Prioritisation Tiers Strategy 1 Strategy 2: LK0139-001 
Strategy 2: 
LK0139-005 
Variants in family 8,557   
Sharing strategy  2,597 2,826 3,134 
CADD scaled C score 
≥ 10 
387 336 439 
Most interpretable 
impact on gene 
function 
25 33 43 
IPA®/Phevor/NCG 
4.0 prioritisation 
8 18 19 
Specific gene / 
variant prioritisation  
5 -- -- 
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Table 3.11 LK0139 family prioritised variants  
 
 
 
 
 
Family 
Strategy 
Gene Variant / dbSNP138 
ID if known 
Type Functional effect RefSeq Gene237 biological function summary 
 
S1 NOTCH1 chr9:139417464 T>G Exonic 
SNV 
T194P Has a role in a variety of developmental processes by 
controlling cell fate decisions. 
S1 
 
PABPC1 chr8:101721839 C>A 
rs202074479 
 
Exonic 
SNV 
V365L Is a poly(A) binding protein, that binds to 3’ poly(A) tail of 
mRNA promoting ribosome recruitment and translation 
initiation. Also required for poly(A) shortening at the 
beginning of mRNA decay. 
S1 DUSP10 chr1:221874839 TG>T 
 
3’UTR 
Deletion 
Predicted miRNA binding 
site for miR-129/129-5p 
miR-450a/450a-5p 
Has a role in cell proliferation and differentiation through 
negative regulation of members of the MAP kinase 
superfamily, specifically p38 and SAPK/JNK. 
S1 PDE4DIP chr1:144863438 G>T 
rs140993521 
Exonic 
SNV 
Q1989K Anchors phosphodiesterase 4D to the Golgi/centrosome 
region of the cell. Defects in gene may cause a 
myeloproliferative disease associated with eosinophilia.  
S1 SPHK2 
 
chr19:49132198 A>C 
rs200347384 
Exonic 
SNV 
Y378S Catalyses phosphorylation of sphingosine to sphingosine 1-
phosphate which mediates diverse cellular processes 
including migration, proliferation and apoptosis. In cancer 
can promote angiogenesis and tumourigenesis. 
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3.4.4.5 Heuristic tiered analysis of the LK0153 family 
Three family sharing Tier Two strategies were used in the analysis of the LK0153 
family as shown in Figure 3.10.  
 
The first strategy used was to identify variants shared between the two HM cases, 
siblings LK0153-003 and LK0153-004, and their unaffected parent, LK0153-029, 
who is the genetic connection into the other HM affected members of this family. 
This strategy hypothesises that closely related cases share susceptibility variants and 
that in this context LK0153-029 is an unaffected obligate carrier of these variants. 
 
The second strategy used was to identify variants shared between the two HM cases, 
LK0153-003 and LK0153-004, which were not present in their unaffected parent, 
LK0153-029. This strategy hypothesises that the siblings LK0153-003 and LK0153-
004 share HM susceptibility variants that were not inherited from their parent 
LK0153-029. 
 
The third strategy used was to identify non-shared variants present individually in 
each HM case. This strategy hypothesises that each HM case has their own genetic 
variants that in addition to the shared genetic predisposition contributed to HM 
development. 
 
The results of these three strategies are shown in Table 3.12. From the tiered 
prioritisation analysis in LK0153 seven Tier Six variants were identified for 
laboratory-based follow-up as described in Table 3.13. 
 
  103 
 
Figure 3.10 Schematic of the prioritisation strategies used in the analysis of 
family LK0153. 
A reduced pedigree is shown for reference. The full pedigree is located in Figure 2.5 
on page 57. 
 
Tier Two Strategy 3!!
Non-shared variants 
individually in:!
LK0153-003 
LK0153-004
Tier One!
Variants in family
Tier Two!
Family sharing 
strategies
Tier Three!
CADD scaled C score ≥ 
10
Tier Four!
Most interpretable 
impact on gene function
Tier Five!
IPA® / Phevor / NCG 4.0 
prioritisation
Tier Six!
Specific gene / variant 
prioritisation
Tier Two Strategy 2!!
Variants shared in:!
LK0153-003 
LK0153-004
Tier Two Strategy 1!!
Variants shared in:!
LK0153-003 
LK0153-004 
LK0153-029
Overall Tiered 
prioritisation strategy
Family LK0153 Tier Two!
sharing strategies
LK0153-004!
Waldenström !
macroglobulinemia > !
myelodysplastic syndrome > !
Acute myeloid leukaemia!
Diagnosed age 55
WGSWGS
LK0153-029!
WGS
LK0153-003!
Mucosa associated !
lymphoid tissue!
lymphoma!
Diagnosed age 58
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Table 3.12 LK0153 family heuristic-based analysis results. 
 
 LK0153 Tier Two Sharing Strategies 
Prioritisation Tiers Strategy 1 Strategy 2 Strategy 3: 
 LK0153-003 
Strategy 3: 
 LK0153-004 
Variants in family 10,649    
Sharing strategy  1,388 1,218 1,705 1,711 
CADD scaled C score 
≥ 10 
191 215 253 210 
Most interpretable 
impact on gene 
function 
32 23 25 26 
IPA®/Phevor/NCG 
4.0 prioritisation 
11 12 14 13 
Specific gene / 
variant prioritisation  
3 4 -- -- 
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Table 3.13 LK0153 family prioritised variants. 
  
Family 
Strategy 
Gene Variant / dbSNP138 
ID if known 
Type Functional effect RefSeq Gene237 biological function summary 
S1 HAL chr12:96371767 A>G 
rs150591434 
Exonic 
SNV 
W537R Catalyses first reation in histidine catabolism. 
S1 RARS chr5:167929060 
CCTT>C 
Exonic 
deletion 
F337del Catalyses the aminoacylation of transfer-RNA by their 
congnate amino acid, linking amino acids with transfer-
RNA codons. 
S1 RIPK2 chr8:90796371 
GTAA>G 
Splicing 
deletion 
Deletes the second to fifth 
intronic nucleotides 
immediately 3’ after exon 8, 
could affect splicing 
efficiency 
Member of the receptor-interacting protein family of 
serine/threonine protein kinases. A component of 
complexes in the innate and adaptive immune pathways, 
activator of NF-kappaB and inducer of apoptosis. 
S2 GIT1 chr17:27904190 G>A 
rs202085570 
Exonic 
SNV 
R353W No summary reported. Literature indicates a role in 
cancer cell migration and metastasis.  
S2 MET chr7:116381047 A>G 
rs374733251 
 
Exonic 
SNV 
T557A A proto-oncogene associated with papillary renal 
carcinoma, is the hepatocyte growth factor receptor and 
encodes tyrosine-kinase activity. 
S2 NAT10 chr11:34152973 C>A 
rs146685334 
Exonic 
SNV 
A472D No summary reported. Literature indicates a role in 
cytokinesis regulation. 
S2 NID2 chr14:52509033 G>A 
rs143412278 
 
Exonic 
SNV 
H539Y Cell-adhesion protein that binds collagens I, IV and 
laminin and may be involved in basement membrane 
structure maintenance. 
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3.4.4.6 Heuristic tiered analysis of the LK2042 family 
Two family sharing Tier Two strategies were used in the analysis of the LK2042 
family as shown in Figure 3.11.  
 
The first strategy used was to identify variants shared in two or more distantly related 
cases or obligate carriers. This strategy hypothesises that distantly related (> 8 
meioses) cases and obligate carriers in a large family with multiple occurrences of 
HMs will share disease susceptibility variants.  
 
The second strategy used was to identify non-shared variants present individually in 
each HM case. This strategy hypothesises that each HM case has their own genetic 
variants that in addition to the shared genetic predisposition contributed to HM 
development. 
 
The results of these two strategies are shown in Table 3.14. From the tiered 
prioritisation analysis in LK2042 ten Tier Six variants were identified for laboratory-
based follow-up as described in Table 3.15. 
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Figure 3.11 Schematic of the prioritisation strategies used in the analysis of 
family LK2042.  
As the sequenced individuals are distantly related a reduced pedigree is not an 
informative reference, the full pedigree is shown in Figure 2.6 on page 59. 
Tier Two Strategy 2!!
Non-shared variants 
individually in:!
LK2042-003!
LK2042-005!
LK2042-006!
LK2042-231!
LK2042-257!
LK2042-281!
LK2042-290!
LK2042-300
Tier One!
Variants in family
Tier Two!
Family sharing 
strategies
Tier Three!
CADD scaled C score ≥ 
10
Tier Four!
Most interpretable 
impact on gene function
Tier Five!
IPA® / Phevor / NCG 4.0 
prioritisation
Tier Six!
Specific gene / variant 
prioritisation
Tier Two Strategy 1!!
Variants shared in at 
least 2 of:!
LK2042-003!
LK2042-005!
LK2042-006!
LK2042-018!
LK2042-231!
LK2042-257!
LK2042-281!
LK2042-290!
LK2042-300
Overall Tiered 
prioritisation strategy
Family LK2042 Tier Two!
sharing strategies
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Table 3.14 LK2042 family heuristic based analysis results.  
 
 LK2042 Tier Two Sharing Strategies      
Prioritisation 
Tiers 
S1 S2:  
LK2042-003 
S2:  
LK2042-005 
S2:  
LK2042-006 
S2:  
LK2042-231 
S2:  
LK2042-257 
S2:  
LK2042-281 
S2:  
LK2042-290 
S2:  
LK2042-300 
Variants in family 23,223         
Sharing strategy  5,687 2,502 1,104 2,460 1,821 1,670 2,205 2,523 929 
CADD scaled C 
score ≥ 10 
593 486 383 434 293 212 427 490 318 
Most interpretable 
impact on gene 
function 
96 89 86 67 43 25 78 92 86 
IPA/Phevor/NCG 
4.0 prioritisation 
51 49 46 31 25 11 32 35 39 
Specific gene / 
variant 
prioritisation  
10 -- -- -- -- -- -- -- -- 
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Table 3.15 LK2042 family prioritised variants. 
  
Family 
Strategy 
Gene Variant / dbSNP 
138 ID if known 
Type Functional effect RefSeq Gene237 biological function summary Number 
shared 
in 
S1 NOTCH1 chr9:139417464 T>G Exonic 
SNV 
T194P Has a role in a variety of developmental processes by controlling 
cell fate decisions. 
6 
S1 NF1 chr17:29508805 T>G 
rs200962248 
Splicing 
SNV 
Changes the second intronic 
nucleotide immediately 3’ 
after exon 7, could affect 
splicing efficiency 
Negative regulation of Ras signal transduction pathway, mutations 
are  linked to neurofibromatosis type 1, Watson syndrome and 
JMML. 
7 
S1 PABPC1 chr8:101721839 C>A 
rs202074479 
 
Exonic 
SNV 
V365L Is a poly(A) binding protein, that binds to 3’ poly(A) tail of mRNA 
promoting ribosome recruitment and translation initiation. Also 
required for poly(A) shortening at the beginning of mRNA decay. 
3 
S1 B4GALNT4 chr11:377329 T>G Splicing 
SNV 
Changes the second intronic 
nucleotide immediately 3’ 
after exon 14, could affect 
splicing efficiency 
No summary reported. Gene Ontology data indicates the protein has 
acetylgalactosaminyltransferase activity and is involved in 
metabolic processes. 
4 
S1 L3MBTL2 chr22:41615519 G>C Exonic 
SNV 
A233P No summary reported. Gene Ontology data indicates the protein is 
involved in chromatin modification. 
3 
S1 PRIM2 chr6:57246878 T>C Exonic 
SNV 
L202S Encodes DNA primase, an enzyme with a key role in DNA 
replication. Synthesises the small RNA primers used in cell to 
create Okazaki fragments in lagging DNA strand in DNA 
replications. 
2 
S1 PRIM2 chr6:57398207 G>T Exonic 
SNV 
Inframe STOP codon As above. 3 
S1 SAC3D1 chr11:64811900 C>T Exonic 
SNV 
R260C No summary reported. Gene Ontology data indicates that protein is 
involved in mitotic nuclear division. 
2 
S1 SYVN1 chr11:64898255 T>G Exonic 
SNV 
T328P Encodes a protein involved in endoplasmic reticulum (ER) protein 
degradation of unfolded proteins that accumulate during ER stress. 
3 
S1 TBX21 chr17:45820022 A>C Exonic 
SNV 
T180P Encodes a transcription factor involved in controlling the 
expression of the hallmark cytokine on T-cells and natural killer 
cells, interferon-gamma. 
3 
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3.5 Discussion 
3.5.1 pVAAST probabilistic analysis 
The pVAAST probabilistic approach to disease gene identification has been 
successful previously in other pedigree-based contexts such as a family with dominant 
inheritance of cardiac septal defects223 and in familial breast cancer and lynch-
syndrome spectrum cancers255. It is applicable to inherited conditions, such as familial 
HMs, that have disease penetrance complexities. However when the pVAAST 
approach was trialled with data from the LK0051 family the results indicated further 
development and an alternative approach was required. Quantile-quantile plots of the 
results from the analyses using the default VAAST background and a background 
created from 100 Caucasian samples showed striking inflation of the observed −log P-
values indicating a Type 1 error (Figure 3.4 B and D). In the context of VAAST and 
pVAAST this means that the target data and background control data are not matched.  
 
The default VAAST background sourced from the VAAST developers is built from 
variants called from across the 1000GP populations, so firstly as was expected there 
was a ethnicity / population mismatch between the multi-population background and 
the LK0051 family Caucasian samples used in the target file. Additionally the 
variants used to build the default VAAST background were not identified using the 
same bioinformatics pipeline as the target LK0051 samples, which can also cause 
Type 1 error inflation 254. For the background created from the 100 Caucasian 
samples, 70 Caucasian exomes and 30 Caucasian genomes from the 1000GP were 
downloaded and variants were called using the same methodology as the LK0051 
target samples. Compute cluster storage restrictions were the limiting factor in the 
number of Caucasian samples accessed in the 1000GP. It was expected that using the 
same variant calling method as the target samples would improve the Type 1 error 
because of the matched variant calling pipeline to the target samples reducing biases 
from using a different variant calling software. Some improvement was seen (Figure 
3.4 D vs. B) with the right tail of the Q-Q plot moving closer to the expected 
distribution, however observed −log P-values were still inflated. Given that the 
samples are now population ethnicity matched, Caucasian 1000GP samples and 
Caucasian Tasmanian study samples, this suggests that the inflation is either caused 
by continued population stratification with Tasmanian Caucasians being genetically 
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different to the 1000GP Caucasians, which is unlikely, or the effect is from 
differences in the sequencing platform and bioinformatics alignment and variant 
calling pipelines. The 1000GP samples had been aligned to the NCBI GrCh37 
reference genome, whereas the TFHMS LK0051 samples were aligned to UCSC’s 
hg19 reference genomes. Differences in the encoding of the two versions of the 
reference genome prevented multi-sample variant calling of TFHMS and 1000GP 
samples together. This is the most likely explanation for the Type 1 error inflation as 
VAAST and pVAAST protocols advise strict target and background matching. The 
1000GP genome and exome BAM files should be demultiplexed to FASTQ raw read 
files and realigned to the UCSC hg19 following the same bioinformatics pipeline as 
the TFHMS samples and then target and background samples multi-called together 
using the same variant calling software. This approach should control completely for 
the Type 1 error inflation. This was not, however, feasible with available 
computational resources and time at the time of analysis. Thus the results from the 
LK0051 pVAAST analysis using these two backgrounds were not further pursued at 
this time. Rigorously matched controls, ideally Tasmanian population matched, will 
be required as will further trialling of different analysis parameters in the pVAAST 
software dependant upon the disease family. 
 
To control for the factors influencing the Type 1 error in the analyses using the first 
two backgrounds a third background control file to analyse LK0051 against was 
formed from the remaining 26 TFHMS samples, which had all undergone identical 
bioinformatics pipeline processing and had been variant called together. Initial results 
from this background were promising with a decrease in Type 1 error inflation seen 
(Figure 3.5 B) however the Q-Q plot was still abnormal in comparison to what is 
expected for the conservative VAAST-based analysis254. A supplementary pVAAST 
analysis by filtering the 11,959,582 variants to 96,200 rare variants with MAF ≤ 1% 
in the 1000GP and UK10K Caucasian populations improved the Q-Q plot, meeting 
the expectations outlined in Kennedy et al.254 (Figure 3.5 D). The result of this 
analysis using only rare variants identified one genome-wide significant hit, MAGEC1 
on chromosome X with a P-value of 1×10−6. However analysis of the variants 
contributing to this association revealed that they were not consistent with the 
expected inheritance pattern due to absence of the variants in the obligate carrier 
LK0051-007. Additionally, LK0051-128 was chosen to be the representative disease 
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case for the family, thus requiring the variant to be present in LK0051-128 and the 
default options used in the analysis applied a penalty to incomplete penetrance, so any 
variants inherited in LK0051-001, LK0051-007 and LK0051-128 would have been 
statistically penalised because LK0051-007 is not affected. Analysis removing this 
penalty did not alter the findings.  
 
3.5.2 Heuristic filtering-based analysis using a tiered approach 
The probabilistic approach, when successful, is ideally complemented by a heuristic 
approach. Such an approach is logical and hypothesis driven, relying on a defined 
series of questions to filter the total number of variants identified to a smaller number, 
depending upon the questions asked. With further work required on the application of 
pVAAST, a heuristic filtering-based approach to variant prioritisation was adopted as 
the main analysis method in this study. 
 
The heuristic approach used here was developed to focus on variants shared between 
related cases, with sharing analysis strategies constructed for each family. Then by 
using ANNOVAR, and several other variant-based annotation tools (as detailed in 
Table 3.2) variants were prioritised using a tiered strategy to find the shared variants 
most likely to contribute to disease development in each of these families.  
 
The use of WES of individuals in these families supplemented the WGS information 
and aided the prioritisation strategy employed. However as shown in Figure 3.3, 
overall coverage of exome capture regions was lower than WGS, with approximately 
20% of the WES regions across samples having a read depth lower than the threshold 
of ≥10 used in this analysis. This suggests that a number of informative variants in 
these individuals have been missed and is a limitation of the use of a combined WES 
and WGS approach in these families. 
 
3.5.2.1 Variants prioritised in family LK0051 
In family LK0051 two sharing strategies were applied in the tiered prioritisation. The 
first was to examine variants shared between all three HM cases and the obligate 
carrier, the second was to focus on variants in the uncle-nephew case pair and their 
connecting female relative, separating them from their affected distant cousin. These 
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two strategies together identified seven variants of interest for further laboratory-
based follow-up (Table 3.7).  
 
In the second sharing strategy in this family, two variants in NEB and OBSCN were 
specifically excluded in Tier Five due to their identification in the NCG 4.0 
database249 as likely false positive results due to gene length249. From Tier Five to 
Tier Six a further three variants were excluded after closer examination of the specific 
variant effects. Two of these were excluded as they were predicted to be non-
conserved residues by Project HOPE250. That is, the presence of the variant amino 
acid in other homologous sequences for that protein, indicates that the change is 
unlikely to affect protein function. The third was a predicted splicing variant which 
was excluded based this variant being unlikely to affect the critical splicing 
nucleotides at the exon-intron junction, as reviewed in Baralle and Baralle251.  
 
Of the variants prioritised in LK0051, both the NF1 and NOTCH1 variants were also 
present in the analyses of two (LK0124, LK2042) and three (LK0124, LK0139, 
LK2042) other sequenced families respectively. NOTCH1 in particular has been 
shown to be somatically mutated in HMs and has a known role in haematopoietic cell 
differentiation177,178,184,256-260. Mutation to NF1 is known to cause Neurofibromatosis 
type 1 (NF1) (MIM #162200) a familial cancer syndrome, of which development of a 
HM, juvenile myelomonocytic leukaemia, can be a feature amongst other diverse 
phenotypes. Occurrence of NF1 is not suspected in the families carrying the mutation 
based on known medical histories, however NF1 has been shown to have diverse 
presentations in different families261. Evidence of the occurrence of HMs in NF1 
mutation carriers without other NF1 symptoms has also been reported262,263.  
 
The five variants arising from the second sharing analysis strategy in LK0051 in 
TNFSF9, MMP8, TDP2, LRP5 and PEX6 all present as interesting candidates for 
further laboratory-based consideration. A connection between HM predisposition and 
variants in these genes is a novel finding and disruption to the biological roles of each 
of these genes could be hypothesised to contribute to malignancy development. These 
variants occur in the uncle-nephew pair, with a T-cell and a B-cell HM respectively. 
TNFSF9 is of particular interest as the glycine to alanine amino acid change at 
position 139 affects a completely conserved residue across all homologous protein 
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sequence alignments. This together with known roles of TNFSF9 in both T-cell and 
B-cell biology strengthens interest in this gene and variant in HM predisposition. 
 
3.5.2.2 Variants prioritised in family LK0124 
In family LK0124, due to more distant relationships between the three HM cases 
sequenced, the sharing strategy chosen was to focus on variants shared in two or more 
cases. The tiered analysis identified three variants of interest, two are the same afore 
mentioned NOTCH1 and NF1 variants in family LK0051. The third is a SNV in 
STT3B causing the F384V amino acid change.  
 
3.5.2.3 Variants prioritised in family LK0139 
Family LK0139 presented an opportunity to identify shared variants between a father-
daughter HM affected pair who had plasmacytoma (a multiple myeloma precursor 
condition) and multiple myeloma respectively. Five shared variants were identified 
including the previously mentioned variant in NOTCH1. Of the remaining four 
variants, one in PABPC1 was also observed in the LK2042 family. PABPC1 has an 
important role in mRNA translation and the amino acid change identified, V365L, 
may be altering this role. However, while the lysine residue has not been observed at 
this position, other amino acids with similar properties to lysine have been, which 
may suggest that this variant does not have a functional effect on the protein. A 
3’UTR mutation in a TargetScanS predicted miRNA binding site in DUSP10 was also 
identified in this family. Confirmation that miRNAs bind at this 3’ location, and that 
this binding is disturbed by the variant would be required to show the functional role 
of this variant. The remaining two variants of interest in the LK0139 family are amino 
acid changes that occur in PDE4DIP (Q1989K) and SPHK2 (Y378S). Both genes are 
known to have a role in cell proliferation, which may indicate a potential role in HM 
development when disrupted.  
 
3.5.2.4 Variants prioritised in family LK0153 
Sequencing in family LK0153 was conducted in an affected sibling pair and their 
unaffected father who had a family history of HMs. Two family sharing analyses 
were conducted to identify variants shared between the siblings, and separately 
  115 
variants that the siblings also shared with their father, as it was possible that the 
disease susceptibility shared between the siblings was independent of their father. The 
two analyses identified seven variants, three between all family members and four 
shared between the siblings and not their father. Of these seven variants, a splicing 
variant in RIPK2 that deletes three intronic nucleotides immediately after exon eight 
occurred in all three sequenced family members. This variant may produce a RIPK2 
transcript variant that affects the reported role of this gene in apoptosis, indeed 
previously a splice variant without exon 2 was identified which resulted in a loss of 
activity of the RIPK2 protein264. Shared between the affected siblings but not their 
father were four exonic variants resulting in amino acid changes in functional protein 
domains. Particularly of interest are the variants in MET, because it is a known proto-
oncogene265 and NAT10, because this gene has suggested roles in cytokinesis 
regulation destabilization of which can contribute to cancer266. 
 
3.5.2.5 Variants prioritised in family LK2042 
Family LK2042, as for family LK0124, is a large family with the eight sequenced 
cases each being distantly related. This presented an analytical challenge, as 
identification of variants with Mendelian inheritance was not possible. As for LK0124 
the sharing strategy selected for LK2042 was to focus on variants in two or more 
cases. This identified over fifty Tier Five variants for individual prioritisation. 
Individual analysis of each of these variants prioritised ten in Tier Six. Given the 
genetic distance between the related cases in this family, a shared variant analysis 
may not be the best analysis option in this family. However variants in interesting 
candidate genes were prioritised, including the previously mentioned NOTCH1, NF1 
and PABPC1 variants. In addition two variants in the gene PRIM2 encoding a 
component of the primase enzyme responsible for the synthesis of Okazaki fragments 
during DNA replication were identified267. PRIM2 has been shown in a mouse model 
of virus induced HM to be a candidate gene involved in HM development268. In 
LK2042, one variant caused an amino acid change, L202S, with the lysine residue 
being conserved across 53% of alignments according to the Pfam database246 and no 
evidence of the serine residue occurring in homologous sequences. This variant was 
identified in LK2042-281 and LK2042-300. The second PRIM2 variant introduces an 
in frame stop codon in exon nine of the gene in LK2042-006, LK2042-290 and 
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LK2042-300. The occurrence of multiple variants in PRIM2 in the LK2042 family 
warrants further investigation of this gene in HM development.  
 
3.5.2.6 Non-shared variants prioritised in each HM case 
Additionally for each affected HM case a secondary Tier Two analysis was 
undertaken to identify and prioritise non-shared variants. This analysis revealed that 
non-shared variants, those that are not shared between related cases and are just 
present within an individual HM affected family member, might also be relevant to 
disease predisposition. Such solo variants may work in concert with the identified 
shared candidate predisposition variants to contribute to the individual’s risk of HM 
development. A group of sequenced Tasmanian population controls would assist in 
identifying whether individuals in these families are enriched for more Tier Five and 
Tier Six variants than would be expected in unrelated controls. This is planned, but 
was not available at the time of analysis.  
 
Non-shared variants are not the focus of this dissertation, so accordingly a Tier Six 
variant-based analysis was not undertaken, but it is interesting to note that in these 
analyses individuals had, on average, 35 (95% C.I. = 27–43) Tier Five variants. 
Several of these variants are striking candidates for HM disease predisposition, 
including the JAK2 V617F mutation in LK2042-290 who has essential 
thrombocythaemia (a MPN, a diagnostic feature of which is JAK2 V617F mutations; 
in this individual this mutation was confirmed in their clinical record). While it is 
likely that the JAK2 mutation was somatically acquired, the mother of LK2042-290 
also had a MPN, which may indicate the inheritance of the JAK2 mutation, or 
inheritance of other genetic variants contributing to a MPN predisposition. 
 
3.6 Conclusion  
This chapter detailed the bioinformatics approach to quality assessment and variant 
identification from the 31 next generation sequenced samples used in this study. 
Initial variant filtering and annotation, as described, was conducted primarily using 
ANNOVAR226 and other web-based tools. This strategy reduced the total number of 
variants identified using SAMtools mpileup from 12,183,143 to 96,220 rare SNVs 
and indels in coding or potential regulatory regions. This set of variants formed the 
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basis of a family-based tiered prioritisation strategy to identify potential interesting 
variants for further follow up in relation to HM development. Future work for variant 
identification using the NGS data from these samples would be to explore the 
identification and prioritisation of structural variants, particularly copy number 
variants.  
 
In total, twenty-six very promising novel candidate variants with clear biological links 
to HMs, that have not been previously described in relation to HM predisposition, 
have been identified through a family-based analysis in this study. Each of these 
variants requires laboratory validation to confirm the presence of the variant in the 
sequenced samples. In particular, the occurrence of rare variants across families raises 
the concern that these variants may be false positives arising from artefacts related to 
the next generation sequencing and analysis process.  
 
Laboratory validation ideally uses a NGS independent method to verify sequence 
variants. Chapter 4 details the laboratory validation work completed on a selection of 
these variants, and in particular the high-throughput screening of two variants across 
the TFHMS resource and a group of Tasmanian population controls.  
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Chapter 4 - Validation and population screening of selected 
prioritised variants 
 
4.1 Introduction 
The prioritisation of sequence variants through bioinformatics analysis of NGS data is 
a strategy designed to identify potential disease susceptibility variants. Not all 
prioritised variants will be true sequence variants, or necessarily be truly disease 
causing. The occurrence of false positive sequence variants is an expectation in NGS 
data269 and so a NGS independent method of variant detection, such as Sanger 
sequencing, is required for variant validation. The occurrence of prioritised variants in 
diseased individuals is not evidence that the variant truly contributes to disease. A 
prioritised and validated variant must be screened within an ethnicity matched control 
population to ensure that the variant is not common within that specific population, 
but rare within community control data such as the 1000GP and EVS populations. 
Additionally a prioritised, validated and rare variant should be screened, where 
samples are available, in the specific disease resource of individuals. This is a first 
step in determining whether the variant might contribute more widely to disease 
susceptibility. 
 
In this study twenty-six variants were identified from the analyses of NGS data in five 
TFHMS families, as described in Chapter 3, that are promising candidates of HM 
susceptibility in these families. To first confirm that the identified variants are not 
artefacts of the NGS process, laboratory-based confirmation of each of these variants 
is required. Variant validation by Sanger sequencing was necessarily prioritised due 
to time and funding constraints and so was only conducted on the prioritised variants 
in families LK0051, LK0124, LK0139 and LK0153. From the successfully validated 
variants, two genes for which there was the greatest supporting biological evidence 
such that they could be hypothesised to be involved in HM development, were chosen 
from family LK0051 and high-throughput genotyping screens using a TaqMan 
genotyping assay were completed. Allele frequencies were used to test whether either 
variant was enriched in the TFHMS resource. Subsequently, based on the results of 
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this analysis, one of these genes was screened by amplicon-based NGS on a MiSeq 
system across 96 HM cases, in search of other mutations in this gene that may be 
contributing to HM development.  
 
4.2 Aims 
The objective of this analysis was to first use an independent method to validate 
prioritised sequence variants identified through NGS. Then, for selected validated 
variants, conduct a high-throughput genotyping screen of the TFHMS resource and a 
group of population controls to establish further evidence for the potential 
contribution of the variants to HM susceptibility.  
 
4.3 Methods 
4.3.1 Sanger sequencing confirmation of identified variants 
4.3.1.1 Oligonucleotide DNA PCR primer design 
Sanger sequencing was used to confirm variants identified through NGS. PCR 
amplicons were designed to amplify a 200-500 base pair fragment spanning the 
variant site using the UCSC genome browser to obtain the reference sequence in these 
regions as well as known SNPs for masking prior to primer design234. Primer-
BLAST270 was used to design sequence specific oligonucleotide DNA primers, using 
the human genome for primer pair specificity checking. Primer sequences are listed in 
Appendix 4.1.  
 
Primers were synthesised by GeneWorks or Sigma Aldrich. Primers were optimised 
using gradient PCR to determine appropriate annealing temperatures for PCR 
amplification. Primers were used for both PCR amplification and Sanger sequencing. 
 
 
 
 
  120 
4.3.1.2 DNA amplification by PCR 
PCR amplicons were amplified from 10 ng/µL genomic DNA, obtained as per 
Section 2.2.4, according to the following reaction conditions:  
 
10 µL reactions, per sample: 
5 µL  Promega GoTaq Green master mix, or Bioline MyTaq HS 
master mix  
0.8 µL  Forward oligonucleotide primer at 10 µM 
0.8 µL  Reverse oligonucleotide primer at 10 µM 
2.4 µL  H2O 
1 µL  DNA at 10 ng/µL 
 
Thermal cycling conditions: 
 
  GoTaq Green PCRs  MyTaq PCRs 
95ºC  3 mins   95ºC  2 mins 
40 cycles of:   40 cycles of: 
95ºC  1 min   95ºC  10 secs 
XºC  30 secs   XºC  10 secs 
72ºC  1 min   72ºC  20 secs 
72ºC  5 mins   4ºC hold 
4ºC  hold     
 
(X = optimised PCR annealing temperature)  
 
Thermal cycling was conducted using Veriti thermal cyclers from Life Technologies. 
Each PCR was conducted with both a placenta derived human genomic DNA positive 
control (Bioline) and a DNA-free negative control. PCR products were visualised by 
gel electrophoresis (85 volts for 25 mins) on 1% agarose gels with SYBR Safe DNA 
gel stain (Life Technologies).  
 
4.3.1.3 PCR product purification  
10 µL PCR reaction products were prepared for sequencing by magnetic bead 
purification using Agencourt AMPure XP beads (Beckman Coulter) according to the 
manufacturer’s instructions. 18 µL of beads were used for 10 µL PCR reactions. 
Purified PCR products were eluted from beads in 40 µL of nuclease free H2O in 
preparation for Big Dye Terminator (BDT) PCR for Sanger sequencing.  
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4.3.1.4 BDT Sanger sequencing PCR 
BDT PCR amplification was conducted using 1 µL of AMPure purified PCR product 
using either the forward or reverse primers from the initial PCR amplification 
according to the following reaction conditions: 
 
10 µL reactions, per sample: 
 
0.25 µL  BDT enzyme    
1.75 µL  Sequencing buffer  
1 µL   Primer at 3.3 µM  
6 µL   H2O    
1 µL   AMPure purified PCR product 
 
Thermal cycling conditions: 
 
96ºC  1 mins 
25 cycles of: 
96ºC  10 secs 
50ºC  5 secs  
60ºC  4 min 
4ºC  hold  
 
Veriti thermal cyclers from Life Technologies were used to conduct BDT PCR 
amplification. 
 
4.3.1.5 BDT PCR product purification and capillary sequencing 
Following PCR amplification the BDT PCR products were purified using Agencourt 
CleanSeq (Beckman Coulter) beads according to the manufacturer’s instructions with 
10 µL of beads used per 10 µL PCR reaction. Purified PCR products were eluted 
from beads with 40 µL of nuclease free H2O. 30 µL of purified PCR product was 
loaded into an ABI 310 or ABI 3100 capillary sequencer. Sanger sequencing results 
were analysed using the Sequencher software package, version 4.10.1 from the Gene 
Codes Corporation.  
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4.3.1.6 TaqMan probe-based genotyping  
TaqMan probe-based genotyping was used for a high-throughput assessment of 
selected variants. TaqMan genotyping probes were obtained from Life Technologies. 
Each selected variant required a custom probe design. These were designed according 
to the manufacturer’s specifications. Briefly, up to 500bp upstream and downstream 
of the variant of interest was extracted from UCSC genome browser with masking of 
known SNPs and repeats (as determined by RepeatMasker) and submitted to Life 
Technologies. Variants were screened in all available TFHMS DNA samples (N=320) 
as well as 225 Tasmanian population control samples. Sample reactions were 8 µL 
with the following per sample: 
 
4 µL   Bioline SensiFAST™ SYBR® No-ROX master mix 
0.1 µL  40× TaqMan custom genotyping probe 
2.9 µL  H2O 
1 µL   Sample DNA at 10 ng/µL 
 
Thermal cycling was conducted on a LightCycler® 480 system in a 96 well plate 
format with the following cycling conditions: 
 
95ºC  10 mins 
45 cycles of: 
95ºC  10 secs 
60ºC  30 secs   
Signal acquisition  
72ºC  1 sec 
40ºC  hold  
 
 
Analysis was conducted in the LightCycler® 480 software, version 1.5.0 to determine 
sample genotypes. Confirmation by Sanger sequencing was used for samples 
identified as variant carriers, and those yielding ambiguous genotyping results.  
 
4.3.1.7 Statistical analysis of TaqMan genotyping results 
To calculate whether there is a statistical enrichment of the identified variants in the 
TFHMS resource allelic odds ratios were calculated, using a two-tailed Fisher’s exact 
test where sample size permitted. Alternatively a two-tailed Chi-square test with 
Yates’ correction was used. The variant allele frequencies in the TFHMS samples 
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were compared to the frequencies in Tasmanian population controls, and also 
separately to the Exome Variant Server (EVS) European American population 
samples271. The null hypothesis for each analysis was that the occurrence of the minor 
allele of the variant in the TFHMS samples was not enriched in comparison to the 
control samples. As the TFHMS samples contained related individuals in different 
families each family was only counted once, regardless of the number of people 
genotyped in that family. When the family contained a carrier of the minor allele this 
individual was chosen, otherwise the chosen individual was homozygous for the 
major allele. Exceptions were made in large families with multiple carriers of the 
minor allele that were separated by greater than eight meioses. This reduced the 
TFHMS samples from N=320 to N=137. Statistical tests were calculated using Prism 
6 for Mac OS X, version 6.0f from GraphPad Software, Inc. 
   
4.3.1.8 Illumina MiSeq Nextera® XT DNA custom amplicon sequencing of TNFSF9 
Overlapping amplicons, 1 kb to 5 kb in length, were designed to encompass exons, 
introns and regulatory regions of TNFSF9 using NCBI’s Primer-BLAST270. For 
primer design, known SNPs and repetitive or low complexity regions were taken into 
account and avoided by Primer-BLAST. A minimum PCR product size of 1 kb and a 
maximum of 5 kb were selected with specificity tested against the human genome. 
The primer sequences, optimised PCR reaction conditions and thermal cycling 
conditions used for each amplicon are detailed in Appendix 4.2.  
 
DNA samples from 96 TFHMS cases were selected for amplicon sequencing of 
TNFSF9. These samples were selected on the basis of disease subtype and age at 
diagnosis with preference firstly for B-cell and T-cell HMs, to match the subtypes of 
HMs diagnosed in the TNFSF9 mutation carriers, and then a preference for younger 
ages of diagnosis. Sample details are located in Appendix 4.3. For each sample, 25 ng 
of DNA was amplified for each PCR amplicon. Each PCR product was assessed by 
agarose gel electrophoresis and samples where amplicons failed to amplify were re-
amplified where possible. For each amplicon six samples were quantitated using a 
Qubit 2.0 fluorometer system with the high sensitivity (HS) assay, according to the 
manufacturer’s instructions. The measured concentrations were averaged per 
amplicon to represent the approximate PCR product concentration of each PCR 
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amplicon plate of 96 samples. For the Nextera® XT sequencing, approximately equal 
amounts of each amplicon were pooled together per sample. 12 pooled amplicon 
samples were quantitated, again using the Qubit HS assay, and the concentration was 
averaged across all samples to obtain an approximate global pooled amplicon 
concentration. The global pooled amplicon concentration was then serially diluted to 
0.2 ng/µL. This dilution was then quantitated using the Qubit HS assay to confirm 
that all samples were approximately 0.2 ng/µL. 5 µL (1 ng) of each pooled amplicon 
sample was used in the Nextera® XT kit following the manufacturer’s October 2012 
protocol. Briefly pooled amplicon samples were fragmented, into approximately 300 
bp fragments, and tagged with adapter sequences using transposomes. Index 
sequences per sample were applied in a reduced-cycle PCR amplification creating 
fragments to facilitate pooling of all 96 samples ready for high-throughput sequencing 
on the MiSeq.  
 
Paired end 300 bp read length sequencing was conducted on an Illumina MiSeq 
system. The MiSeq software automatically separated samples according to the sample 
specific indexes and generated a FASTQ data file for each sample. FASTQ files were 
aligned to the hg19 reference genome and variants called as described in section 
3.3.2. Sequencing coverage analysis was performed for the target region as described 
in section 3.3.3. Variants were filtered and annotated using ANNOVAR as described 
in section 3.3.5.  
4.4 Results 
4.4.1 Sanger sequencing confirmation of nineteen variants 
The nineteen prioritised variants, resulting from the tiered analysis in Chapter 3, from 
families LK0051, LK0124, LK0139 and LK0153, underwent laboratory confirmation 
by Sanger sequencing. This confirmed thirteen of the variants as true positives from 
the NGS analysis, as shown in Table 4.1. The variants in NOTCH1, PABPC1 and 
SPHK2 could not be confirmed. Additionally the PDE4DIP variant was unable to be 
confirmed by Sanger sequencing as specific primers could not be designed to this 
region. Accordingly a custom TaqMan genotyping probe was designed but this probe 
was unable to differentiate between variant carriers and non-carriers.  
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With thirteen variants in three families verified by Sanger sequencing, together with 
time and funding constraints, a secondary subjective prioritisation was needed to 
select two variants for more extensive laboratory analysis. Variants from LK0051 
were focused on first because of the clear inheritance pattern between the uncle-
nephew pair and their unaffected female relative; this narrowed selection to five 
variants in five genes. From these, based on the potential relevance of gene function 
to HM development; the novelty of the association between these genes and HM 
predisposition; and the specific interesting amino acid changes; the variants in TDP2 
and TNFSF9 were selected for high-throughput genotyping using custom designed 
TaqMan genotyping probes.  
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Table 4.1 Sanger sequencing confirmation of selected variants. 
 
Family Gene Variant / dbSNP138 ID if 
known 
Sanger 
sequencing 
confirmed 
LK0051 LRP5 chr11:68181292 C>A Yes 
LK0051 MMP8 chr11:102585288 T>G rs138686754 Yes 
LK0051 PEX6 chr6:42934551 G>A Yes 
LK0051 TDP2 chr6:24658126 C>T rs200729372 Yes 
LK0051 TNFSF9 chr19:6534728 G>C rs61750000 Yes 
LK0051, 
LK0124, 
LK0139, 
LK2042 
NOTCH1 chr9:139417464 T>G No 
LK0051, 
LK0124, 
LK2042 
NF1 chr17:29508805 T>G rs200962248 No 
LK0124 STT3B chr3:31659458 T>G rs199778452 No 
LK0139 DUSP10 chr1:221874839 TG>T Yes 
LK0139 PDE4DIP chr1:144863438 G>T rs140993521 
No, unable to 
design specific 
primers 
LK0139 SPHK2 chr19:49132198 A>C rs200347384 No 
LK0139, 
LK2042 PABPC1 
chr8:101721839 C>A 
rs202074479 No 
LK0153 GIT1 chr17:27904190 G>A rs202085570 Yes 
LK0153 HAL chr12:96371767 A>G rs150591434 Yes 
LK0153 MET chr7:116381047 A>G rs374733251 Yes 
LK0153 NAT10 chr11:34152973 C>A rs146685334 Yes 
LK0153 NID2 chr14:52509033 G>A rs143412278 Yes 
LK0153 RARS chr5:167929060 CCTT>C Yes 
LK0153 RIPK2 chr8:90796371 GTAA>G Yes 
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4.4.2 TaqMan genotyping of TDP2 rs200729372 and TNFSF9 rs61750000 
The TDP2 rs200729372 and TNFSF9 rs61750000 variants were examined using 
custom TaqMan genotyping probes. The variants were validated as heterozygous 
using this method in the known carriers LK0051-001, LK0051-007 and LK0051-128, 
as was confirmed by Sanger sequencing. Figures 1 and 2 in Appendix 4.4 show 
representative TaqMan genotyping plots with two of the three known variant carriers 
(LK0051-001 and LK0051-007) genotyped on the assay plate shown along with 92 
other samples homozygous for the reference allele.  
 
For TDP2 rs200729372, using TaqMan genotyping, one additional heterozygous 
variant carrier was identified as listed in Table 4.2 and was an unaffected daughter of 
a familial case with NHL. Sanger sequencing confirmed the identified variant carrier.  
 
Table 4.2 TDP2 rs200729372 additional variant carrier identified through 
TaqMan genotyping screen of TFHMS samples and population controls. 
 
ID Details Confirmed by 
Sanger sequencing 
LK0124-209 Unaffected daughter of a familial 
HM case with NHL (DNA 
unavailable) 
Yes 
  
 
For TNFSF9 rs61750000, a further eight additional heterozygous variant carriers were 
identified as listed in Table 4.3. One of these was a population control sample (out of 
225 population controls screened), resulting in a minor allele frequency (MAF) of 
0.002 in this small population. This is lower than the 0.005 MAF from the EVS 
European American population data for this variant271. The remaining seven variant 
carriers were HM cases or unaffected relatives from the TFHMS sample set, as 
described in Table 4.3. Sanger sequencing confirmed the identified variant carriers.  
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Table 4.3 TNFSF9 rs61750000 additional variant carriers identified through 
TaqMan genotyping screen of TFHMS samples and population controls. 
 
 
*LK0016-005, LK0016-007, LK0016-008 are siblings, and LK0016-004 is their uncle 
and sibling of their CLL affected parent. LK0016-187 is a distant relative, more than 
eight meioses away. 
 
 
4.4.3 Statistical analysis of population screening of TDP2 rs200729372 and 
TNFSF9 rs61750000 
To determine whether carriers of the variants identified in TDP2 and TNFSF9 from 
analysis of the LK0051 family are statistically enriched in the TFHMS resource, in 
comparison to control populations, odds ratio calculations were performed. Control 
populations for comparison were the 225 Tasmanian population controls in one 
analysis, and a second analysis conducted using a population control data set drawn 
from the EVS European and American populations271. As shown in Table 4.4, carriers 
of the TDP2 rs200729372 variant are enriched in the TFHMS resource when 
compared with the EVS samples (P=0.0028, OR=63.14 [5.71−698.80]), but not the 
Tasmanian population control samples (P=0.14), using a Fisher’s exact test.  
 
For rs61750000 in TNFSF9, as shown in Table 4.5, carriers of this variant were 
enriched in the TFHMS resource, when compared to both the EVS samples (P=0.01, 
OR=3.78 [1.49−9.64]), and the Tasmanian population control samples (P=0.03, 
ID Details Confirmed by 
Sanger sequencing 
DVA1746 Population control, no genealogical 
evidence of a family history of 
disease 
Yes 
LK0001-094 Unaffected offspring of a MM patient 
(DNA unavailable) 
Yes 
LK0016-004* Unaffected sibling of five familial 
CLL cases (DNA unavailable) 
Yes 
LK0016-005* Unaffected offspring of familial HM 
case with CLL (DNA unavailable) 
Yes 
LK0016-007* Unaffected offspring of familial HM 
case with CLL (DNA unavailable) 
Yes 
LK0016-008* Unaffected offspring of familial HM 
case with CLL (DNA unavailable) 
Yes 
LK0016-187* Familial HM case with NHL nodular Yes 
LK0628-001 Non-familial DLBCL case Yes 
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OR=8.35 [0.96−71.85]). Due to the larger number of variant carriers in the EVS 
samples a Chi-square test with Yates’ correction was performed, whereas the Fisher’s 
exact test was used for the comparison with the Tasmanian population control 
samples.  
 
Table 4.4 Statistical analysis of population screening of TDP2 rs200729372. 
 
 Minor allele 
(T) 
Major allele 
(C) 
P-value OR [95% 
CI] 
Test 
TFHMS 3 271    
Tasmanian 
population 
controls 
2 448 0.14 8.27 
[0.39−172.90] 
Fisher’s 
exact test 
EVS European / 
American 
population 
controls 
1 8587 0.0028* 63.14 
[5.71−698.80] 
Fisher’s 
exact test 
*Indicates a statistically significant finding 
 
 
Table 4.5 Statistical analysis of population screening of TNFSF9 rs61750000. 
 
 Minor allele 
(C) 
Major allele 
(G) 
P-value OR [95% 
CI] 
Test 
TFHMS 5 269    
Tasmanian 
population 
controls 
1 449 0.03* 8.35 
[0.96−71.85] 
Fisher’s 
exact test 
EVS European / 
American 
population 
controls 
42 8548 0.01* 3.78 
[1.49−9.64] 
Chi-square 
with Yates’ 
correction 
*Indicates a statistically significant finding 
 
4.4.4 Custom amplicon sequencing of TNFSF9 
With evidence that the rs61750000 variant in TNFSF9 was enriched in the TFHMS, 
when compared to both Tasmanian population controls and the EVS population 
controls, TNFSF9 was selected for whole gene screening in 96 HM cases from the 
TFHMS. Overlapping PCR amplicons were designed to cover the TNFSF9 gene. 
These amplicons were amplified in 96 HM cases from the TFHMS, as described in 
Appendix 4.3, including LK0051-001 as a known positive control, to screen for 
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variants in TNFSF9 other than rs61750000 that may be contributing to HM 
predisposition. HM cases were selected on the basis of being a familial case, or non-
familial cases with similar subtypes to the known variant carriers, LK0051-001 and 
LK0051-128, a T-cell non-Hodgkin lymphoma and a B-cell Burkitt lymphoma 
respectively. Figure 4.1 shows the sequencing depth coverage of the TNFSF9 in each 
sample, calculated as per section 3.3.3. Two samples, LK0004-012 and LK0024-001, 
had low coverage with less than 50% of the gene covered at 10× depth or greater. 
Excluding these two samples, the other 94 samples have coverage of greater than 10× 
depth for over 80% of the target region.  
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Figure 4.1 TNFSF9 coverage plot. 
Calculated in BEDTools and plotted in R this plot shows the fraction of bases (Y-
axis) at a coverage depth (X-axis). Two samples have low coverage while the 
remaining 94 samples have ≥ 80% of the region with ≥ 10× read depth.  
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Analysis of the custom amplicon sequencing data identified the known TNFSF9 
rs61750000 variant in LK0051-001 who was sequenced as a positive control as well 
as LK0016-187 and LK0628-001 as previously identified by TaqMan genotyping 
(Table 4.3). After variant filtering as per section 3.4.2 there were nineteen variants 
identified across the 96 samples, as shown in Table 4.6. As per section 3.3.7.3, when 
the CADD scoring model is applied to these variants, none are predicted to be 
deleterious using a CADD phred-like scaled C score threshold of ≥ 10. All variants 
are non-coding variants in the upstream and downstream regions of TNFSF9. No 
additional exonic variants, or variants predicted to be deleterious using CADD, were 
identified.  
  
Table 4.6 Summary of additional TNFSF9 variants identified through gene 
sequencing. 
 
Variant / dbSNP 138 ID if 
known 
Gene 
location 
CADD phred-
like scaled C 
score 
Number 
of variant 
carriers 
chr19:6530040 GACAT>G  Upstream 7.175 40 
chr19:6530956 G>A  
rs2234171 
Upstream 6.721 1 
chr19:6530033 ACAG>A  Upstream 6.229 2 
chr19:6530103 T>C  Upstream 6.188 2 
chr19:6530037 ACAG>A  Upstream 6.168 40 
chr19:6530038 CAGA>C  Upstream 6.168 40 
chr19:6535291 ATATATAT>A  3’UTR 6.166 2 
chr19:6530020 CAGAG>C  Upstream 6.106 1 
chr19:6535078 C>T  
rs75982228 
3’UTR 5.023 1 
chr19:6530036 GACA>G  Upstream 4.74 40 
chr19:6535801 C>T  
rs3865470 
3’UTR 2.87 1 
chr19:6530034 C>CACA  Upstream 2.479 6 
chr19:6530035 AGAC>A  Upstream 1.45 40 
chr19:6536461 G>A  Downstream 1.016 1 
chr19:6535297 AT>A  3’UTR 0.865 2 
chr19:6530027 AAAG>A  Upstream 0.814 3 
chr19:6530032 G>GACAC  Upstream 0.761 7 
chr19:6530024 GAGAA>G  Upstream 0.755 5 
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4.5 Discussion 
4.5.1 Validation of sequencing variants 
Sanger sequencing was used for validation of the nineteen prioritised variants that 
resulted from the family-based analyses of the LK0051, LK0124, LK0139 and 
LK0153 families in Chapter 3. Thirteen of the nineteen variants were validated. It is 
interesting to note that of the five variants that failed validation, three were identified 
across multiple families. The remaining variant of the nineteen in PDE4DIP was 
unable to be validated by Sanger sequencing or by using a custom TaqMan 
genotyping probe. This variant is located in a region of high homology to other 
genomic locations, explaining the difficulty in designing specific PCR primers. 
Further optimisation is required to genotype this variant. The remaining variants that 
failed validation in NF1, NOTCH1, PABPC1, SPHK2 and STT3B are likely to be 
artefacts of the NGS process, or result from errors in sequence alignment and variant 
calling. The identification of these false positives highlights the need for variant 
validation by an alternate method such as Sanger sequencing.  
 
The occurrence of false positives is an expectation in NGS data as the current 
technologies have error rates ranging from one error in one thousand nucleotides 
(99.9%) to one error in ten million nucleotides (99.9999%) as reviewed in Robasky et 
al.269. With limitless funding false positive rates could, hypothetically, be reduced by 
sequencing multiple replicates of the same sample across multiple NGS technologies. 
However as such an approach is not typically feasible, read depth and base call 
quality are relied upon, as was used in this study. Setting a higher threshold for these 
values may reduce the number of false positives, at the risk of removing true variants. 
Sharing analyses, as was used to identify the prioritised variants in this chapter, also 
assists in reducing the number of false positives, as identification of the same variant 
across different samples increases support for this variant being a true positive.  
 
4.5.2 Resource genotyping of selected prioritised and validated variants  
With thirteen variants validated by Sanger sequencing from NGS analysis and 
prioritisation in three of the five TFHMS families analysed, the two variants with the 
strongest biological evidence supporting a role in HM susceptibility in family 
LK0051 were selected for genotyping across the TFHMS resource (N=320) and a set 
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of Tasmanian population controls drawn from the case-control study of prostate 
cancer outlined in section 2.2.3 (N=225). The variants selected were the rs200729372 
C>T variant in TDP2, based on the DNA damage repair role of the encoded 
protein272, and the rs61750000 G>C variant in TNFSF9 based on the established role 
of the encoded protein in B-cell and T-cell biology273.  
 
4.5.2.1 TDP2 rs200729372 C>T 
Genotype screening of the TDP2 rs200729372 variant in the TFHMS resource and 
Tasmanian population controls identified this variant in the unaffected daughter of a 
familial HM case with NHL (DNA of the case was unavailable) in addition to the 
LK0051 family. Statistical analysis of the allele frequencies of this variant using a 
Fisher’s exact test did not identify enrichment of the variant in the TFHMS resource 
in comparison to the genotyped Tasmanian population controls. However in 
comparison to the allele frequency in the EVS Caucasian population (N=4295) a P-
value of 0.0028 and an OR of 63.14 [5.71−698.80] was found. This finding provides 
supportive evidence that the variant may be contributing to HM predisposition. Even 
so, a larger number of Tasmanian population controls should be screened for this 
variant. As well as genotyping of other HM cases, for this and other TDP2 variants, 
particularly B-cell and T-cell HM subtypes given the occurrence of this variant in 
TFHMS cases with these types of HMs. The connection between this TDP2 variant 
and HM development is a novel finding. Additionally, it is interesting to note that this 
variant appears only in Caucasian populations in large public databases of genetic 
variation, including the EVS271, 1000GP236 and the recent Exome Aggregation 
Consortium (ExAC)274 populations. This is consistent with the higher prevalence of 
HMs in Caucasian populations, as discussed in Section 1.4. 
 
The TDP2 variant causes an amino acid change converting a serine residue to an 
asparagine residue at position 144 of the tyrosyl-DNA phosphodiesterase 2 protein. 
The asparagine residue is a larger amino acid with different hydrophobicity properties 
to the serine residue. While the specific protein structure of human TDP2 is unknown, 
the homologous mouse Tdp2 protein structure has been determined275 which allowed 
structural modelling of this variant using the Project HOPE interface250. Located on 
the surface of the protein the S144N amino acid change may disturb hydrophobic 
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interactions with other molecules at the protein surface, however molecular contacts 
with this specific residue have not been identified. The change occurs within the 
phosphodiesterase protein family domain of TDP2. This domain is responsible for the 
repair of topoisomerase-induced DNA double strand breaks by cleaving the 
covalently bound topoisomerase at the 5’ end of the DNA break, freeing the end for 
DNA repair272.  
 
The DNA repair role of TDP2 has been shown to occur through error-free non-
homologous end-joining276. Transgenic mice with a Tdp2 deficiency do not show an 
overt phenotype276. However, when challenged with the topoisomerase inhibitor and 
anti-cancer drug etoposide, mice with a Tdp2 deficiency have an increase in genome 
instability in haematopoietic cells in the bone marrow276. This is evidence that TDP2 
has a role in maintaining genomic stability through its interactions with 
topoisomerase. It is possible that the S144N mutation in the LK0051 family causes a 
dysfunctional TDP2, which increases genome instability and contributes to HM 
predisposition. Furthermore, publically accessible microarray gene expression 
profiling data from the GeneAtlas dataset252,253 for TDP2 shows that this gene has 
elevated mRNA expression in haematopoietic cells, as well as the small intestine and 
colon (Appendix 4.5 A). Increased expression in these tissues suggests a biological 
role for this gene. The elevated expression in the small intestine and colon is 
interesting in light of the HM subtype of one of the carriers of this variant, LK0051-
128, who has BL of the small intestine. This suggests that TDP2 activity may be 
important in haematopoietic tissues, particularly those of the small intestine, and 
deregulation may have contributed to a HM predisposition in variant carriers.  
 
4.5.2.2 TNFSF9 rs61750000 G>C 
Genotype screening of the TNFSF9 rs61750000 variant in the TFHMS resource and 
Tasmanian population controls identified this variant in a non-familial DLBCL case, 
one other familial HM case with NHL and five unaffected first-degree relatives of 
familial cases. Statistical analysis of the allele frequencies of this variant identified 
evidence for enrichment of the variant in the TFHMS resource in comparison to both 
the genotyped Tasmanian (N=225) and the EVS population controls (N=4295) with 
P-values of 0.03 (OR=8.35 [0.96−71.85]) and 0.01 (OR=3.78 [1.49−9.64]) 
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respectively. Additionally, it is interesting to note that this variant appears in 
Caucasian, African and Latino populations, but not Asian, in large public databases of 
genetic variation, including the EVS271, 1000GP236 and the recent Exome Aggregation 
Consortium (ExAC)274 populations. This is consistent with the higher prevalence of 
HMs in Caucasian populations, as discussed in Section 1.4 and also raises the 
question of whether this variant may also contribute to specific HMs in African or 
Latino populations, particularly given that BL, related to EBV infection, is endemic to 
Africa63. 
 
With statistical evidence implicating the TNFSF9 variant rs61750000 in HM 
development a set of 96 HM cases from the TFHMS were screened for additional 
TNFSF9 variants that may be contributing to HM development, using custom 
amplicon sequencing of the gene. Several variants were detected, however none were 
predicted to have an effect on gene function, leaving rs6175000 as the most 
deleterious variant identified in TNFSF9. It is possible that screening more HM cases, 
specifically cases with Burkitt lymphoma or T-cell non-Hodgkin lymphoma, would 
identify additional variant carriers of the rs61750000 variants or other coding or 
regulatory variants that impact upon gene function.  
 
The rs61750000 variant results in a glycine to alanine amino acid change at residue 
139 (G139A) of the TNF ligand superfamily member 9 protein, within the TNF 
protein domain. The TNFSF9 protein occurs as a homotrimer of three TNFSF9 
subunits in a ‘propeller’ conformation277. The glycine to alanine residue change in 
terms of amino acid properties is a very conservative change; the alanine residue 
differs from the glycine by a single methyl group. However, the change occurs at a 
residue that is completely conserved across all homologous alignments of the TNF 
protein domain (Appendix 4.6 Figure 1), indicating that the glycine amino acid at this 
location is biologically important and a small change may have a significant impact 
on protein function. The change also occurs nearby two residues that form part of the 
trimer interface between the TNFSF9 subunits, potentially impacting on formation of 
the TNFSF9 homotrimer (Appendix 4.6 Figure 2). Indeed the introduction of a 
V140A mutation directly next to the G139A prevents homotrimer formation in 
vitro277.  
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TNFSF9 is an extracellular transmembrane protein277. It is the ligand for the 
TNFRSF9 receptor, also expressed on the cell membrane and is able to act as a 
bidirectional signalling molecule273. Functionally, TNFSF9 is mainly expressed on 
antigen presenting cells including dendritic cells, monocytes, macrophages and B-
cells273. It is able to co-stimulate proliferation of T-cells through the TNFRSF9 
receptor and can signal back into the antigen presenting cells inducing proliferation, 
prolonging cell survival and enhancing the secretion of proinflammatory cytokines273. 
However, when expressed on T-cells, TNFSF9 when stimulated leads to an inhibition 
of T-cell proliferation and promotes apoptosis278,279. This highlights the ability of 
TNFSF9 to affect opposite signalling pathways depending upon the cell type 
involved. Evidence implicating the involvement of TNFSF9 in HM development 
includes the finding of recurrent deletion of the gene in DLBCL and BL280 and the 
development of B-cell lymphomas in 60% of transgenic Tnfsf9 deletion mice by one 
year of age281. Furthermore gene expression profiling data from the GeneAtlas 
dataset252,253 for TNFSF9 shows elevated expression in B-cells and two HM cell lines; 
the BL DAUDI cell line and the APML HL60 cell line (Appendix 4.5 B). How the 
observed increase in TNFSF9 expression in the HM cell lines reconciles with the loss 
of expression in TNFSF9 transgenic knock-out mice and human HMs remains to be 
determined. However, it is possible that, paradoxically, both loss of function and gain 
of function in TNFSF9 contributes to HM development, as is known for RUNX1282. 
Taken together, these data provide compelling evidence that supports a potential role 
for deleterious variants in TNFSF9 contributing to the biology of familial HM 
predisposition. 
 
The connection between a germline mutation in TNFSF9 and HM predisposition is a 
novel finding. The plausible biological links that support the role of TNFSF9 in the 
development of familial HMs present a new avenue of research in this area. It is 
possible that the TNFSF9 rs61750000 variant contributed to HM development in 
LK0051-001 and LK0051-128 in combination with the other candidate variants 
identified. Functional validation of the effect of this variant on TNFSF9 protein 
activity, together with identification of this, or other, recurring deleterious TNFSF9 
variants in familial and non-familial HM cases will provide the supporting evidence 
to implicate disruption of this gene as a causal factor in HM development.  
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4.6 Conclusion 
This chapter described the validation experiments of nineteen prioritised variants 
implicated in HM development from NGS analysis of four TFHMS families. Thirteen 
variants were validated by Sanger sequencing as true variants. Two of these variants, 
rs200729372 in TDP2 and rs61750000 in TNFSF9, from the LK0051 family, because 
of compelling biological evidence implicating the potential involvement of these 
genes in HM development, were genotyped in the full 320 individuals of the TFHMS 
resource and 225 Tasmanian population controls. Statistical analyses of allele 
frequencies identified the TDP2 variant as statistically enriched in the TFHMS 
resource in comparison to EVS Caucasian controls, but not Tasmanian population 
controls, whereas the TNFSF9 variant was enriched in TFHMS in comparison to both 
control groups. Screening of the TNFSF9 gene by amplicon-based NGS in 96 
TFHMS cases did not identify any other deleterious variants in addition to rs6175000.  
 
This is the first report of a connection between HM susceptibility and germline 
variation in TDP2 and TNFSF9. The analyses conducted here are the first stage in 
establishing a causal role for variants in these genes and HM predisposition. These 
novel findings suggest that further studies of the biological effect of these specific 
variants, and these genes, in the context of HM development are warranted.  
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Chapter 5 - Variance components modelling of telomere 
length in TFHMS 
 
5.1 Preface 
Sections of this chapter were published in Oncology Reports in 2015. The article, 
entitled ‘A retrospective examination of mean relative telomere length in the 
Tasmanian Familial Haematological Malignancies Study’1, is included in this 
dissertation as Appendix 5.1. 
 
5.2 Introduction 
Telomeres are hexameric nucleotide repeat sequences of TTAGGG found at the ends 
of chromosomes283. The primary role of the telomere is to cap chromosome ends to 
prevent aberrant recombination as a result of exposed chromosomal DNA making 
telomeres essential for maintenance of genomic integrity284. Due to the incomplete 
DNA replication of chromosome ends by DNA polymerases, with each cell division 
telomeres shorten, eventually triggering cell senescence or apoptosis to prevent 
further shortening and exposure of chromosomal DNA285. While the telomerase 
complex counteracts telomere shortening in actively dividing cells by catalysing the 
addition of TTAGGG repeats to chromosome ends285,286, telomeres nevertheless 
progressively shorten with age285,287,288. 
 
5.2.1 Telomere length in haematological malignancies 
There is accumulating evidence that implicates telomere length as an important factor 
in the development of a range of HMs. As discussed in section 1.5.4.1 inherited 
changes in telomere length as a result of mutations in the telomere complex genes 
TERT and TERC have been identified in four HM families with MDS-AML147. Other 
studies have identified shorter telomeres in circulating tumour cells of patients with 
AML289, cutaneous T-cell lymphoma290, MM291, MPNs292, APML293 and ALL294. 
While these studies have revealed important insights into telomere dynamics in 
circulating tumour cells there has been less focus on pre-disease and remission 
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telomere lengths of non-malignant blood cells in HM patients. Indeed, one 
prospective study of telomere length in pre-disease blood samples surprisingly 
showed that longer telomere length was associated with a future risk of NHL295. 
Further, in a study of chronic leukaemia, Mansouri and colleagues elegantly show that 
telomere length has potential as a clinical prognostic marker in HMs296. In their study 
patients with shorter telomeres were associated with high-risk genetic markers and in 
patients with otherwise good prognostic markers, telomere length was an independent 
prognostic factor that subdivided the good prognosis group into groups with distinct 
outcomes. Therefore there is potential for telomere length to be a clinically relevant 
prognostic risk factor for HMs.  
 
The compounding effects of disease and chemotherapy regimens may complicate 
retrospective studies as it has been suggested that these factors contribute to telomere 
length shortening. Although, examination of telomere length in APML showed that 
whilst telomere length changed over the course of disease and chemotherapy, when 
complete remission was achieved there was no difference between telomere length in 
patients and controls293. A recent larger study in a chronic leukaemia, CLL, that also 
sequentially followed patients over disease course and treatment showed that telomere 
length at diagnosis remained unaffected by chemotherapy in remission296.  
 
5.2.2 Telomere length as a quantitative trait in cancer 
A number of studies have reported an association between telomere length, as a 
quantitative trait in lymphocytes, and an increased risk of age-related diseases, 
including cancer297,298. Excessive telomere shortening leads to increased genetic 
instability, decreased chromosomal stability and chromosome end-to-end 
fusions284,299, which can lead to a malignant cell transformation299. Thus telomere 
length is a proposed risk factor for cancer given its importance in maintaining 
genomic integrity. Shorter telomeres have been associated with a range of cancers 
including cancers of the head and neck, bladder, lung and renal cells297,298,300. 
 
Studies of monozygotic and dizygotic twins and large families have indicated a 
genetic component to the determination of telomere length. Estimates of the 
heritability of telomere length as a trait range between 78% and 82% in studies of 
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twins and sibling pairs301,302 and 44% in a study of large Amish families303. Although 
it has been proposed that the heritability of telomere length can be accounted for by 
shared environmental factors304 the consensus is that telomere length is primarily 
determined by parental inheritance including at least partial inheritance of 
chromosome specific telomere lengths305,306. This view is strongly supported by 
mouse models of telomere length inheritance307.  
 
Telomere length, as a quantitative trait, can be measured by a range of different 
techniques including flow-FISH, single telomere length analysis (STELA), southern 
blotting and quantitative PCR-based methods308. For many years southern blotting 
was viewed as the gold standard for measuring telomere length309. The development 
of the monochrome multiplex quantitative PCR-based assay has introduced a method 
of measuring telomere length that has many practical and analytical improvements on 
southern blotting, and in addition, shows linear correlations with the original 
technique310,311. This assay has facilitated large-scale quantitative studies of telomere 
length in a variety of contexts. 
 
5.2.3 Quantitative traits 
Quantitative traits, such as telomere length, are useful as disease markers. As 
explained by Almasy312, identifying the sources of variance in a quantitative trait 
between individuals, identifies why they are different to each other. The two sources 
of variance are genotype and environment, that is, variance in a trait is the result of a 
genetic contribution and/or an environmental contribution (or their interaction). The 
heritability of a trait is a measure of the genetic contribution to the variation in the 
trait. A trait that is highly heritable will therefore be driven primarily by genetics, 
whereas low heritability can suggest that environmental factors such as lifestyle are a 
larger contributor to variation in the trait.  
 
One method of examining the factors or covariates that contribute to variation in a 
quantitative trait like telomere length is to measure the trait in large families with 
known pedigree structures313. With the pedigree structure comes relationship 
information from which kinship coefficients can be calculated. As shown by Almasy, 
first degree relative pairs (siblings, parent-offspring) will share 50% of their genetics 
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with the degree of sharing halving with each degree of familial separation312,313. 
People related by multiple lines of descent, through consanguineous relationships for 
example, will share more than the same relationship without multiple lines of descent. 
These kinship coefficients, together with the phenotypic information from the 
quantitative trait, allow the calculation of the trait’s heritability. If a trait is heritable it 
follows that more closely related relatives, due to shared genetics, will have more 
similar trait values with distant relatives still having a closer trait correlation than two 
unrelated individuals. In this way family studies have a much greater power for 
detecting the genetic contributions to trait variation than population studies of 
unrelated individuals. In a population study the trait of interest may be influenced by 
many different genes, specific to each person, which may dilute rare and low 
frequency genetic variants that have a large effect on trait variation to an undetectable 
level186. Whereas when studying a family or series of families, the analysis is based 
on related individuals, so there is enrichment for the same genetic variants due to 
identical by descent (IBD) flow of chromosomes through the pedigree. The dilution 
that is seen in population studies is therefore avoided. This enhances the ability to 
detect factors contributing to trait variation186.   
 
Using the method of variance components modelling, accounting for kinship, the 
degree to which various covariates contribute to the variation in the trait can be 
assessed313. A significantly associated covariate indicates that changes in that 
covariate account for part of the measured difference in the trait. Covariates can be 
factors such as age, sex, disease status or genotype data. This means that variance 
components modelling analysis can be used to identify phenotypic covariates and 
genetic variants that account for trait variation.  
 
Given the evidence supporting a role for telomere length and genes influencing 
telomere biology in cancer and HMs, as well as its heritability as a quantitative trait, 
telomere length was examined in the TFHMS resource. Examining telomere length in 
HM families may identify factors related to HM disease development and inform 
biomarkers for disease risk estimation. Variance components modelling was 
employed to analyse telomere length in the TFHMS resource, to identify new 
evidence of whether telomere length is involved in HMs. 
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5.3 Aims 
The aim of this study was to explore in the TFHMS resource whether telomere length 
as a quantitative trait is involved in familial HMs and to find new evidence supporting 
telomere length as a prognostic risk factor for HMs. 
 
5.4 Methods 
5.4.1 Study samples for telomere length measurement 
Telomere length was measured in DNA extracted from peripheral blood samples, as 
per section 2.2.4, from 55 familial HM cases, 191 unaffected relatives of familial 
cases and 75 non-familial cases. DNA from 40 TFHMS families was available for this 
study with samples available from both HM cases and unaffected relatives in 14 
families.  The remaining families were comprised of samples from HM cases with a 
known family history of disease alone or from unaffected relatives of HM cases. Of 
the 191 unaffected relatives, 171 were first-degree relatives of HM cases and the 
remainder were more distantly related or spouses. For HM cases, DNA was collected 
from 1 month to 64.9 years post HM diagnosis (mean 9.9 years). Population controls 
(N=758) are detailed in section 2.2.3. 
 
5.4.2 Telomere length measurement 
Mean relative telomere length was measured in peripheral blood samples using a 
slightly amended protocol for a validated monochrome multiplex quantitative PCR 
method outlined by Cawthon311. This method measures the relative telomere length 
by calculating the ratio, T/S, between telomere repeat copy number amplification (T) 
and the amplification of a single-copy gene, albumin ALB (S). The average T/S ratio 
was obtained as the mean of the triplicate measurements for each sample. Individual 
measurements were excluded from average T/S ratio calculation when the replicate 
failed or a large standard error was observed. The coefficient of variation calculated 
across all assay plates using repeated cross-plate samples was 3.4%. 
 
Telomere length measurement was performed in 10 µl reaction volumes using a 
LightCycler480 in a 96 well plate format. Each 96 well plate contained a six point 
standard curve 2 ng, 5 ng, 15 ng, 50 ng, 100 ng and 150 ng, a unique sample common 
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to each plate, a no template control and 24 unknown case / controls samples all 
repeated in triplicate, with 1.6% sample replication across plates. The genomic DNA 
used for the standard curve was from a 27-year-old female control study participant.  
 
Final reagent concentrations per sample were:  
5 ng  Genomic DNA,  
200 nM  primer telg (5’-acactaaggtttgggtttgggtttgggtttgggttagtgt-3’) 
700 nM  primer telc (5’-tgttaggtatccctatccctatccctatccctatccctaaca-3’) 
500 nM  primer albu  
(5’-cggcggcgggcggcgcgggctgggcggaaatgctgcacagaatccttg-3’) 
500 nM  primer albd  
(5’-gcccggcccgccgcgcccgtcccgccggaaaagcatggtcgcctgtt-3’) 
0.625 U  Amplitaq gold (Applied Biosystems Inc.)  
GeneAmp 10×PCR buffer (Life Technologies) containing:  
50 mM KCl  
10 mM Tris-HCl pH 8.3  
1.5 mM MgCl2  
1 mM   DTT  
1 M   Betaine (Sigma-Aldrich)  
0.0025 mM  Syto 9 (Life Technologies)  
0.25 mM  Of each dNTP (Bioline)  
 
Thermal cycling conditions were as follows:  
95°C  15 mins  
Two cycles of:   
94°C  15 secs  
49°C  60 secs  
Four cycles of:  
84°C  20 secs  
59°C 30 secs  
40 cycles of:  
94°C 15 secs  
59°C 30 secs 
Signal acquisition for telomere repeat copy number amplification   
84°C  30 secs  
85°C 20 secs  
Signal acquisition for albumin amplification  
 
A melt curve was generated for each plate. CT values were calculated using 
LinRegPCR314 and a standard curve was generated for both the telomere and albumin 
PCRs. A linear regression of the standard curve measurement values was used to 
correct for any variation in fluorescence levels derived from small fluctuations in 
DNA concentration. The equations from the linear regression of each standard curve 
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were then used to calculate the log(DNA) value for the unknown case / control 
samples. 
 
5.4.3 Statistical analysis 
Average T/S ratios greater than 4 standard deviations from the control mean were 
excluded as outliers. For analysis, to prevent non-normal distribution errors, mean 
relative T/S ratios were transformed to fit a normal distribution using the inverse-
normalisation option in SOLAR (version 6.6.2)312,313. In order to fully utilise the 
extended pedigree study design, correct for relatedness, and to maximise the 
information provided by telomere length as a quantitative trait we used variance 
components modelling in SOLAR312,313 to determine the heritability of telomere 
length (adjusting for kinship and significant covariates) and to calculate the 
association between telomere length and disease. The primary benefit to using 
SOLAR is its ability to incorporate relatedness through the use of a kinship matrix 
and to fully utilise the quantitative trait data, which increases the power and accuracy 
of the trait heritability calculation. 
 
Sex, age, age2 and their interactions were included as covariates in all relevant 
analyses. Potential batch effects were adjusted for by applying household 
modelling312,313, coding each assay plate as a separate household. SOLAR has been 
used previously in the analysis of telomere length in related individuals302,303,315. The 
algorithms utilised in SOLAR for the analysis of quantitative traits in related 
individuals are more appropriate to employ in this study than a more traditional 
approach of analysing quantitative traits using percentiles or quartiles. Nevertheless, 
observations from a quartile analysis of inverse normalised relative T/S ratios 
adjusted for age, sex and batch effects in SOLAR with quartiles defined from the 
adjusted T/S ratios in the control population, are also presented. Bean plots in Figure 
1 were constructed using the R package ‘beanplot’316. 
 
5.4.4 Analysis of genetic variants in telomere biology related genes 
Variants identified through NGS of 31 TFHMS individuals as described in Chapter 3, 
section 3.3.5, were used as a variant set to identify variants contributing to shorter 
telomere length in measured individuals, particularly sequenced HM cases who were 
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in the lowest quartile of telomere length. The 96,220 variants from section 3.3.5 were 
filtered as per section 3.3.7.3 to contain variants with CADD phred-like scaled C 
scores ≥ 10. These are variants within the top 10% of variants predicted by the CADD 
model to be deleterious244.  
 
Then, variants in a curated list of genes known to be related to telomere biology were 
extracted for analysis. The curated list of 162 genes (Appendix 5.2) is built from 
genes located in the following human pathways from NCBI’s Biosystems317, 
‘Extension of Telomeres’, ‘Regulation of Telomerase’, ‘Telomere Extension By 
Telomerase’, ‘Telomere Maintenance’, together with 43 telomere biology genes 
defined by Mirabello et al.318. The average number of variants of samples in the 
lowest quartile of telomere length was compared to samples not in this quartile using 
two-tailed t tests (assuming a Gaussian distribution), conducted in Prism 6 for Mac 
OS X, version 6.0f from GraphPad Software, Inc. 
 
5.5 Results 
5.5.1 Participant characteristics  
Families and the numbers of individuals in which telomere length was measured in 
this study are shown in Table 5.1. Table 5.2 shows the mean age and sex 
characteristics of the sample groups measured, together with mean relative T/S ratios 
with 95% confidence intervals. The distribution of HM case subtypes for whom 
telomere length was measured are summarised in Table 5.3. 
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Table 5.1 Summary of the TFHMS families used in this study. 
 
Family Known 
HM cases 
Generations 
with HM 
cases 
HM cases with 
telomere 
length 
measurement 
Unaffected 
relatives with 
telomere length 
measurement 
LK0001 14 4 1 16 
LK0002 15 3 1 5 
LK0004 7 2 1 11 
LK0016 18 5 2 19 
LK0024 3 2 1 0 
LK0026 6 2 1 5 
LK0040 7 4 2 2 
LK0051 21 5 3 26 
LK0054 9 3 0 2 
LK0065 8 2 0 8 
LK0124 24 5 2 34 
LK0132 5 2 0 7 
LK0139 7 2 1 2 
LK0153 9 2 3 2 
LK0511 2 2 1 0 
LK0512 2 1 1 0 
LK0537 2 1 2 0 
LK0546 2 2 1 0 
LK0560 2 2 1 0 
LK0561 2 2 1 0 
LK0600 5 3 2 0 
LK0625 4 2 2 0 
LK0647 2 2 1 0 
LK0672 3 3 1 0 
LK0836 6 3 2 5 
LK1155 2 1 1 3 
LK2042 32 5 6 40 
LK2447 3 2 1 2 
LK6000 6 2 1 0 
LK7739 2 1 1 0 
LK7740 2 2 2 0 
LK7743 3 2 2 0 
LK7744 2 2 0 1 
LK7748 2 2 1 0 
LK7749 3 2 1 0 
LK7750 4 2 2 0 
LK7751 9 3 1 0 
LK7754 3 1 1 0 
LK7755 2 2 1 0 
LK7768 2 1 1 0 
Non-familial cases -- -- 75 1 
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Table 5.2 Mean age, sex distribution and relative telomere length in the sample 
groups. 
 
Sample group Number Male sex, 
No. (%) 
Mean age (range) Mean relative T/S 
ratio* (95% CI) 
Controls 758 578 (76.3) 67.51 (30.67 – 87.97) 0.64 (0.62 – 0.66) 
Unaffected relatives of 
HM cases 
191 77 (40.3) 61.65 (27.26 – 92.95) 0.73 (0.69 – 0.76) 
All HM cases 130 73 (56.2) 65.14 (13.24 – 95.53) 0.53 (0.50 – 0.56) 
Familial HM cases 55 32 (58.2) 64.45 (13.24 – 87.45) 0.57 (0.52 – 0.63) 
Non-familial HM cases 75 41 (54.7) 68.79 (22.42 – 95.53) 0.50 (0.46 – 0.53) 
*Mean relative T/S ratio is the ratio between telomere repeat copy number (T) and a single-copy 
gene, ALB, copy number (S), a measure of mean relative telomere length 
 
 
Table 5.3 Disease characteristics of study samples. 
 
HM Subtypes HM Familial 
cases No. (%) 
HM Non-familial 
cases No. (%) 
All HM cases 
No. (%) 
Acute lymphoblastic leukaemia 2 (3.6) 0 2 (1.5) 
Acute myeloid leukaemia 5 (9.1) 8 (10.7) 13 (10.0) 
Chronic myeloid leukaemia 0 3 (4.0) 3 (2.3) 
Essential Thrombocythemia 1 (1.8) 1 (1.3) 2 (1.5) 
Hodgkin Lymphoma 5 (9.1) 4 (5.3) 9 (6.9) 
Myelodysplastic syndrome 2 (3.6) 0 2 (1.5) 
Myeloproliferative neoplasm 1 (1.8) 2 (2.7) 3 (2.3) 
T-cell Non-Hodgkin lymphoma 1 (1.8) 2 (2.7) 3 (2.3) 
Mature B Cell Neoplasms       
Non-Hodgkin lymphoma unclassified 2 (3.6) 10 (13.3) 12 (9.2) 
Chronic lymphocytic leukaemia 12 (21.8) 12 (16.0) 24 (18.5) 
Diffuse large B-cell lymphoma 4 (7.3) 10 (13.3) 14 (10.8) 
Follicular Lymphoma 4 (7.3) 9 (12.0) 13 (10.0) 
Multiple myeloma 7 (12.7) 5 (6.7) 12 (9.2) 
other* 9 (16.4) 9 (12.0) 18 (13.8) 
Total 55 75 130 
*other includes Burkitt lymphoma, hairy cell leukaemia, lymphoma of mucosa-associated 
lymphoid tissue and Waldenström macroglobulinemia 
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5.5.2 Heritability of telomere length in TFHMS 
Telomere length in familial and non-familial HM cases, unaffected relatives and 
control subjects was measured and the heritability of telomere length was calculated 
to be 62.5% (P=4.7×10−5, SE=0.14). The removal of HM cases (n=130) from analysis 
only marginally altered the heritability value of mean relative telomere length (75.5%; 
P=1.2×10−5, SE=0.15). 
 
5.5.3 Variance components modelling analysis of telomere length in TFHMS 
The use of variance components modelling in SOLAR permits appropriate statistical 
analyses inclusive of familial relationships. These analyses revealed that disease 
status was significantly associated with mean relative telomere length (Table 5.4, 
primary analysis model 1, P=2.9×10−6) with HM cases having shorter mean relative 
telomere length when compared with unaffected individuals. We conducted a separate 
analysis distinguishing familial and non-familial cases. Familial cases and non-
familial cases each had significantly shorter mean relative telomere length (Table 5.4; 
primary analysis model 2, P=2.2×10−4 and 2.2×10−5, respectively). 
 
The most frequent type of HM diagnosed in our study was the mature B-cell 
neoplasms (MBCNs; Table 5.3). Analysis of MBCNs as one group and HMs other 
than MBCNs as a second group (combined due to small numbers of other subtypes) 
showed that both groupings had shorter mean relative telomere length than unaffected 
individuals from both study families and population controls (Table 5.4; primary 
analysis model 3, P=3.5×10−5, P=9.3×10−5 respectively). These groupings were then 
divided according to whether the HM case was familial or non-familial. Analysis 
showed that all HM case subgroupings maintained significantly shorter mean relative 
telomere length (Table 5.4; primary analysis model 4). An analysis using specific HM 
subtypes was not possible due to insufficient statistical power at this level of HM 
classification with small numbers of HM subtypes (Table 5.3).  
 
Variance components modelling also identified age and sex (Table 5.4; primary 
analysis model 1, P=4.8×10−8 and 4.0×10−3 respectively) as significant covariates for 
mean relative telomere length variation across all models. Mean relative telomere 
length declined with age and males had shorter telomeres than females. Age2 was also 
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a significant covariate, indicating that the decline of mean relative telomere length 
with age has a non-linear component (Table 5.3; primary analysis model 1, 
P=8.0×10−3). 
 
Four sub-analyses of the primary data were also performed to determine whether 
particular features of the study population were contributing to the disease 
associations found in the primary analysis models (Table 5.4). Sub-analyses included 
exclusion of HM cases, controls and unaffected relatives 80 years or older (n=126), 
exclusion of CLL cases (n=24), exclusion of cases with samples collected within two 
years of diagnosis (n=24) as well as all three exclusions together (n=162, some 
individuals were in multiple exclusion categories). In each sub-analysis the principle 
findings from the primary analysis models were maintained. 
 
Categorisation of cases into quartiles of mean relative telomere length determined 
from the distribution of age, sex and batch effect adjusted mean relative telomere 
length in controls (Figure 5.1) shows that 43.1% of HM cases were in the lowest 
quartile of mean relative telomere length (below lower interquartile dashed line). 
With 36.4% of familial HM cases and 48% of non-familial HM cases in the lowest 
quartile, only 13.1% of unaffected relatives were compartively in the lowest quartile. 
Similarly a low percentage of cases (5.4%) were in the highest quartile of mean 
relative telomere length (above upper interquartile dashed line) whereas 28.3% of 
unaffected relatives were in the highest quartile. A clear trend for shorter mean 
relative telomere length in a higher percentage of HM cases is observed but this 
analysis does not permit familial relationships to be included in the analysis. 
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Table 5.4 Variance component modelling analysis of inverse normalised mean 
relative telomere length - primary analysis and sub-analyses with exclusions. 
 
Models and variables 
Primary 
Analysis 
P-values 
≥ 80 
years old 
excluded 
(N=126) 
P-values 
CLL cases 
excluded 
(N=24) 
P-values 
Possible 
malignant 
samples 
excluded* 
(N=24) 
P-values 
All  
exclusions 
applied 
(N=162) 
P-values 
Model 1      
age 4.8×10−8 7.5×10−5 1.6×10−8 6.9×10−8 3.4×10−5 
age2 8.0×10-3 0.04 6.0×10-3 0.01 0.07 
sex  4.0×10-3 0.01 7.0×10-3 2.0×10-3 0.01 
all HM cases 2.9×10−6 7.3×10−6 2.9×10−7 1.1×10−4 4.6×10−5 
% trait variance 
accounted for by model 
10.07% 9.46% 10.38% 9.56% 9.38% 
Model 2      
age 4.3×10−8 5.1×10−5 1.6×10−8 7.4×10−8 3.7×10−5 
age2 8.0×10-3 0.04 6.0×10-3 0.01 0.07 
sex 3.0×10-3 0.01 6.0×10-3 2.0×10-3 9.0×10-3 
familial HM cases 2.2×10−4 1.0×10-3 1.6×10−5 0.01 8.0×10-3 
non-familial HM cases 2.2×10−5 6.9×10−6 7.1×10−5 3.3×10−5 2.7×10−5 
% trait variance 
accounted for by model 
10.62% 10.29% 10.55% 10.48% 10.00% 
Model 3      
age 4.7×10−8 7.2×10−5 1.7×10−8 7.7×10−8 3.7×10−5 
age2 8.0×10-3 0.04 6.0×10-3 0.01 0.07 
sex 4.0×10-3 0.01 6.0×10-3 2.0×10-3 0.01 
MBCNs 3.5×10−5 7.8×10−5 5.5×10−6 5.7×10−4 3.8×10−4 
HMs other than 
MBCNs 
9.3×10−5 1.5×10−4 3.4×10−5 1.0×10-3 5.8×10−4 
% trait variance 
accounted for by model 
10.08% 9.50% 10.37% 9.56% 9.39% 
Model 4      
age 4.8×10−8 4.1×10−5 1.9×10−8 6.6×10−8 3.8×10−5 
age2 9.0×10-3 0.05 7.0×10-3 0.02 0.08 
sex 3.0×10-3 0.01 6.0×10-3 2.0×10-3 9.0×10-3 
familial MBCNs 0.02 0.04 3.0×10-3 0.18 0.07 
familial cases other 
than MBCNs 
5.2×10−4 3.0×10-3 5.7×10−4 0.01 0.04 
non-familial MBCNs 2.4×10−5 1.5×10−5 1.3×10−4 4.8×10−5 1.5×10−4 
non-familial cases 
other than MBCNs 
2.0×10-3 4.2×10−4 3.0×10-3 2.0×10-3 3.2×10−4 
% trait variance 
accounted for by model 
10.87% 10.58% 10.57% 10.45% 10.05% 
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Figure 5.1 Bean plot quartile analysis of adjusted inverse normalised relative 
telomere lengths.  
The adjusted inverse normalised relative telomere length for each group is displayed 
as a bean plot with individual sample measurements as lines within the bean and the 
overall distribution of all samples in each group shown. Horizontal bars for each bean 
indicate the mean of each group. The solid line and dashed lines show the mean and 
interquartile range of the control group. 
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5.5.4 Genetic variants in telomere biology genes in individuals in the lowest 
quartile of telomere length 
Of the 31 individuals genome or exome sequenced as per Chapter 3, 21 also have 
telomere length measurements. Within these 21 individuals, five HM cases (LK0124-
179, LK0124-202, LK0153-004, LK2042-006, LK2042-257) and one unaffected first-
degree relative of a case (LK2042-018), all genome sequenced, had telomere lengths 
in the lowest quartile.  
 
Overall, 145 variants were identified in 99 telomere biology genes. Table 5.5 shows 
the number of variants in telomere biology genes with CADD phred-like scaled C 
scores ≥ 10 per individual, for whom telomere length was measured. A comparison of 
average variant counts between individuals in the lowest quartile of telomere length 
and individuals not in the lowest quartile did not reveal a statistical difference either 
with all individuals (P=0.9), or just restricted to genome sequenced individuals 
(P=0.2). Restricting the variants to only telomere biology genes as specified in 
Mirabello et al318 did not alter this result.  
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Table 5.5 Variants in telomere biology genes from TFHMS NGS samples, with 
measured telomere length, with CADD phred-like scaled C scores ≥ 10. 
 
Individual NGS Lowest Quartile of 
Telomere length 
Number variants with CADD 
phred-like scaled C scores ≥ 10 
LK0051-001 WGS  35 
LK0051-007 WES  30 
LK0051-128 WGS  36 
LK0051-159 WGS  41 
LK0124-117 WGS  34 
LK0124-179 WGS Yes 36 
LK0124-202 WGS Yes 36 
LK0139-001 WGS  39 
LK0139-004 WES  29 
LK0139-005 WGS  37 
LK0153-003 WGS  48 
LK0153-004 WGS Yes 41 
LK2042-003 WGS  40 
LK2042-006 WGS Yes 36 
LK2042-018 WGS Yes 41 
LK2042-231 WGS  41 
LK2042-232 WES  31 
LK2042-257 WGS Yes 32 
LK2042-258 WES  29 
LK2042-281 WGS  40 
LK2042-290 WGS  49 
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5.6 Discussion 
These analyses determined that mean relative telomere length is highly heritable 
within the TFHMS families, supporting previously reported heritability estimates in 
non-disease families301-303. The finding that mean relative telomere length was shorter 
in both familial and non-familial HM cases indicates that telomere length is likely to 
be important in the genetic etiology of HMs. A previous study of mean relative 
telomere length in familial myelodysplastic syndrome MDS-AML has shown that 
affected individuals from four small families had shorter telomeres concurrent with 
mutations in the telomerase gene TERT and its RNA component TERC147. Of the five 
cases across the four families reported to have shorter telomeres two had aplastic 
anaemia, two had MDS and one had MDS-AML. This study extends the findings of 
Kirwan and colleagues147 to that of large families with multiple HM subtypes, finding 
new evidence of the involvement of telomere length in both familial and non-familial 
HMs. 
 
Age, sex and age2 as covariates explained a proportion of the variation in mean 
relative telomere length in this study. This is in keeping with telomere length 
declining with age and males having shorter telomeres than females297. A significant 
age2 indicates a non-linear component in the age-related telomere length decline, a 
finding in line with a recent report showing a differential rate of decrease of telomere 
length over different age ranges319. The population controls measured do have a 
higher percentage of males, which could be suggested to be driving the association 
with sex, however SOLAR was used to correct mean relative telomere length for sex 
effects. 
 
An important caveat with this retrospective study is that the finding of shorter mean 
relative telomere lengths in HM cases could also be related to disease susceptibility, 
treatment or the disease process. This study does not have the necessary clinical 
information to appropriately analyse these factors. Currently the literature 
surrounding the role of chemotherapeutic agents in telomere shortening remains 
controversial and inconclusive. In a study of telomere length in breast cancer patients 
before and after chemotherapy, Schröder et al. report individual changes in patient 
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telomere length, some shortening, some lengthening, but overall no statistically 
significant changes in response to chemotherapy320. Similarly in 2010 Mirabello et al. 
did not find a difference in telomere length measured in peripheral blood samples 
between breast cancer patients who had undergone chemotherapy and those that had 
not321. In their 1998 study of children with acute leukaemia, Engelhardt et al.322 
reported telomere length shortening after repeated rounds of chemotherapy but in 
their 2003 follow up study323 their findings suggest that there is little effect of 
chemotherapy on telomere length in children with acute leukaemia and a 
heterogeneous effect on telomere length in children with solid tumours, similar to the 
findings of Schröder et al. in 2001320. In their study of APML patients, Ghaffari and 
colleagues showed that after chemotherapy, when patients had achieved remission, 
there was no difference in telomere length between patients and controls293. This is 
consistent with a study of CLL patients who were followed over time and showed that 
chemotherapy did not have an effect on telomere length296. A study of TP53 mutation 
carriers in Li-Fraumeni syndrome families also found that cancer therapy is unlikely 
to affect telomere length324. Recently a small study of patients with HMs suggested 
that chemotherapy induces telomere length shortening325. However, since this study 
did not report pre-chemotherapy telomere length, an alternative interpretation is that 
telomere length shortening is a disease related feature and not chemotherapy 
induced325.  
 
It could be concluded from these reports, and others, that chemotherapy has no 
consistent influence on telomere length in blood cells particularly when examining 
multiple chemotherapeutic treatment regimens. As this study features a variety of HM 
subtypes in several generations exposed to a range of therapeutic regimens, analysis 
stratified on treatment type is not possible due to low sample numbers in each 
category.   
 
A second consideration is that shorter telomeres in HM cases could be the result of 
malignant cell DNA within the genomic DNA sample. It is recognised that circulating 
malignant cells can be present for many years in chronic HM subtypes such as CLL. 
Based on the clinical diagnoses of HM cases in this study two additional sub-analyses 
of the primary data were conducted. In the first analysis all CLL cases (N=24) were 
removed on the basis that DNA obtained from blood of cases with this subtype of HM 
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was likely to contain DNA from diseased cells (Table 5.4). In the second analysis all 
cases for which blood samples were obtained for DNA within 2 years of diagnosis 
were removed (N=24; Table 5.4). Repeating the variance components modelling in 
these two analyses maintained the key significant associations with HM disease, 
suggesting that circulating disease is not contributing to the telomere length 
associations identified. In an additional sub-analysis all HM cases, controls and 
unaffected relatives (N=126) aged 80 years and above were excluded on the basis that 
the population HM risk increases with age. This did not change the principle findings 
of shorter telomeres in familial and non-familial HM cases, nor did a final combined 
sub-analysis excluding individuals from all 3 sub-analyses. All cases, controls and 
unaffected relatives were included in the primary analysis models reported in Table 
5.4. 
 
With NGS data available for 21 individuals with telomere length measurements an 
analysis was conducted of variants located in telomere biology genes and predicted by 
CADD244 to be within the top 10% most deleterious variants. Six of the 21 individuals 
with NGS data available were located in the lowest quartile of mean relative telomere 
length (Figure 5.1), however these individuals did not show an enrichment of 
deleterious variants in telomere biology genes in comparison to the remaining 
individuals not in the lowest quartile of mean relative telomere length. This analysis 
was limited by the small number of individuals for whom both NGS variants and 
telomere length measurements were available for. Association testing using a larger 
number of NGS individuals comparing variants in telomere biology genes between 
those in the lowest and highest quartiles of telomere length, particularly comparing 
HM cases to population controls, is warranted given the association identified 
between HMs and shorter telomere length. Additionally, GWASs have identified 31 
loci significantly associated with variation in telomere length326-336, both in recognised 
telomere biology genes such as TERT and TERC, and genes not previously implicated 
in telomere length. Therefore while this analysis focussed on rare variants with MAF 
≤ 1%, common genetic variants may also play an important role in telomere length 
variation and influence disease in this cohort. Further there has been interest recently 
in the inheritance of TERT promoter mutations in the predisposition to familial and 
sporadic melanoma337 and other cancers338, however in this study no such promoter 
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mutations were identified in the analyses. The underlying genetic factors contributing 
to the association between HMs and shorter telomere length remain to be identified.   
 
5.7 Conclusion 
These analyses show for the first time that mean relative telomere length is heritable 
in large HM families with multiple generations affected by multiple subtypes of HMs, 
indicating a strong genetic effect driving trait variation. Both familial and non-
familial HM cases from the same population have shorter mean relative telomere 
length. Taken together, the results from this retrospective study provide new evidence 
that telomere length is an important genetic factor in a wide range of HM subtypes 
and in individuals with and without a family history of disease. These findings 
contribute further support to the use of telomere length as a prognostic risk factor for 
HMs. Indeed HMs may fall broadly into the telomere syndromes proposed by 
Armanios and Blackburn339,340. Interestingly, evidence for anticipation has been 
previously reported in Tasmanian families in this TFHM study97 and recent studies of 
familial breast cancer157, Lynch syndrome341, dyskeratosis congenita154 and familial 
chronic myeloproliferative disorders342 have suggested that changes to telomere 
length may underlie the observation of anticipation. Whilst the role of telomere length 
in anticipation in familial HMs remains to be elucidated, the finding that telomere 
biology is likely to be involved provides clues as to the underlying genetic mechanism 
of disease. 
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Chapter 6 - Conclusions 
 
6.1 A strong but largely unknown genetic component to HMs 
For haematological malignancies both population-based and family-based studies 
indicate a strong genetic component contributing to disease risk, with relatives of 
cases repeatedly shown to have an increased risk of developing disease. Further, 
families have been identified with clusters of HMs occurring indicating disease 
inheritance. The identification of a familial risk for a disease indicates that there is a 
genetic component underlying the disease. Identification of what specifically this 
genetic component is, and accordingly the cause of the familial risk, is needed to 
increase the understanding of the factors that lead to the development of HMs. 
Identification of these factors informs clinical targets for predicting an individuals risk 
of disease, and will ideally lead to the development of new biological markers for 
more efficient disease diagnosis as well as new therapeutic targets for better prognosis 
and patient outcomes. 
 
Previous work toward identifying the genetic susceptibilities underlying HMs has 
focussed on population-based case-control studies of specific HM subtypes using 
genome-wide scans of common variation to identify localisation signals that are 
associated with increases in disease risk, as discussed in section 1.5.3. Such studies 
have identified and replicated a large number of common genetic variants with small 
increases in disease risk, which together explain only a minor portion of the inherited 
susceptibility for disease. While such studies have been moderately successful and 
contribute to the understanding of HMs, the clinical translation of these associations 
has yet to be realised. 
 
The use of multigenerational families with clusters of HM cases to identify factors 
shared between related cases was successful in identifying the early genes 
contributing to disease in high risk families, as described in sections 1.5.2, 1.5.4, 1.5.5 
and 1.6.2. This family-based approach has arguably shown more success than 
population-based approaches with several genes identified, that when mutated are a 
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primary causal factor in the development of disease. One classical example is the 
contribution of germline mutations in RUNX1 to the development of familial AML, 
discussed specifically in section 1.5.2.1. While germline mutation carriers require 
additional somatic mutations for malignancy development, the inherited mutations in 
RUNX1 are the cancer-initiating event. RUNX1 has been shown to be dysfunctional in 
several cancers and there is much ongoing research into the potential of RUNX1 
directed therapies343. Further, the relatively recent advent of NGS and the associated 
bioinformatics techniques has enabled the examination of the genetics of familial HM 
cases in unprecedented detail and with a much sharper focus. Amongst several others, 
mutations in genes including TP53187 and PAX5189 as contributing to familial ALL, as 
described in section 1.6.2. While specific therapies targeted at these genes for use in 
mutation carriers are developing, an immediate benefit to their identification is the 
ability to screen these genes for mutations in other ALL patients. This is clinically 
significant as it can inform treatment strategies such as selection of relatives without 
the mutation as potential bone marrow donors for haematopoietic stem cell transplant, 
as has occurred in an ALL family carrying TP53 mutations187.  
 
6.2 Studying HM families to identify new genetic susceptibilities  
Studying HM families has been a successful approach to identifying key genetic 
susceptibilities underlying HMs. While the contribution of several genes to HM 
predisposition have been described there are families for which there is a clear genetic 
predisposition to HMs, based on the pattern of disease occurrence, where the 
underlying genetic cause has not been identified. Such families present an opportunity 
for identifying unknown predisposing genetic factors contributing to HM 
development. This is due to related affected individuals having a shared genetic 
background contributing to disease predisposition, which can be targeted and used to 
reveal new disease related factors. Identification of new disease related factors from 
family-based studies stands to generate new focuses for targeted therapies as a result 
of the increase in biological understanding of disease development. This in turn may 
provide new targets for drug design directed against novel cellular pathways for 
which the contributions to the development of HMs were previously unclear. 
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Accordingly, as outlined in section 1.8,we employed these newly available tools to 
identify new genetic factors contributing to the familial predisposition of HMs. To 
achieve this aim a rare HM family resource, the Tasmanian Familial Haematological 
Malignancies Study was used, as described in Chapter 2. This resource consists of 
large multigenerational families from a genetically homogenous Tasmanian 
population with clusters of multiple HM subtypes occurring in each family. Where 
previous studies of familial HMs have typically focussed on families with single HM 
subtypes for disease gene identification, the TFHMS families instead show 
inheritance of multiple subtypes of HMs. This is an important feature of this resource 
as it allows identification and exploration of the contribution of genetic factors to HM 
predisposition in families with mixed disease phenotypes. The concept of a shared 
genetic predisposition to multiple HM subtypes is intuitive when haematopoietic stem 
cell differentiation is considered as a continuum, whereby a mutation may predispose 
to multiple malignancies across the spectrum of haematopoiesis, as discussed in 
section 1.2. 
 
6.3 Application of next generation sequencing to the TFHMS to identify 
variants predisposing to familial HMs 
To identify new genetic factors contributing to familial HM predisposition a NGS 
approach using both genome and exome sequencing was used. As described in 
Chapter 2, five families from the TFHMS were selected for genome and exome 
sequencing, with the primary aim of identifying novel inherited variants that are likely 
to contribute to HM disease predisposition. Families LK0051, LK0139 and LK0153 
had dense aggregations of HMs occurring in first and second-degree relatives. Family 
LK0124, comprising three sequenced cases, had evidence of clinically interesting HM 
subtypes with rare CNS presentations, with the cases selected for sequencing 
including a family member with a CNS lymphoma. Family LK2042 was the largest 
family studied with eight HM cases selected for sequencing. As for family LK0124 
these cases were spread across multiple branches of the family and were selected to 
address the question of whether distantly related cases, separated by eight meioses or 
more, have a shared genetic predisposition to disease. In total 31 individuals were 
sequenced, including 18 HM cases and 13 unaffected relatives. 
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6.3.1 A tiered prioritisation analysis strategy for variant identification 
To analyse and identify rare disease related variants from the NGS data a tiered 
prioritisation analysis strategy was developed in Chapter 3, as specifically described 
in section 3.3.7. This strategy made use of family specific sharing analyses to identify 
variants shared amongst related cases but not unaffected, non-obligate carrier 
relatives. This approach was used because identifying variants shared by related cases 
increases the evidence that the variant is disease causing, and reduces the spectrum of 
variants to interrogate. Importantly the tiered prioritisation strategy used both variant-
based and gene-based evidence to identify new candidate variants contributing to 
disease. It was reasoned that variants that had a bioinformatics prediction of having an 
effect on gene function, together with evidence of involvement of the gene in 
phenotypes related to HMs and the known genetic basis of HMs were more likely to 
be related to HM predisposition and therefore were a higher priority for analysis.  
 
Together the outcome of this strategy was the identification of 26 novel candidate HM 
susceptibility variants in 26 genes across the five families, as described in section 
3.4.4. The identification of multiple variants likely to be related to disease in each 
family differs from previous studies of familial HMs as described in section 1.5 and 
1.6.2. Previous studies have focussed on specific genetic linkage regions or have been 
biased studies of specific candidate genes148,191. Both types of study design have 
potentially missed variants contributing to disease that were not in their focus regions 
or candidate genes. Here the unbiased analysis used instead identified multiple 
variants in each study family, which is in line with the concept of multiple genetic 
factors contributing to complex diseases such as HMs.  
 
6.3.2 Variants in TDP2 and TNFSF9 implicated in HM predisposition 
The two variants from family LK0051 with the most compelling biological evidence 
of a likely involvement in the development of HMs were validated by Sanger 
sequencing and prioritised to establish further evidence of their contribution to HM 
predisposition. These variants were rs200729372 in TDP2 and rs61750000 in 
TNFSF9. The aim here was to identify whether the identified variants were enriched 
in the TFHMS resource in comparison to population controls using high-throughput 
genotyping. As described in section 4.4.3 these analyses found that the TDP2 variant 
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was significantly enriched in the TFHMS resource, in comparison to the Exome 
Variant Server control data (P=0.0028), and the TNFSF9 variant as significantly 
enriched in comparison to both Tasmanian population controls (P=0.03), and EVS 
control data (P=0.01). The identification of recurrence of these variants in other 
familial and non-familial HM cases is important evidence supporting their 
contribution to disease. This is in line with other familial HM studies that have used 
variant recurrence as a measure of the contribution of the variant to disease risk148,189 
with recurring variants in multiple HM families, as is seen here, being compelling 
support that the variants are involved in HM susceptibility.  
 
Additionally, other familial HM studies have used whole gene sequencing in sets of 
familial and non-familial HM cases to identify additional variants in the implicated 
gene contributing to disease148. In this dissertation, targeted NGS of the TNFSF9 gene 
in 96 additional HM cases did not identify further variants related to disease as 
described in section 4.4.4, with the rs61750000 variant remaining the most 
biologically significant variant identified. However screening TNFSF9 within a larger 
collection of HM samples, by accessing a tissue bank such as the Australasian 
Leukaemia & Lymphoma Group344, specifically HM cases with similar subtypes to 
the variant carriers in this study, may identify other variants in this gene involved in 
disease susceptibility.  
 
Within the LK0051 family the TNFSF9 variant occurred in the WGS uncle and 
nephew pair, who were affected by a T-cell lymphoma, and a B-cell Burkitt 
lymphoma respectively, as well as their connecting unaffected female relative. The 
occurrence of disease variants in unaffected family members has been found in other 
studies147,148,189 and is expected as the underlying premise of identifying these variants 
is that they contribute to disease predisposition with additional genetic changes 
required for malignancy to develop. In contrast to previous studies that have focussed 
on identifying predisposition variants in single HM subtypes, a novel finding from this 
study was the identification and validation of variants shared in multiple HM 
subtypes in the same family. This is supportive of a common genetic predisposition to 
multiple subtypes and is in line with the continuum of haematopoietic differentiation 
discussed in section 1.2 whereby inherited mutations predispose to multiple different 
types of HMs. 
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A further eleven variants in three families were validated by Sanger sequencing with 
each warranting TFHMS resource and control population based screening to identify 
whether these variants are enriched in HM families and potentially contributing to 
disease susceptibility.  
 
6.4 Future directions to confirm a biological role for TNFSF9 in HM 
susceptibility 
6.4.1 Previous research supports a role for TNFSF9 in the biology of HMs  
Previous research strongly supports a role for TNFSF9 in the biology of HM 
development in both B-cell and T-cell malignancies. When this gene is deleted in 
mice, 60% of them develop B-cell lymphomas within a year of birth281. It is 
recurrently deleted in human HMs in cases of DLBCL and BL182,280 and has 
established biological roles in both B-cell, and T-cell, proliferation and 
function273,278,279. Examining TNFSF9 through the cBioPortal for Cancer Genomics 
(January 20, 2015 release), an open-access resource for exploring cancer genomics 
datasets345,346 reveals no somatic cancer genome mutations or copy number alterations 
to TNFSF9 in HM datasets, however a recurring deletion mutation L41del is present 
in 19 of 90 pancreatic cancer cases indicating that TNFSF9 may also play a role in 
subset of pancreatic cancers. A recent study of 166 B-cell lymphomas with bone 
marrow involvement has shown expression of TNFSF9 in greater than 50% of 
samples studied and proposes that TNFSF9 expression be used as a factor in HM 
disease staging as well as minimal residual disease assessment347. Further, TNFSF9 in 
this study was also found to differentiate bone marrow involvement of B-cell 
lymphomas from normal and reactive lymphoid infiltrates347. Recent work has also 
shown that in addition to its roles in lymphoid cell biology, TNFSF9 also has a role in 
myeloid cell biology. While Zhao and colleagues found that TNFSF9 expression is 
absent in myeloid cells as well as AML347, Cheng and colleagues found that 
activation of TNFSF9 through application of recombinant TNFRSF9, the receptor for 
TNFSF9’s cell-to-cell interactions with T-cells, induced differentiation of malignant 
cells in AML patients348. Together these studies provide further evidence supporting a 
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role for disruption in TNFSF9 through inherited variants contributing to HM 
development. 
 
 
6.4.2 Determining the function of the TNFSF9 rs61750000 variant 
As the identified variant is a coding, non-regulatory change, the analysis of gene 
expression does not immediately present itself as an ideal strategy to show an effect 
on gene function. However, potentially, variant carriers may have an increase in 
TNFSF9 expression in an attempt to compensate for a deficiency in gene function 
resulting from the variant. Alternatively, if the variant results in altered TNFSF9 
activity there may be corresponding changes in downstream gene expression that 
could be detectable in variant carriers. It is possible that both loss of function, as 
observed by somatic TNFSF9 deletions in HMs, and gain or increase of function 
through mutation or overexpression can paradoxically both contribute to malignancy 
development. Evidence suggests that it is disruption of TNFSF9 function that 
contributes to HMs with the direction of the effect of the disruption (gain or loss) 
potentially modulating the size of the contribution. Within the TFHMS study, as RNA 
is available for both the HM affected mutation carriers and several TFHMS cases 
without this variant, a logical starting point would be to examine TNFSF9 gene 
expression.  
 
With compelling support for a role for the TNFSF9 gene in HM predisposition, the 
challenge is then to determine whether the specific variant, rs6175000, causing the 
amino acid change G139A, is deleterious to protein function. Contributing to its 
identification in Chapter 3 and prioritisation for further experimentation in Chapter 4 
of this study, at the in silico level bioinformatics tools, including CADD244, PolyPhen-
2349 and SIFT350, consistently predict that this variant has a functional effect on the 
TNFSF9 protein. However specific experiments are required that demonstrate a direct 
effect of this variant on the biological role of TNFSF9.  
 
For future work to demonstrate this effect, cell culture models of B-cells and T-cells 
present as an attractive option for addressing whether the TNFSF9 G193A variant is 
biologically important. Cell lines could be altered to overexpress the TNFSF9 G139A 
variant, and the native TNFSF9 protein, and the effect on cell proliferation and 
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survival measured comparatively. Alternatively, induced pluripotent stem cell models 
could be developed from living variant carriers, allowing targeted differentiation and 
direct characterisation of the biology of a model of haematopoietic cells of variant 
carriers and exploration of the effect of correcting the variant using genome editing 
technologies such as the CRISPR/Cas9 system, as has been applied in a recent study 
of β-thalassemia 351. The results from these experiments would show whether the 
variant has a functional effect on T-cell and B-cell biology. Evidence of a biological 
effect of the variant should be followed by protein centred experiments to determine 
the mechanism by which the G193A variant exerts an effect.  
 
Potentially, protein-centred future work could use protein modelling and protein-
protein interaction experiments to determine the effect of the G193A variant on the 
ability of the TNFSF9 trimer to form, or the ability of the TNFSF9 trimer to bind with 
its TNFRSF9 receptor. Together experiments targeted at determining the biological 
role of the G193A variant in TNFSF9 in contributing to HM predisposition, together 
with experiments targeted at the mechanism of how this variant affects gene function 
are needed to provide the necessary evidence for disease causality. 
 
6.5 Telomere length is a potential risk factor for haematological 
malignancies 
Concurrent with the identification of shared variants likely to contribute to HM 
predisposition another major finding of this dissertation was an association between 
telomere length and HMs. This work was published in Blackburn et al.1. Telomere 
biology has a well-characterised role in cancer development. Disruption of key 
telomere biology genes has been shown to lead to a spectrum of syndromes, of which 
haematological malignancies are a feature, such as dyskeratosis congentia and aplastic 
anaemia340. Further, mutations in key telomere biology genes have been identified in 
families with MDS/AML147. Therefore, the aim of this project was to measure 
telomere length, a quantitative trait relevant to cancer development, across the 
TFHMS resource to identify new evidence implicating telomere length as a genetic 
factor in HMs. The findings from these analyses showed that telomere length, as a 
trait is highly heritable (62.5%, P=4.7×10−5), and shorter in HM cases (P=2.9×10−6), 
with both familial and non-familial cases having shorter telomeres (P=2.2×10−4 and 
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P=2.2×10−5 respectively). Several analyses were conducted to determine whether the 
observed association with HM case status and shorter telomere length was explained 
by particular sub-divisions of the cases, based on familial and non-familial cases or 
major HM types. Regardless of how HM cases were analysed results consistently 
showed shorter telomeres in HM cases, in line with the hypothesis that telomere 
length is a risk factor for HMs. However, as a retrospective study, accounting for 
factors such as disease duration, chemotherapy and radiotherapy, was not possible in 
these analyses. These findings do highlight that telomere length is a potential risk 
factor in HMs, suggesting that larger prospective studies of populations measuring 
telomere length and HM incidence over time are warranted. Further, a wide variation 
of telomere length was observed in the population controls used in this study. This 
together with the observed association with HMs, suggests that telomere length as a 
clinical measurement may be of use in conjunction with other disease measurements 
or genetic markers as a method of stratifying existing HM cases and predicting 
treatment outcomes, rather than a population level screen to determine HM risk. 
 
 
6.6 Recommendations for future familial HM studies 
The advances to genetics research provided by NGS have renewed interest in the 
potential of family-based resources, such as the TFHMS, for the identification of the 
genetic variants underlying inherited disease and the work presented here in this 
dissertation can be used to suggest a number of recommendations to help guide 
genetic studies utilising a similar family-based approach. 
 
6.6.1 Selection of family members for sequencing  
The strength of familial resources is tied to their family pedigrees and sample 
availability. Identification and recruitment of families with clusters of HM cases 
separated by no more than five meioses (second cousins), or more distantly related 
cases with a clear genetic transmission of the disease, is essential. Recruitment and 
sequencing of unaffected relatives is also informative as variants identified in these 
individuals can be used as within and between family controls, as the HM unaffected 
branch of the LK0153 family was used in this study in Chapter 3. When selecting 
unaffected family members for sequencing, ideally they should undergo standard 
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clinical evaluation to determine whether they are disease-free or potentially have a 
pre-malignant condition. Such comprehensive clinical evaluation is not always 
possible or practical, therefore selection of older unaffected relatives, particularly 
when the HM cases in that family have an earlier than average onset of disease, is a 
valuable alternative. Sequencing of unaffected relatives as within family controls 
must be done with due consideration to disease penetrance. In HMs, due to the 
multifactorial nature of disease, unaffected relatives may be disease-free but carry 
some or all of the disease predisposing variants present in the related HM cases. In 
this study, when unaffected siblings were sequenced, such as in family LK0139, 
variants within the unaffected sibling were removed from the HM cases in the 
heuristic filtering analysis described in section 3.3.7. This is one valid strategy; an 
alternative would be to not filter these variants, at the cost of keeping variants not 
connected to disease and consequently more candidate variants to prioritise. Presence 
or absence of variants in the unaffected relative could then be informative in the final 
stage of variant prioritisation after other possibilities have been filtered.  
 
6.6.2 Focus on families with closely related HM cases 
Overall, in this study, sequencing of closely related clusters of HM cases had the most 
success in identifying shared candidate variants that validated when analysed using 
Sanger sequencing as described in section 4.4.1. While the variants identified in 
family LK2042, the largest family with multiple distantly related HM cases 
sequenced, were not selected for validation by Sanger sequencing, those identified as 
shared between cases in the LK0124 family presented as a comparable family 
structure for evaluation of sequencing distantly related cases. Indeed the results of the 
sharing based analyses of family LK0124, which identified three candidate variants, 
did not validate when these variants were Sanger sequenced. Two of these variants 
that failed validation were also identified as false positives in other sequenced 
families.  
 
These findings from the analyses in Chapter 3 and 4 highlight two points that may be 
useful in future analyses of similar families. Firstly, rare variants that are identified 
across multiple families may be false positives generated as an artefact of the 
sequencing, alignment or variant calling processes. This is useful to know as such 
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variants can be scrutinised closer during prioritisation. The second point is that studies 
such as this should focus on sequencing closely related HM cases, within five meioses 
of each other, as rare variants shared by distant relatives that are separated by eight 
meioses or greater, are unlikely to be true variants when using the heuristic filtering 
approach employed in this study, as was shown for family LK0124 in section 4.4.1.  
 
To that end a future direction for NGS in the TFHMS, would be to focus on two 
recently identified families in which newly diagnosed HM cases were identified at the 
end of this dissertation. One is a family of five siblings with three affected by B-cell 
HMs and two unaffected siblings, all of similar ages. The other is an affected sibling 
pair with an affected first cousin, all with B-cell HMs. Until recently each of these 
families contained only two HM cases, however continued genealogical monitoring of 
HM incidence using the Tasmanian Cancer Registry identified the third case in each 
family when diagnosed, highlighting the importance of a longitudinal familial 
resource such as the TFHMS.  
 
Disease subtype is an additional important consideration in selection of families for 
NGS based studies. The focus in this field has been primarily on studies of families 
with single subtypes of HMs, which has successfully identified disease related 
mutations in genes such as PAX5 in familial ALL189. A valuable and important aspect 
of this dissertation was that the families studied had multiple different subtypes of 
HMs. From Chapters 3 and 4 a novel finding was that disease related variants were 
shared between relatives with different HM subtypes, supporting a shared 
predisposition to multiple subtypes. Future NGS studies should therefore not be 
limited to single HM subtype families, in contrast to the current families studied by 
NGS and reported in the literature. 
 
6.6.3 Recent expert guideline recommendations for implicating causality and 
identifying cancer predisposition genes 
Recently, expert perspective guidelines have been published on the process of 
investigating causality of identified NGS variants in human disease352, and on 
identifying familial cancer predisposition genes111. MacArthur et al.352 highlight that 
implicating a gene and variant in a disease is a process involving the accumulation 
and integration of different levels of evidence that together support a role for the gene 
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or variant in disease. Evidence is required at both the variant and the gene level. 
Bioinformatics tools should predict that the variant has a deleterious effect on gene 
function and this prediction must be confirmed experimentally. The gene itself should 
be expressed in tissues relevant to the disease, and demonstrated in model systems 
such as transgenic mice or cell culture that when disrupted a phenotype consistent 
with the disease is generated.  
 
The process for disease variant identification used in this study was underpinned by 
layers of biological evidence implemented through a tiered prioritisation strategy that 
lead to the identification of the thirteen validated sequence variants in three TFHMS 
families. In line with the guidelines from MacArthur et al.352 at the variant-level 
bioinformatics tools predict that the top candidate variant from this study, G193A in 
TNFSF9, affects gene function. At the gene-level, this gene is expressed in 
haematopoietic tissues and a HM phenotype has been demonstrated in transgenic 
mice where the function of the gene has been disrupted. Additionally the gene has 
been shown in humans to be a HM disease marker and is intrinsically involved in the 
cell biology of HM development.  
 
Nazneen Rahman, a leading researcher in the field of familial cancer, in her 2014 
review111, cautions that many reported cancer predisposition genes are incorrectly 
classified due to mistaken data interpretations including overestimation of causality 
due to a variant being rare, coding and not in a control population. Collectively, rare 
coding variants occur frequently353, and studying families inherently increases the rate 
at which rare coding variants are identified in related cases due to multiple copies of 
the variants being present in the family. Rahman proposes that support for a suggested 
cancer predisposition gene must stem from identification of multiple families where 
this gene is dysfunctional, requiring large-scale international collaborations. In light 
of this recommendation, the TNFSF9 variant, which was identified as present in 
multiple TFHMS families and enriched in the TFHMS resource in comparison to 
population controls, remains a striking candidate for HM predisposition and further 
investigation. 
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6.8 Conclusion 
The field of NGS is still in its infancy. Each year, with falling sequencing costs, 
development of new data sources and new analysis methodologies, this area is 
dynamic and ever changing. In the context of familial HMs the application of this 
technology to multigenerational families with multiple subtypes of disease and 
clusters of HM cases stands to identify the predisposing genetic factors underlying 
disease. In Chapter 3 a tiered prioritisation strategy was applied to NGS data from 
five Tasmanian families with HMs, identifying twenty-six likely candidate variants 
contributing to disease predisposition. In Chapter 4 thirteen of these variants were 
validated in three of these families. These variants are new candidates in the field of 
HM susceptibility, particularly the rs61750000 variant in TNFSF9, warranting further 
analysis as to their contributions to disease. These variants may lead to identification 
of new pathways and drug targets for the diagnosis and management of HMs. Indeed 
recent research in TNFSF9 implicating it as a biomarker in HMs highlights the 
potential translation of these findings in the broader HM context. In Chapter 5 new 
evidence supporting a role for telomere length as a genetic factor in HMs was 
identified and indicates that telomere biology should be examined closer in this 
disease as telomere length may also be a prognostic factor clinically useful for 
diagnosis, disease risk estimation, or disease monitoring in HMs.  
 
Novel genetic factors were identified in each family analysed by NGS in this study. 
These findings show that there appears to be multiple rare variants predicted to impact 
on gene function that are likely to contribute to HM susceptibility. This serves to 
highlight the challenges that are being encountered utilising these approaches. This is 
consistent with similar published studies and further highlights the complexity of the 
genetic architecture underlying the predisposition to HMs.  
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Appendix 1.1 Summary of the GWAS significant loci from HM studies 
HM 
Subtype Initial Sample Size 
Replication Sample 
Size Region 
hg19 
Chromosome and 
position 
RefSeq gene 
location or 
genes within +/- 
10 kb when 
intergenic 
RefSeq gene 
region SNP rsIDs p-Value p-Value note 
OR [95% CI] 
(NR = not 
reported) 
Platform 
[SNPs passing 
QC] 
Reference 
ALL 
1,658 European 
ancestry child cases, 
4,723 European 
ancestry controls 
1,449 European 
ancestry child cases, 
1,488 European 
ancestry controls 
10p12.2 chr10:22839628 PIP4K2A exonic rs2230469    2×10-9  1.23 [1.15-1.32] 
Illumina 
[382,776] 
(imputed) 
354 
10q21.2 chr10:63721176 ARID5B downstream rs7090445 5×10-54  NR 
10p14 chr10:8104208 GATA3 intronic rs3824662 9×10-12  1.31 [1.21-1.41] 
14q11.2 chr14:23589057 CEBPE intronic rs2239633 1×10-16  NR 
7p12.2 chr7:50469981 IKZF1 intronic rs11980379 3×10-33  NR 
9p21.3 chr9:21984661 CDKN2A intronic rs3731217 2×10-8  NR 
ALL 
1,268 cases of 
European, South Asian, 
East Asian, African 
American/Afro-
Caribbean, Hispanic 
and other ancestries 
1,267 cases of 
European, South 
Asian, East Asian, 
African 
American/Afro-
Caribbean, Hispanic 
and other ancestries 
1p31.3 chr1:66762466 PDE4B intronic rs546784 9×10-6  1.40 [1.20-1.62] 
Affymetrix 
[444,044] 
355 
1p31.3 chr1:66769100 PDE4B intronic rs6683977 5×10-6  1.41 [1.22-1.64] 
10q22.1 chr10:72040805 NPFFR1 intronic rs41322152 8×10-6  2.52 [1.68-3.79] 
14q22.1 chr14:51403531 PYGL intronic rs7142143 7×10-9  3.61 [2.34-5.57] 
18q12.3 chr18:40591084 RIT2 intronic rs9958208 5×10-6  1.62 [1.32-1.99] 
2q23.2 chr2:150397218 intergenic intergenic rs7578361 8×10-6  1.40 [1.21-1.63] 
2q23.2 chr2:150457624 LOC101929231 intronic rs10170236 4×10-6  1.45 [1.24-1.69] 
3p22.1 chr3:39847072 MYRIP upstream rs17079534 2×10-7  4.07 [2.40-6.87] 
7q34 chr7:139702593 TBXAS1 intronic rs17837497 2×10-6  2.34 [1.65-3.31] 
7q21.11 chr7:78331465 MAGI2 intronic rs1496766 5×10-6  2.84 [1.81-4.44] 
ALL 
317 European descent 
cases, 17,958 European 
descent controls 
NA 
1q31.3 chr1:196844593 CFHR4 intronic rs6428370 7×10-6  1.43 [1.20-1.60] 
Affymetrix 
[307,944] 
356 
1q43 chr1:237266603 RYR2 intronic rs7554607 2×10-6  1.49 [1.20-1.70] 
1q44 chr1:247689532 GCSAML, GCSAML-AS1 intronic rs1881797 7×10
-6  1.52 [1.20-1.80] 
1p31.1 chr1:76772328 ST6GALNAC3 intronic rs10873876 4×10-6  1.55 [1.20-1.80] 
10p11.21 chr10:34817988 PARD3 intronic rs563507 9×10-6  2.00 [1.40-2.70] 
10q21.2 chr10:63723577 ARID5B intronic rs10821936 1×10-15  1.91 [1.60-2.20] 
12q24.22 chr12:117002658 MAP1LC3B2 intronic rs2089222 8×10-8  2.26 [1.60-3.00] 
12p13.32 chr12:4425122 c12orf5 upstream rs10849033 9×10-6  2.55 [1.60-3.80] 
18p11.32 chr18:2498054 intergenic intergenic rs1879352 9×10-6  1.53 [1.20-1.80] 
19q13.31 chr19:44511389 ZNF230 intronic rs2191566 4×10-7  1.52 [1.20-1.70] 
2q36.1 chr2:223917983 KCNE4 downstream rs12621643 3×10-6  1.48 [1.20-1.70] 
3q26.32 chr3:178429939 KCNMB2 intronic rs9290663 6×10-6  1.58 [1.20-1.90] 
6q24.1 chr6:141169825 intergenic intergenic rs11155133 3×10-7  3.62 [2.10-6.00] 
7p12.2 chr7:50466304 IKZF1 intronic rs11978267 8×10-11  1.69 [1.40-1.90] 
ALL 
419 European ancestry 
cases, 474 European 
ancestry controls 
Up to 1,277 
European ancestry 
cases and 3,061 
European ancestry 
controls 
11p11.2 chr11:48115089 PTPRJ intronic rs3942852 1×10-6 ETV6-RUNX1 positive NR 
Affymetrix 
[355,750] 
21 
11q12.1 chr11:56175671 OR5R1 downstream rs1945213 3×10-8 Combined ALL  1.30 [1.19-1.43] 
11q12.1 chr11:56175671 OR5R1 downstream rs1945213 4×10-8 ETV6-RUNX1 positive NR 
14q24.3 chr14:76703351 intergenic intergenic rs7156960 3×10-6 Combined ALL 1.22 [1.12-1.33] 
14q24.3 chr14:76703351 intergenic intergenic rs7156960 1×10-6 ETV6-RUNX1 positive NR 
15q26.1 chr15:92657373 SLCO3A1 intronic rs207954 1×10-6 ETV6-RUNX1 positive NR 
3q28 chr3:189401776 TP63 3'UTR rs17505102 2×10-8 Combined ALL 1.47 [1.28-1.67] 
3q28 chr3:189401776 TP63 3'UTR rs17505102 9×10-9 ETV6-RUNX1 positive NR 
4q13.1 chr4:59503726 intergenic intergenic rs282708 8×10-6 Combined ALL 1.23 [1.12-1.35] 
6q14.1 chr6:77789808 intergenic intergenic rs7738636 6×10-6 Combined ALL 1.27 [1.15-1.41] 
8p21.3 chr8:19651161 intergenic intergenic rs920590 2×10-6 ETV6-RUNX1 positive NR 
ALL 
907 European ancestry 
cases, 2,398 European 
ancestry controls 
NA 
10q21.2 chr10:63752159 ARID5B intronic rs7089424 7×10-19  1.65 [1.54-1.76] 
Illumina 
[291,473] 
357 14q11.2 chr14:23589057 CEBPE intronic rs2239633 3×10
-7  1.34 [1.22-1.45] 
7p12.2 chr7:50470604 IKZF1 intronic rs4132601 1×10-19  1.69 [1.58-1.81] 
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HM 
Subtype Initial Sample Size 
Replication Sample 
Size Region 
hg19 
Chromosome and 
position 
RefSeq gene 
location or 
genes within +/- 
10 kb when 
intergenic 
RefSeq gene 
region SNP rsIDs p-Value p-Value note 
OR [95% CI] 
(NR = not 
reported) 
Platform 
[SNPs passing 
QC] 
Reference 
ALL 
972 European ancestry 
cases, 1,386 European 
ancestry controls, 89 
African American 
cases, 1,363 African 
American controls, 305 
Hispanic cases, 1,008 
Hispanic controls 
574 European 
ancestry cases, 2,601 
European ancestry 
controls, 128 
African American 
cases, 1,075 African 
American controls, 
143 Hispanic cases, 
640 Hispanic 
controls 
10q21.2 chr10:63723577 ARID5B intronic rs10821936 6×10-46  1.86 [1.71-2.03] 
Affymetrix 
[709,059] 
139 
14q11.2 chr14:23585333 CEBPE intronic rs4982731 9×10-12  1.36 [1.24-1.48] 
7p12.2 chr7:50473251 IKZF1 3'UTR rs6964969 2×10-29  1.67 [1.53-1.83] 
AML 
(therapy-
related) 
80 European ancestry 
cases, 150 European 
ancestry controls 
70 European 
ancestry cases, 95 
European ancestry 
controls 
10q21.1 chr10:59949736 IPMK intronic rs1199098 3.43×10-3  0.46 [0.27-0.79] Affymetrix 
[10,136] 
358 17q12 chr17:31789043 ASIC2 intronic rs1394384 4.55×10
-5  0.29 [0.15-0.56] 
3p24.1 chr3:28749314 LINC00693 intronic rs1381392 4.19×10-3  2.08 [1.29-3.35] 
B-cell NHL 
253 Singaporean 
Chinese ancestry cases; 
1,438 Singaporean 
Chinese ancestry 
controls 
1,175 Han Chinese 
ancestry cases, 5,492 
Han Chinese 
ancestry controls 
3q27.3 chr3:187649419 intergenic intergenic rs6773854 3×10-13  1.44 [1.31-1.59] 
Illumina 
[550,946] 
359 
CLL 
1,739 European 
ancestry cases, 5,199 
European ancestry 
controls 
1,144 European 
ancestry cases, 3,151 
European ancestry 
controls 
10q23.31 chr10:90749963 ACTA2 intronic rs1800682 2×10-8  1.25 [NR] 
Illumina 
[450,000] 
(Imputed) 
138 
11q24.1 chr11:123361397 intergenic intergenic rs735665 4×10-24  1.64 [NR] 
11p15.5 chr11:2322829 C11orf21 intronic rs11022157 3×10-6  1.22 [NR] 
15q15.1 chr15:40414116 intergenic intergenic rs8023845 2×10-6  1.27 [NR] 
15q21.3 chr15:56382295 RFX7 intronic rs16976734 4×10-7  1.36 [NR] 
15q23 chr15:70018990 intergenic intergenic rs7176508 8×10-18  1.42 [NR] 
16q24.1 chr16:85955671 IRF8 3'UTR rs1044873 1×10-9  1.29 [NR] 
2q13 chr2:111871897 ACOXL intronic rs1439287 5×10-15  1.37 [NR] 
2q37.1 chr2:231091223 SP140 intronic rs13397985 5×10-13  1.43 [NR] 
2p22.2 chr2:37467264 NDUFAF7 downstream rs2041840 9×10-6  1.20 [NR] 
3q26.2 chr3:169492101 MYNN coding rs10936599 2×10-9  1.26 [1.17-1.35] 
4q26 chr4:114683844 CAMK2D 3'UTR rs6858698 3×10-9  1.31 [1.20-1.44] 
5p15.33 chr5:1344458 CLPTM1L coding rs31490 2×10-7  1.18 [1.11-1.26] 
6q25.2 chr6:154478440 IPCEF1 / OPRM1 
3'UTR / 
intronic rs2236256 2×10
-10  1.23 [1.15-1.30] 
6p21.32 chr6:32257566 intergenic intergenic rs926070 4×10-8  1.27 [NR] 
6p21.31 chr6:33540209 BAK1 coding rs210134 3×10-6  1.31 [NR] 
6p25.3 chr6:411064 IRF4 intronic rs872071 3×10-16  1.39 [NR] 
7q31.33 chr7:124462661 POT1 downstream rs17246404 3×10-8  1.22 [1.14-1.31] 
8q24.21 chr8:128188019 intergenic intergenic rs2466024 3×10-6  1.21 [NR] 
CLL 
505 European ancestry 
cases, 1,438 European 
ancestry controls 
1,024 European 
ancestry cases, 1,677 
European ancestry 
controls 
11q24.1 chr11:123361397 intergenic intergenic rs735665 4×10-12  1.45 [1.31-1.61] 
Illumina 
 
[345,665] 
137 
15q23 chr15:70018990 intergenic intergenic rs7176508 5×10-12  1.37 [1.26-1.50] 
19q13.32 chr19:47207654 PRKD2 intronic rs11083846 4×10-9  1.35 [1.22-1.49] 
2q13 chr2:111797458 ACOXL intronic rs17483466 2×10-10  1.39 [1.25-1.53] 
2q37.1 chr2:231091223 SP140 intronic rs13397985 6×10-10  1.41 [1.26-1.57] 
6p25.3 chr6:411064 IRF4 intronic rs872071 2×10-20  1.54 [1.41- 1.69] 
CLL 
4 - stage followup of 
previous study 
{DiBernardo:2008is} 
2503 total European 
ancestry cases, 5789 
total European 
ancestry controls 
15q21.3 chr15:56340896 intergenic intergenic rs7169431 4.74×10-7  1.36 [1.21-1.53] 4-stage follow 
up of previous 
CLL findings 
in 137 
360 16q24.1 chr16:85975659 intergenic intergenic rs305061 3.60×10
-7  1.22 [1.13-1.31] 
2q37.3 chr2:242371101 FARP2 upstream rs757978 2.11×10-9  1.39 [1.25-1.56] 
8q24.21 chr8:128192981 CASC19 downstream rs2456449 7.84×10-10  1.26 [1.17-1.35] 
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CLL 
1,121 European 
ancestry cases, 3,745 
European ancestry 
controls 
861 European 
ancestry cases, 2,033 
European ancestry 
controls 
11q24.1 chr11:123361397 intergenic intergenic rs735665 3×10-12  1.52 [1.35-1.72] 
Affymetrix & 
Illumina 
[~1,500,000] 
(imputed) 
361 
15q23 chr15:70018990 intergenic intergenic rs7176508 3×10-11  1.42 [1.28-1.58] 
16q24.1 chr16:85975659 intergenic intergenic rs305061 9×10-8  1.33 [1.2-1.49] 
2q13 chr2:111797458 ACOXL intronic rs17483466 5×10-9  1.43 [1.27-1.61] 
2q37.1 chr2:231091223 SP140 intronic rs13397985 2×10-7  1.39 [1.23-1.59] 
2q37.3 chr2:242371101 FARP2 upstream rs757978 3×10-6  1.46 [1.25-1.72] 
6p21.31 chr6:33546837 BAK1 intronic rs210142 9×10-16  1.40 [1.25-1.57] 
6p25.3 chr6:411064 IRF4 intronic rs872071 8×10-14  1.47 [1.33-1.63] 
CLL 
407 European ancestry 
cases, 296 European 
ancestry controls 
252 European 
ancestry cases, 965 
European ancestry 
controls 
16q24.1 chr16:85944439 IRF8 intronic rs391525 3×10-9  1.56 [1.35-1.82] 
Affymetrix 
[827,777] 
362 6p21.32 chr6:32578082 intergenic intergenic rs674313 7×10
-9  1.69 [1.41-2.01] 
6p21.32 chr6:32606756 HLA-DQA1 intronic rs9272535 9×10-8  1.61 [1.35-1.92] 
6p25.3 chr6:417727 IRF4 downstream rs9378805 2×10-6  1.38 [1.20-1.58] 
 
CLL 
2,179 European 
ancestry cases, 6,221 
European ancestry 
controls 
1,709 European 
ancestry cases, 6,318 
European ancestry 
controls 
10q23.31 chr10:90759724 FAS intronic rs4406737 1×10-14  1.27 [1.19-1.33] 
Illumina 
[549,934] 
145 
11q24.1 chr11:123361397 intergenic intergenic rs735665 4×10-39  1.62 [NR] 
11p15.5 chr11:2311152 C11orf21 downstream rs7944004 2×10-10  1.20 [1.13-1.27] 
15q21.3[ chr15:56775597 intergenic intergenic rs11636802 2×10-13  1.41 [NR] 
15q23 chr15:70018990 intergenic intergenic rs7176508 1×10-17  1.32 [NR] 
16q24.1 
chr16:85927814, 
chr16:85944823, 
chr16:85975659 
IRF8 
upstream, 
intronic, 
downstream 
rs391023,  
rs2292982,  
rs305061 
5×10-17  1.33 [NR] 
18q21.32 chr18:57622287 intergenic intergenic rs4368253 3×10-8  1.19 [1.12-1.27] 
18q21.33 chr18:60793549 BCL2 3'UTR rs4987855 3×10-12  1.47 [1.32-1.61] 
18q21.33 chr18:60793921 BCL2 intronic rs4987852 8×10-11  1.41 [NR] 
2q13 chr2:111616104 ACOXL upstream rs13401811 2×10-18  1.41 [1.30-1.52] 
2q13 chr2:111797458 ACOXL intronic rs17483466 4×10-17  1.37 [NR] 
2q33.1 chr2:202111380 CASP8 intronic rs3769825 3×10-9  1.19 [1.12-1.25] 
2q37.1 chr2:231091223 SP140 intronic rs13397985 1×10-22  1.45 [NR] 
2q37.3 chr2:242371101 FARP2 upstream rs757978 1×10-7  1.29 [NR] 
4q25 chr4:109016824 LEF1 intronic rs898518 4×10-10  1.20 [1.14-1.27] 
6p21.32 
chr6:32626272,  
chr6:32578082,  
chr6:32611641 
HLA-DQA1 / 
HLA-DQB1 
intergenic, 
intergenic, 
3'UTR 
rs9273363,  
rs674313,  
rs9273012 
2×10-10  1.24 [NR] 
6p21.31 chr6:33546837 BAK1 intronic rs210142 5×10-8  1.22 [NR] 
6p25.3 chr6:411064 IRF4 intronic rs872071 6×10-20  1.33 [NR] 
8q22.3 chr8:103578874 ODF1 downstream rs2511714 5×10-8  1.19 [1.12-1.27] 
8q24.21 
chr8:128211229, 
chr8:128192981, 
chr8:128209820 
CASC19 
upstream, 
downstream, 
5'UTR 
rs2466035,  
rs2456449,  
rs2466032 
2×10-8  1.21 [NR] 
9p21.3 chr9:22206987 intergenic intergenic rs1679013 1×10-8  1.19 [1.12-1.27] 
CML 
201 Korean ancestry 
cases, 497 Korean 
ancestry controls 
237 Korean ancestry 
cases, 1000 Korean 
ancestry controls, 
232 European 
ancestry cases, 576 
European ancestry 
controls 
17q11.1 chr17:25541278 intergenic intergenic rs4795519 1×10-12  1.85 [1.56-2.17] 
Affymetrix 
[456,522] 
363 6q25.1 chr6:151907748 CCDC170 intronic rs4869742 2×10-6  1.67 [1.35-2.04] 
FL 
189 European ancestry 
cases, 592 European 
controls 
456 European 
ancestry cases, 2,785 
European ancestry 
6p21.33 chr6:31074030 C6orf15 downstream rs6457327 5×10-11  1.69 [1.43-2.00] 
Illumina 
[~500,000] 
(pooled) 
364 
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controls 
FL 
681 European ancestry 
cases, 750 European 
ancestry controls 
up to 3,164 
European ancestry 
cases, 6,208 
European ancestry 
controls 
11q24.1 chr11:123361397 intergenic intergenic rs735665 4×10-9 CLL/SLL 1.81 [1.50-2.20] 
Illumina 
[312,768] 
365 
6p21.33 chr6:31074030 C6orf15 downstream rs6457327 7×10-6 FL 1.47 [1.27-1.72] 
6p21.32 chr6:32665420 intergenic intergenic rs10484561 1×10-29 FL 1.95 [1.72-2.22] 
FL 
379 European ancestry 
cases, 791 European 
ancestry controls 
1,049 European 
ancestry cases, 3,952 
European ancestry 
controls 
6p21.32 chr6:32664458 intergenic intergenic rs2647012 2×10-21  1.56 [1.43-1.72] 
Illumina 
[298,168] 
366 
HL 
589 European ancestry 
cases, 5,199 European 
ancestry controls 
2,057 European 
ancestry cases, 3,416 
European ancestry 
controls 
10p14 chr10:8093034 GATA3-AS1 intronic rs501764 7×10-8  1.25 [1.15-1.36] 
Illumina 
[504,374] 
367 
2p16.1 chr2:61066666 LINC01185 downstream rs1432295 2×10-8  1.22 [1.14-1.30] 
6p21.32 chr6:32428285 intergenic intergenic rs6903608 3×10-50  1.70 [1.58-1.82] 
8q24.21 chr8:129075832 PVT1 upstream rs2608053 1×10-7  1.20 [1.12-1.28] 
8q24.21 chr8:129192271 intergenic intergenic rs2019960 1×10-13  1.33 [1.23-1.44] 
HL 
1,200 European 
ancestry cases, 6,417 
European ancestry 
controls 
563 European 
ancestry cases, 613 
European ancestry 
controls 
5q31.1 chr5:131995964 IL13 intronic rs20541 1×10-8 EBV-negative cHL 1.47 [1.29-1.68] 
Illumina 
[502,514] 
368 5q15 chr5:96101944 CAST / ERAP1 
coding / 
upstream rs27524 7×10
-6 Total cHL 1.22 [1.11-1.33] 
6p21.33 chr6:31446796 HCG26 downstream rs2248462 7×10-16 Total cHL 1.64 [1.45-1.85] 
6p21.32 chr6:32433167 intergenic intergenic rs2395185 4×10-31 Total cHL 1.82 [1.67-2.00] 
HL 
1,465 European 
ancestry cases, 6,417 
European ancestry 
controls 
1,071 European 
ancestry cases, 953 
cases, 1,853 controls 
10p14 chr10:8093034 GATA3-AS1 intronic rs501764 4×10-10  1.39 [NR] 
Illumina 
[296,129] 
369 
2p16.1 chr2:61066666 LINC01185 downstream rs1432295 1×10-6  1.24 [NR] 
3p24.1 chr3:27764623 EOMES intronic rs3806624 1×10-12  1.26 [1.18-1.34] 
6q23.3 chr6:135415004 intergenic intergenic rs7745098 3×10-9  1.21 [1.14-1.29] 
6p21.32 chr6:32428285 intergenic intergenic rs6903608 5×10-27  1.62 [NR] 
8q24.21 chr8:129192271 intergenic intergenic rs2019960 6×10-10  1.37 [NR] 
DLBCL 
74 Japanese ancestry 
cases, 934 Japanese 
ancestry controls 
325 Japanese 
ancestry cases, 3,309 
Japanese ancestry 
controls 
13q12.2 chr13:28197436 POLR1D intronic rs7097 7×10-6  1.44 [1.23-1.67] Illumina 
[444,361] 
370 14q32.32 chr14:103484825 CDC42BPB intronic rs751837 3×10-7  3.51 [2.13-5.88] 
Lymphoma 
275 FL, 269 DLBCL 
cases, 198 other NHL 
cases, 202 HL cases, 
4,044 controls 
202 European 
ancestry FL cases, 
367 European 
ancestry DLBCL 
cases, 577 European 
ancestry other NHL 
cases, 99 European 
ancestry HL cases, 
2,596 European 
ancestry controls 
11q12.1 chr11:58060192 intergenic intergenic rs12289961 4×10-8 Multiple lymphomas 1.29 [1.17-1.40] 
Affymetrix 
[530,583] 
371 
11q12.1 chr11:58060192 intergenic intergenic rs12289961 1×10-7 NHL 1.29 [1.17-1.42] 
11q12.1 chr11:58347765 ZFP91, ZFP91-CNTF intronic rs948562 6×10
-7 Multiple lymphomas 1.29 [1.16-1.43] 
11q12.1 chr11:58347765 ZFP91, ZFP91-CNTF intronic rs948562 3×10
-7 NHL 1.32 [1.18-1.46] 
6p23 chr6:14636963 intergenic intergenic rs707824 6×10-7 NHL 1.33 [1.17-1.47] 
6p21.32 chr6:32429643 C6orf10 downstream rs9268853 2×10-10 FL 1.56 [NR] 
6p21.32 chr6:32581889 intergenic intergenic rs4530903 3×10-6 Multiple lymphomas 1.29 [1.16-1.43] 
6p21.32 chr6:32581889 intergenic intergenic rs4530903 2×10-8 NHL 1.37 [1.23-1.54] 
6p21.32 chr6:32581889 intergenic intergenic rs4530903 3×10-12 FL 1.93 [NR] 
6p21.32 chr6:32668100 intergenic intergenic rs2647045 4×10-10 FL 1.69 [NR] 
6p21.32 chr6:32668336 intergenic intergenic rs2647046 2×10-6 NHL 1.25 [1.14-1.37] 
6p21.32 chr6:32730012 HLA-DQB2 intronic rs7453920 5×10-6 Multiple lymphomas 1.19 [1.11-1.3] 
6p21.32 chr6:32741868 intergenic intergenic rs2621416 2×10-9 FL 1.57 [NR] 
MM 
1,675 European 
ancestry cases, 5,903 
European ancestry 
controls 
169 European 
ancestry cases, 927 
European ancestry 
controls 
2p23.3 chr2:25659244 DTNB intronic rs6746082 4×10-7  1.29 [1.17-1.42] Illumina 
[422,839] 
372 3p22.1 chr3:41925398 ULK4 coding rs1052501 2×10
-8  1.32 [1.20-1.45] 
7p15.3 chr7:21938240 DNAH11 upstream rs4487645 3×10-14  1.38 [1.28-1.50] 
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MM 
2,335 European 
ancestry cases, 7,306 
European ancestry 
controls 
2,357 European 
ancestry cases, 3,684 
European ancestry 
controls 
10q25.2 chr10:112036975 MXI1 intronic rs11195062 3×10-6  1.13 [NR] 
Illumina 
[414,804] 
373 
17p11.2 chr17:16849139 TNFRSF13B intronic rs4273077 8×10-9  1.26 [1.16-1.36] 
2q37.1 chr2:232176541 ARMC9 downstream rs7580717 5×10-6  1.13 [NR] 
22q13.1 chr22:39542292 CBX7 intronic rs877529 8×10-16  1.23 [1.17-1.29] 
3q26.2 chr3:169492101 MYNN coding rs10936599 9×10-14  1.26 [1.18-1.33] 
6p21.33 chr6:31107258 PSORS1C1 intronic rs2285803 1×10-10  1.19 [1.13-1.26] 
MM 
up to 1,660 European 
ancestry cases, 7,306 
European ancestry 
controls 
 
1p32.3 chr1:54375570 DIO1 intronic rs2235544 6×10-7 Hyperdiploid (HD) vs. controls 1.30 [1.17-1.44] 
Illumina 
[414,804] 
(Imputed) 
374 
11p14.3 chr11:21896880 intergenic intergenic rs11026318 9×10-6 
Non-HD without IgH 
translocations vs. 
controls 
2.33 [1.60-3.38] 
11q13.3 chr11:69457293 CCND1 intronic rs1352075 2×10-6 HD vs. non-HD 1.42 [1.23-1.64] 
14q21.1 chr14:43403459 intergenic intergenic rs11157317 9×10-6 HD vs. controls 1.29 [1.15-1.44] 
17q21.1 chr17:38179492 MED24 intronic rs2302777 8×10-7 HD vs. controls 1.31 [1.18-1.46] 
22q13.1 chr22:39519196 intergenic intergenic rs139371 2×10-9 HD vs. controls 1.37 [1.24-1.52] 
3q26.2 chr3:168916240 MECOM intronic rs9864370 9×10-6 HD vs. non-HD 2.04 [1.49-2.80] 
3p22.1 chr3:41786009 ULK4 intronic rs6599175 1×10-9 HD vs. controls 1.48 [1.30-1.68] 
3p22.1 chr3:41996136 ULK4 intronic rs2272007 2×10-9 HD vs. controls 1.47 [1.30-1.67] 
5q35.2 chr5:173777520 LINC01411 intronic rs12659144 3×10-6 HD vs. non-HD 1.67 [1.35-2.07] 
7p15.3 chr7:21938240 DNAH11 upstream rs4487645 1×10-9 HD vs. controls 1.43 [1.27-1.60] 
8p23.1 chr8:9395532 intergenic intergenic rs6601327 8×10-6 HD vs. controls 1.27 [1.14-1.41] 
8p23.1 chr8:9601699 TNKS 3'UTR rs12545912 7×10-6 HD vs. controls 1.30 [1.16-1.45] 
8p23.1 chr8:9792662 intergenic intergenic rs2055729 8×10-7 HD vs. controls 1.30 [1.17-1.45] 
1q21.3 chr1:153640827 ILF2 intronic rs7536700 4×10-6 Any IgH translocation vs. controls 1.53 [1.28-1.84] 
1q21.3 chr1:153640827 ILF2 intronic rs7536700 9×10-6 
non t11;14 and t4;14 
IgH translocations vs. 
controls 
1.86 [1.42-2.46] 
10p15.1 chr10:4676196 intergenic intergenic rs7086888 8×10-6 
non t11;14 and t4;14 
IgH translocations vs. 
controls 
1.87 [1.42-2.46] 
10q22.1 chr10:72767409 intergenic intergenic rs10509328 1×10-6 
non t11;14 and t4;14 
IgH translocations vs. 
controls 
1.86 [1.45-2.39] 
10q24.1 chr10:98639846 LCOR intronic rs17112190 9×10-7 t(11;14) vs. controls 1.80 [1.42-2.27] 
11q13.3 chr11:69462910 CCND1 exonic rs9344 8×10-11 t(11;14) vs. controls 1.82 [1.52-2.19] 
11q13.3 chr11:69462910 CCND1 exonic rs9344 2×10-11 t(11;14) vs non t(11;14) 1.95 [1.61-2.38] 
13q14.2 chr13:49466931 intergenic intergenic rs1449572 8×10-6 t(4;14) vs. controls 1.73 [1.36-2.21] 
14q22.3 chr14:57607067 intergenic intergenic rs7144018 9×10-6 t(4;14) vs. controls 1.85 [1.41-2.44] 
15q13.1 chr15:28488888 HERC2 intronic rs8028689 7×10-6 Any IgH translocation vs. controls 1.65 [1.33-2.05] 
16q23.3 chr16:82787053 CDH13 3'UTR rs8056064 2×10-6 t(11;14) vs. controls 1.68 [1.36-2.08] 
16q24.3 chr16:89448663 ANKRD11 intronic rs3096299 4×10-6 t(11;14) vs non t(11;14) 1.54 [1.28-1.86] 
16q24.3 chr16:89471246 ANKRD11 intronic rs2086824 2×10-6 t(11;14) vs non t(11;14) 1.58 [1.31-1.91] 
18q22.1 chr18:64952213 intergenic intergenic rs8099213 5×10-6 
non t(11;14) and t(4;14) 
IgH translocations vs. 
controls 
1.52 [1.27-1.81] 
2q31.1 chr2:174504924 intergenic intergenic rs13028485 2×10-6 t(11;14) vs non t(11;14) 2.17 [1.57-2.99] 
2p23.3 chr2:25613146 DTNB intronic rs7577599 6×10-6 Any IgH translocation 1.43 [1.22-1.67] 
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2p23.3 chr2:25633242 DTNB intronic rs10180663 2×10-6 t(11;14) vs. controls 1.64 [1.34-2.02] 
22q13.1 chr22:39519196 intergenic intergenic rs139371 9×10-6 
non t(11;14) and t(4;14) 
IgH translocations vs. 
controls 
1.50 [1.26-1.80] 
3q13.33 chr3:121154193 POLQ downstream rs6800901 2×10-6 any IgH translocation vs. controls 1.31 [1.17-1.47] 
3q26.2 chr3:169477506 TERC upstream rs12638862 2×10-6 any IgH translocation vs. controls 1.37 [1.20-1.56] 
4q34.1 chr4:174655914 intergenic intergenic rs4521323 9×10-6 any IgH translocation vs. controls 1.28 [1.15-1.43] 
4q34.3 chr4:180968431 intergenic intergenic rs1994816 5×10-7 
non t(11;14) and t(4;14) 
IgH translocations vs. 
controls 
1.76 [1.41-2.20] 
5p14.3 chr5:22812264 CDH12 intronic rs780179 9×10-7 t(11;14) vs non t(11;14) 1.59 [1.32-1.92] 
6q23.2 chr6:131563577 AKAP7 intronic rs4629710 6×10-6 
non t(11;14) and t(4;14) 
IgH translocations vs. 
controls 
1.60 [1.31-1.96] 
8q12.1 chr8:60545664 intergenic intergenic rs4737547 3×10-6 any IgH translocation vs. controls 1.30 [1.17-1.45] 
MPN 
324 European ancestry 
cases, 2,999 European 
ancestry controls 
NA 9p24.1 chr9:5070831 JAK2 intronic rs10974944 4×10-20  3.10 [2.40-4.00] 
Affymetrix 
[62,775] 
375 
HL 
393 European ancestry 
cases, 3,315 European 
ancestry controls 
113 European 
ancestry cases, 214 
European ancestry 
controls 
6p21.32 
chr6:32109979, 
chr6:32383108, 
chr6:32384721, 
chr6:32428285, 
chr6:32572251 
FKBPL, PRRT1, 
HCG23, HLA-
DRA, HLA-
DRB1 
intergenic 
rs204999,  
rs9268528,  
rs9268542,  
rs6903608,  
rs2858870 
8×10-18  2.50 [NR] 
Illumina 
[705,591] 
376 
6p21.32 
chr6:32109979, 
chr6:32383108, 
chr6:32384721, 
chr6:32428285, 
chr6:32572251 
FKBPL, PRRT1, 
HCG23, HLA-
DRA, HLA-
DRB1 
intergenic 
rs204999, 
rs9268528, 
rs9268542, 
rs6903608, 
rs2858870 
2×10-7  1.70 [NR] 
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Appendix 3.1 Phenol chloroform extraction of genomic DNA 
 
Per volume (V) of diluted DNA ½V of phenol and ½V of chloroform were added and 
mixed using a vortex. Samples were then centrifuged in a bench top microcentrifuge 
at 13,000 rpm for 10 mins. The upper layer was removed to a new tube and the 
bottom layer discarded. 10 µL of  3 M sodium acetate and 1 µL glycogen was added 
and the volume was brought to 200 µL total with nuclease free H2O. 200 µL of ice 
cold 100% molecular grade ethanol was added and the samples were mixed by vortex 
and incubated -20ºC 3 - 6 hours. Following incubation the samples were centrifuge at 
15,000 rpm for 30 mins at 4ºC to pellet the DNA precipitate. The pellet supernatant 
was aspirated and discarded. A 200 µL wash of ice cold 80% molecular grade ethanol 
was added to each sample which were then mixed by vortex and centrifuged at 15,000 
rpm for 5 mins at 4 ºC. The ethanol wash was aspirated from the DNA pellet. This 
was dried for 10 mins at room temperature to remove residual ethanol. The pellet was 
resuspend in a required volume of Tris-EDTA buffer (10 mM 
tris(hydroxymethyl)aminomethane) at pH 8.0 and 1mM ethylenediaminetetraacetic 
acid). Pellets in Tris-EDTA were dissolved using combinations of mixing by vortex, 
centrifugation and heat treatment at 52ºC for 5 mins. 
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Appendix 3.2 Custom awk script for consistency checking of 
mapped metadata and compliance to the SAM/BAM format 
during genome and exome alignment 
 
#Set MAPQ to 0 and CIGAR to * for unmapped reads using 
awk 
 
... 
 
bwa aln/mem ... | awk -v IFS="\t" -v OFS="\t" '{ if($$1 
!~ /^@/ &&  
and($$2,0x0004)) { $$5=0; $$6="*"; } ; print $$0}' 
|  samtools view  
 
... 
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Appendix 3.3 Example SAMtools mpileup and GATK 
commands for one region. 
 
SAMtools_variant_calling_and_quality_flagging.sh 
 
# SAMtools mpileup multisample variant calling command used 
samtools mpileup -C50 -D -g -S -uf hg19-sorted.fasta -r chr1:10000-
177417 LK0051_001.bam LK0051_007.bam LK0051_128.bam LK0051_159.bam 
LK0051_165.bam LK0124_117.bam LK0124_179.bam LK0124_202.bam 
LK0139_001.bam LK0139_004.bam LK0139_005.bam LK0153_003.bam 
LK0153_004.bam LK0153_029.bam LK0153_078.bam LK0153_079.bam 
LK0153_080.bam LK0153_084.bam LK0153_086.bam LK2042_003.bam 
LK2042_005.bam LK2042_006.bam LK2042_018.bam LK2042_231.bam 
LK2042_232.bam LK2042_257.bam LK2042_258.bam LK2042_259.bam 
LK2042_281.bam LK2042_290.bam LK2042_300.bam | bcftools view -vcg - 
> Region_1.vcf 
 
# Adding variant quality flags to each variant in each individual 
using GATK 
/usr/java/latest/bin/java -Xmx2g -jar 
/usr/local/software/gatk/default/GenomeAnalysisTK.jar \ 
   -R hg19-sorted.fasta \ 
   -T VariantFiltration \ 
   -o Region_1.filter.vcf \ 
   --variant Region_1.vcf \ 
 --genotypeFilterExpression "DP >= 10 && GQ >= 20" \ 
 --genotypeFilterName "High_Sample_Confidence" \ 
 --genotypeFilterExpression "DP < 10 && GQ < 20" \ 
 --genotypeFilterName "Low_Sample_Confidence" 
 
# Extracting only variants from the VCF file that have been tagged 
with High_Sample_Confidence in at least one individual 
egrep "^#|High_Sample_Confidence" Region_1.filter.vcf > 
Region_1.High_Sample_Confidence.vcf 
 
 
# Conversion of VCF file to ANNOVAR input using a custom script 
convert_VCF_to_ANNOVAR_input.sh Region_1.High_Sample_Confidence.vcf 
> Region_1.High_Sample_Confidence.annovar 
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Appendix 3.4 Custom VCF to ANNOVAR input conversion 
script 
 
convert_VCF_to_ANNOVAR_input.sh 
 
# Custom script for converting VCF to an input format compatible 
with ANNOVAR 
 
#!/usr/bin/awk -f 
 
# Purpose of this script is to convert multisample VCF files into 
input format ANNOVAR 
 
#awk -v FS="\t"  
BEGIN { 
 FS="\t"; 
 OFS="\t"; 
 # Print header 
 print 
"#CHROM"OFS"START"OFS"END"OFS"REF"OFS"ALT"OFS"INFO"OFS"LK0051-
001"OFS"LK0051-007"OFS"LK0051-128"OFS"LK0051-159"OFS"LK0051-
165"OFS"LK0124-117"OFS"LK0124-179"OFS"LK0124-202"OFS"LK0139-
001"OFS"LK0139-004"OFS"LK0139-005"OFS"LK0153-003"OFS"LK0153-
004"OFS"LK0153-029"OFS"LK0153-078"OFS"LK0153-079"OFS"LK0153-
080"OFS"LK0153-084"OFS"LK0153-086"OFS"LK2042-003"OFS"LK2042-
005"OFS"LK2042-006"OFS"LK2042-018"OFS"LK2042-231"OFS"LK2042-
232"OFS"LK2042-257"OFS"LK2042-258"OFS"LK2042-259"OFS"LK2042-
281"OFS"LK2042-290"OFS"LK2042-
300"OFS"COUNT_ALT"OFS"HAS_ALT"OFS"HAS_REF" 
} 
 
$0 ~/^#CHROM/ { 
 for(i=10;i<NF+1;i++){ 
  sample_name[i]=$i; 
 } 
} 
 
$0 !~ /^#/ { 
 refl=length($4); 
 printf 
"%s"OFS"%i"OFS"%i"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"O
FS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s
"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"
%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s"OFS"%s",$1,$2,$2+refl-
1,$4,$5,$8,$10,$11,$12,$13,$14,$15,$16,$17,$18,$19,$20,$21,$22,$23,$
24,$25,$26,$27,$28,$29,$30,$31,$32,$33,$34,$35,$36,$37,$38,$39,$40 
 
 # Parse the format column 
 n=split($9,format,":") 
 for (i=1;i<n;i++){ 
  if (format[i] == "GT") { 
   gt_field=i; 
   break; 
  } 
  203 
 } 
 sum=0; 
  with=""; 
  without=""; 
 for (i=10;i<NF+1;i++) {  
  split($i,genotypes,":"); 
  gt=genotypes[gt_field]; 
  if ( gt == "0/0" ) { 
   c=0; 
   without=without","sample_name[i] 
  } else if ( gt == "0/1" ) {  
   c=1; 
   with=with","sample_name[i]; 
  } else if ( gt == "1/1" ) {  
   c=1; 
   with=with","sample_name[i]; 
  };  
  sum=sum+c;  
 } 
 sub(",","",with); 
 sub(",","",without); 
 printf OFS"%s"OFS"%s"OFS"%s\n",sum,with,without 
} 
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Appendix 3.5 pVAAST code 
# This parameter file is optimized for rare Mendelian diseases with 
# large pedigrees. If the penetrance and prevalence is known, please 
# also modify "penetrance_lower_bound", "penetrance_upper_bound" and 
# "max_prevalence_filter" parameters. 
 
#------------------------Basic options---------------------------- 
input_ped_cdr_files: LK0051_pedigree.ped LK0051_Target_variants.cdr 
# space separated list of ped and cdr files 
      
pedigree_representatives: LK0051-128  
 
unknown_representatives:  no  
additional_cases:    
inheritance_model:   dominant 
penetrance_lower_bound:  0 
penetrance_upper_bound:  1 
 
 
#--------------------Performance Tuning ------------------------- 
 
informative_site_selection:   3 # 1 stands for selecting sites 
based on CLRT score;  
     # 2 for LOD score; 3 for LOD + CLRT score 
simulate_genotyping_error:  yes # Use this option will prevent 
inheritance error to  
     # achieve 0 p-values in fully sequenced 
trios. For de novo 
     # mutations, set "inheritance_model" to 
"dominant" and 
     # this option to "yes" 
genotyping_error_rate:  1e-4 # Set the genotyping error rate. 
Essential for de novo 
     # mutations. 
 
 
 
#----------------Gene and Variant Filtering ------------------------ 
 
max_prevalence_filter:  0.1  
lod_score_filter:    no  
clrt_score_filter:   no   
nocall_filter:    no     
nocall_filter_cutoff:   no  
inheritance_error_filter:  no   
 
 
 
#-----------------------Developer Options-------------------------- 
clrt_randomization_round:  100   
locus_heterogeneity_penalty:  0       
incomplete_penetrance_penalty:  0      
mcmc_use_functional_score: yes 
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Appendix 3.6 Representative genome (LK2042-003) and 
exome (LK2042-005) FastQC reports and LK2042-005 
Qualimap report 
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Appendix 4.1 Primer sequences and annealing temperatures 
 
Gene Variant Forward Primer  
5’ to 3’ 
Reverse Primer  
5’ to 3’ 
Annealing 
Temp 
PCR* 
TNFSF9 chr19:6534728 
G>C 
ctgacatgttcggtgctcag cctggcctcagtgtgaagat 62ºC GTG 
TDP2 chr6:24658126 
C>T 
tgctttttcctctctatgtccca ggtatgttgtgggatttccttcat 62ºC MyTaq 
MMP8 chr11:102585288 
T>G 
gcttgaaggtttgtaagcaggg aggcaaccaatactgggctc 62ºC MyTaq 
SPHK2 chr19:49132198 
A>C 
acccactggacctgctct ttcggagacgggtgagtgta 62ºC MyTaq 
LRP5 chr11:68181292 
C>A 
cctggctgtgcctttgct cccagaaccagcctgatcta 62ºC GTG 
NOTCH1 chr9:139417464 
T>G 
gtctggggaactcgccatc tgtctccagggaaatcgtgc 62ºC MyTaq 
RIPK2 chr8:90796371 
GTAA>G 
acctatgtgacaagaagaaaatgga acagggacagaactcaatgtca 62ºC MyTaq 
NAT10 chr11:34152973 
C>A 
ccttgtctcagggcatggtt atgttgaggcaatccaggca 62ºC MyTaq 
PABPC1 chr8:101721839 
C>A 
tacctgtgggatagctgcca tgacctggctagggtaatgc 62ºC MyTaq 
MET chr7:116381047 
A>G 
ttgggctgcagacatttcca acttcaggtgcaggacttgg 62ºC MyTaq 
DUSP10 chr1:221874839 
TG>T 
ttgcaggagaggatgacagc tgccttcactggcttcttgt 62ºC MyTaq 
RARS chr5:167929060 
CCTT>C 
tgtgtaccttaccattttctttccc agagtgcctacctctatcttca 62ºC MyTaq 
HAL chr12:96371767 
A>G 
aggaccagcttagttctgcat tgttgactccctctccacca 62ºC MyTaq 
PEX6 chr6:42934551 
G>A 
cacctccaaggacttggtct ggtccctgaaggttcctg 62ºC GTG 
GIT1 chr17:27904190 
G>A 
gctcgaggttgtctgaggac cctgcgtcagtcataagggg 62ºC MyTaq 
NID2 chr14:52509033 
G>A 
aggcctccaattggtgtgag ggaggaggggagaaaacaga 62ºC MyTaq 
STT3B chr3:31659458 
T>G 
gtgtttctctggaagtgggttc gaagtgttgcccaagaactga 62ºC MyTaq 
NF1 chr17:29508805 
T>G 
aggcattttggaactgggtaga ggaagagggttgggcctaattt 62ºC MyTaq 
 
*GTG = GoTaq Green PCR master mix, MyTaq = MyTaq master mix 
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Appendix 4.2 Primer sequences and annealing temperatures for custom amplicon sequencing of 
TNFSF9 
 
TNFSF9 
Fragment 
Primer Sequences 5’ to 3’ Product 
size 
PCR reaction Cycling conditions 
Amplicon 1 F: tcttaatttcaacattcacattccaggt 
R: agtcataaggtagacttctcattcaaca 
2802 bp 5 µL Phusion Taq (NEB Inc.), 0.8 µL each of F 
and R primers at 10 µM, 2.4 µL H2O, 1 µL 
DNA at 25 ng/µL 
66ºC annealing temperature, 40 
cycles, 2 min extension time 
Amplicon 2 F: tctgttgaatgagaagtctaccttatga 
R: aatgtcctaagtcctacatagagaaagg 
3540 bp 5 µL GoTaq Green, 0.8 µL each of F and R 
primers at 10 µM, 0.5 µL 100% DMSO, 1.9 µL 
H2O, 1 µL DNA at 25 ng/µL 
55ºC annealing temperature, 45 
cycles, 3 min 30 sec extension 
time 
Amplicon 3 F: cctttctctatgtaggacttaggacatt 
R: cctggcctcagtgtgaagat 
3015 bp 5 µL MyTaq HS, 0.8 µL each of F and R 
primers at 10 µM, 2.4 µL H2O, 1 µL DNA at 25 
ng/µL 
95ºC 1 min 
95ºC 15 sec 
63ºC 15 sec 
72ºC 2min 
(45 cycles) 
72ºC 5 min 
4ºC hold 
Amplicon 4 F: ctgacatgttcggtgctcag 
R: attcctcacgtattaccataactcagat 
1084 bp 5 µL MyTaq HS, 0.8 µL each of F and R 
primers at 10 µM, 2.4 µL H2O, 1 µL DNA at 25 
ng/µL 
95ºC 1 min 
95ºC 15 sec 
65ºC 15 sec 
72ºC 45 sec 
(40 cycles) 
72ºC 5 min 
4ºC hold 
Amplicon 5 F: atctgagttatggtaatacgtgaggaat 
R: ggaaaagaaacctcaaacaagaaaaaca 
3629 bp 5 µL Phusion Taq (NEB Inc.), 0.8 µL each of F 
and R primers at 10 µM, 2.4 µL H2O, 1 µL 
DNA at 25 ng/µL 
66ºC annealing temperature, 40 
cycles, 2 min extension time 
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Appendix 4.3 Samples selected for custom amplicon 
sequencing of TNFSF9 
 
Individual ID Sex TFHMS case type HM Subtype Age at 
Diagnosis 
LK0001-001 M Familial MALT 72 
LK0002-099 F Familial NHL 39 
LK0004-012 M Familial HL 23 
LK0016-001 M Familial CLL 76 
LK0016-108 M Familial MM 72 
LK0016-137 M Familial CLL 63 
LK0016-187 F Familial FL 56 
LK0024-001 M Familial HCL 59 
LK0051-001 M Familial T-cell NHL 31 
LK0124-117 M Familial AML 24 
LK0153-065 M Familial MDS to AML RAEB-2 63 
LK0508-001 F Non-familial AML 18 
LK0509-001 F Non-familial PV 31 
LK0537-001 F Familial CLL 66 
LK0537-002 M Familial CLL 58 
LK0580-004 M Familial NHL 39 
LK0585-001 F Non-familial MCL 64 
LK0595-001 M Non-familial CLL 70 
LK0625-001 F Familial MM 52 
LK0625-003 M Familial CLL 60 
LK0627-001 F Non-familial B cell gastric NHL 74 
LK0628-001 F Non-familial DLBCL 68 
LK0629-001 M Non-familial AML 40 
LK0633-001 M Non-familial DLBCL 44 
LK0634-001 M Non-familial HL 18 
LK0635-001 M Non-familial DLBCL 57 
LK0647-001 M Familial CLL 68 
LK0650-001 M Non-familial CLL 58 
LK0654-001 F Non-familial CML 29 
LK0658-001 M Non-familial CLL 76 
LK0660-001 M Non-familial WM 33 
LK0661-001 M Non-familial NHL 69 
LK0664-001 F Non-familial FL 41 
LK0672-001 F Familial ALL 18 
LK0673-001 F Non-familial NHL 33 
LK0687-001 M Non-familial CLL 67 
LK0689-001 F Non-familial HL 66 
LK0692-001 M Non-familial CLL 53 
LK0693-001 F Non-familial ET 70 
LK0705-001 F Non-familial NHL 33 
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Individual ID Sex TFHMS case type HM Subtype Age at 
Diagnosis 
LK0717-001 M Non-familial NHL 47 
LK0732-001 M Non-familial NHL 52 
LK0737-001 M Non-familial HCL 53 
LK0739-001 F Non-familial NHL 80 
LK0756-001 M Non-familial DLBCL 62 
LK0760-001 F Non-familial DLBCL 65 
LK0786-001 M Familial CLL 74 
LK0788-001 F Non-familial NHL 86 
LK0802-001 M Non-familial HCL 70 
LK0804-001 F Non-familial T-cell NHL 31 
LK0811-001 M Non-familial DLBCL 61 
LK0818-001 M Non-familial NHL 59 
LK0823-001 M Familial FL 51 
LK0823-002 F Familial NHL 54 
LK0836-001 M Familial CLL 65 
LK0836-002 M Familial HCL 53 
LK0848-001 M Non-familial NHL 64 
LK0849-001 F Non-familial NHL 56 
LK0853-001 F Non-familial NHL Unknown 
LK0855-001 F Non-familial HL 51 
LK0927-001 M Non-familial WM 57 
LK0933-001 M Non-familial HCL 67 
LK0956-001 M Non-familial DLBCL 47 
LK0958-001 M Non-familial HCL 49 
LK0981-001 M Non-familial DLBCL 58 
LK0984-001 M Non-familial HL 13 
LK1033-001 F Non-familial BL 67 
LK1040-001 M Non-familial FL 55 
LK1045-001 F Non-familial HL 35 
LK1155-001 F Familial CLL 60 
LK2447-002 F Familial FL 60 
LK6000-031 F Familial NHL 38 
LK6000-141 F Familial DLBCL 42 
LK7738-001 M Non-familial NHL Unknown 
LK7739-001 F Familial AML 78 
LK7740-001 F Familial MM->CML (BCR-ABL 
+ve) 
Unknown 
LK7740-002 M Familial CLL->CML (BCR-ABL 
+ve) 
Unknown 
LK7743-001 F Familial CLL 48 
LK7743-002 F Familial CLL 77 
LK7746-001 M Non-familial FL Unknown 
LK7748-001 M Familial MCL 62 
LK7749-001 F Familial MM 73 
LK7750-002 M Familial MDS 70 
LK7751-001 F Familial FL 75 
LK7752-001 F Non-familial FL 53 
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Individual ID Sex TFHMS case type HM Subtype Age at 
Diagnosis 
LK7753-001 M Non-familial NHL 56 
LK7754-001 F Familial ET 80 
LK7755-001 M Familial AML 79 
LK7755-004 M Familial NHL 50 
LK7756-004 M Familial AML Unknown 
LK7759-001 F Non-familial B Cell  Unknown 
LK7766-001 F Familial HL 22 
LK7768-001 F Familial CLL 72 
LK7772-001 F Familial NHL 66 
LK7773-001 F Familial MM 73 
LK7773-002 M Familial NHL 73 
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Appendix 4.4 Representative TaqMan genotyping results for 
TDP2 rs200729372 and TNFSF9 rs61750000 
 
Figure 1. Representative TaqMan genotyping results from 94 samples for TDP2 
rs200729372, including two known heterozygous samples.  
 
Figure 2. Representative TaqMan genotyping results from 94 samples for 
TNFSF9 rs61750000, including two known heterozygous samples.  
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Appendix 4.5 Microarray gene expression profiles for TDP2 and TNFSF9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 BioGPS sourced U133A GeneAtlas microarray gene expression profiles249, 250 for TDP2 (A) and TNFSF9 (B). 
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Appendix 4.6 TNFSF9 G139A sequence logo and protein 
structure 
 
Figure 1. Partial protein alignment sequence logo for the TNF superfamily 
protein domain with the TNFSF9 G139A residue indicated by the arrow. 
 
 
Figure 2. TNFSF9 homotrimer protein structure of the TNF superfamily protein 
domain with individual domains indicated by colour and the altered G139A 
amino acid residue indicated by a molecular ball. 
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Appendix 5.1 Chapter 5 Publication 
 
The following article was published in Oncology Reports. 
 
Blackburn, N. B. et al. A retrospective examination of mean relative telomere length 
in the Tasmanian Familial Hematological Malignancies Study. Oncol Rep 33, 25–32 
(2015). 
 
ONCOLOGY REPORTS  33:  25-32,  2015
Abstract. Telomere length has a biological link to cancer, with 
excessive telomere shortening leading to genetic instability 
and resultant malignant transformation. Telomere length is 
heritable and genetic variants determining telomere length 
have been identified. Telomere biology has been implicated 
in the development of hematological malignancies (HMs), 
therefore, closer examination of telomere length in HMs may 
provide further insight into genetic etiology of disease devel-
opment and support for telomere length as a prognostic factor 
in HMs. We retrospectively examined mean relative telomere 
length in the Tasmanian Familial Hematological Malignancies 
Study using a quantitative PCR method on genomic DNA from 
peripheral blood samples. Fifty-five familial HM cases, 191 
unaffected relatives of familial HM cases and 75 non-familial 
HM cases were compared with 758 population controls. 
Variance components modeling was employed to identify 
factors influencing variation in telomere length. Overall, HM 
cases had shorter mean relative telomere length (P=2.9×10-6) 
and this was observed across both familial and non-familial 
HM cases (P=2.2x10-4 and 2.2x10-5, respectively) as well as 
additional subgroupings of HM cases according to broad 
subtypes. Mean relative telomere length was also significantly 
heritable (62.6%; P=4.7x10-5) in the HM families in the present 
study. We present new evidence of significantly shorter mean 
relative telomere length in both familial and non-familial HM 
cases from the same population adding further support to the 
potential use of telomere length as a prognostic factor in HMs. 
Whether telomere shortening is the cause of or the result of 
HMs is yet to be determined, but as telomere length was found 
to be highly heritable in our HM families this suggests that 
genetics driving the variation in telomere length is related to 
HM disease risk.
Introduction
Telomeres are DNA-protein structures at chromosome ends 
consisting of repeating hexameric nucleotide sequences of 
TTAGGG (1). The primary role of the telomere is to cap chro-
mosome ends to prevent aberrant recombination as a result of 
exposed chromosomal DNA; making telomeres essential for 
maintenance of genomic integrity (2). With each cell division 
telomeres shorten due to the incomplete DNA replication of 
chromosome ends by DNA polymerases eventually triggering 
cell senescence or apoptosis to prevent further shortening and 
exposure of chromosomal DNA (3). The telomerase complex 
can counteract telomere shortening in actively dividing cells 
by catalyzing the addition of TTAGGG repeats to chromo-
some ends (3,4), however, this is not a full restoration and 
telomeres progressively shorten with age (3,5,6). A number of 
studies have reported an association between telomere length 
in lymphocytes and an increased risk of age-related diseases 
including cancer (7,8). To date, the main understanding of the 
role of telomeres in cancer is that excessive telomere short-
ening leads to increased genetic instability and chromosomal 
end-to-end fusions (2,9), which then leads to a malignant cell 
transformation (9).
Studies of monozygotic and dizygotic twins and large 
families have established a genetic component to the deter-
mination of telomere length. Estimates of the heritability of 
telomere length ranges between 78 and 82% in studies of twins 
and sibling pairs (which generally produce inflated heritability 
estimates) (10,11) and 44% in a study of large Amish fami-
lies (12). Although it has been proposed that the heritability of 
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telomere length can be accounted for by shared environmental 
factors (13) the consensus is that telomere length is primarily 
determined by parental inheritance including at least partial 
inheritance of chromosome-specific telomere lengths (14,15). 
This view is strongly supported by mouse models of telomere 
length inheritance (16).
Telomere length is a proposed risk factor for cancer given 
its importance in maintaining genomic integrity (2,9) and 
shorter telomeres have been shown to be associated with a 
range of cancers (7,8,17). The proposed role of telomere length 
as a cancer risk factor, coupled with its high heritability, raises 
the idea that telomere length may also be important in familial 
cancers such as familial hematological malignancies (HMs). 
Additionally, inherited changes in telomere length as a result of 
mutations in the telomere maintenance genes TERT and TERC 
have been identified in four HM families with myelodysplastic 
syndrome and acute myeloid leukemia (MDs-AMl) (18). 
Therefore, telomere length may be a risk factor for other HM 
subtypes.
Hematological malignancies arise as a result of the 
neoplastic transformation of cells involved in hematopoiesis 
and include a broad range of subtypes of leukemias, lymphomas 
and myelomas (19). A well-established risk factor for HMs is 
family history indicating that familial HMs have an underlying 
genetic component. For example, a population-based study of 
the swedish cancer registry showed an 8.5-fold increase in 
the risk of developing chronic lymphocytic leukemia (cll) in 
first-degree relatives of cll patients as well as an increased 
risk of developing other HM subtypes providing evidence for a 
shared genetic etiology across HM subtypes (20).
There is accumulating evidence that implicates telomere 
length as an important factor in the development of a range of 
HMs. This includes studies of several different HM subtypes 
where shorter telomeres were found in circulating tumor 
cells (21-26). While these studies have revealed important 
insights into telomere dynamics in circulating tumor cells there 
has been less focus on prospective and retrospective studies 
of pre-disease and remission telomere lengths respectively in 
HM patients. indeed, one prospective study of telomere length 
in pre-disease blood samples surprisingly showed that longer 
telomere length was associated with a future risk of NHl (non-
Hodgkin lymphoma) (27). Furthermore, in a study of chronic 
leukemia, Mansouri and colleagues (28) elegantly showed that 
telomere length has potential as a clinical prognostic marker 
in HMs. in their study, patients with shorter telomeres were 
associated with high-risk genetic markers and in patients with 
otherwise good prognostic markers, telomere length was an 
independent prognostic factor that subdivided the good prog-
nosis group into groups with distinct outcomes. Therefore, 
there is potential for telomere length to be a clinically relevant 
prognostic risk factor for HMs.
The aim of the present study was to explore whether 
telomere length is involved in familial HMs and to find new 
evidence supporting telomere length as a prognostic risk 
factor for HMs. To this end, we examined telomere length in 
the Tasmanian Familial Hematological Malignancies study 
(TFHMs); a genetic study comprising large Tasmanian fami-
lies with multiple cases of HMs and a collection of population 
matched non-familial HM cases (29-31) and controls (32,33). 
Previously, similar collections have focused on families with 
one predominant subtype of HM. The TFHMs includes fami-
lies with a dense aggregation of several HM subtypes across 
multiple generations; for example family lk2042 includes 32 
cases in five generations (Table i).
The strength of a familial approach to examining telomere 
length lies in the enrichment of the shared genetic back-
grounds between related individuals as related cases are likely 
to share genetic variants contributing to variation in telomere 
length which may in turn be affecting their risk of developing 
HMs. in the present study, we used the TFHMs to measure 
the heritability of telomere length as a quantitative trait in the 
study families and then examine whether HMs account for 
measured variation in telomere length.
Materials and methods
Ethics statement. The TFHM study was approved by the 
Human research ethics committee (Tasmanian network), 
reference number: H8551, and written informed consent was 
obtained from all participating individuals.
The Tasmanian Familial Hematological Malignancies Study. 
As previously described (29) during the period 1972-1980 all 
patients with HMs diagnosed in Tasmania (the island state of 
Australia) were invited to participate in a population-based 
study examining the association of occupation and place of 
residence with risk of development of myeloproliferative and 
lymphoproliferative disorders (34,35). using a genealogical 
database at the Menzies research institute Tasmania the 
individuals participating in the original population-based 
study were linked to both current generations and records 
from the Tasmanian Cancer Registry, which has documented 
cases of HMs since 1978. Family members provided further 
information through questionnaires and personal interviews. 
This allowed us to form pedigrees of Tasmanian families with 
multiple cases of HMs as well as a collection of HM cases with 
no reported family history of disease (Table i).
confirmation of diagnosis was, where possible, obtained 
for all cases and in particular 13 study families were classi-
fied by a single experienced hematologist (e.M.T.) according 
to the 2008 World Health Organization classification (19) as 
previously described (29). For the remaining study families, 
case diagnosis was obtained from the Tasmanian Cancer 
registry records and by review of available pathology reports 
of cases that consented to participate in the TFHMs. More 
extensive clinical information is not currently available due to 
the multi-center and multi-specialist nature of the original data 
collection.
Study samples. in this TFHM-based study we used DNA 
obtained from peripheral blood samples from 55 familial HM 
cases, 191 unaffected relatives of familial cases and 75 non-
familial cases. DNA from 40 TFHMs families was available 
for the present study with samples available from both HM 
cases and unaffected relatives in 14 families. The remaining 
families were comprised of samples from HM cases with a 
known family history of disease alone or from unaffected 
relatives of HM cases. Of the 191 unaffected relatives, 171 
were first-degree relatives of HM cases and the remaining 
subjects were more distantly related or spouses. For HM cases, 
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DNA was collected from 1 month to 64.9 years post HM 
diagnosis (mean, 9.9 years). Population controls were recruited 
randomly from the Tasmanian electoral role (n=758) through 
the TAscOG study (33) (a population-based study of gait in 
older Tasmanians) or obtained from the control samples in a 
Tasmanian familial prostate cancer case-control study (32) 
both conducted at the Menzies research institute Tasmania. 
Details concerning the participants in this study are shown in 
Table ii, and the distribution of HM case subtypes in this study 
is summarized in Table iii. Non-familial HM cases had no 
self-reported family history of HMs and did not appear in any 
of our study families after thorough genealogical examination. 
Frequent updates from the Tasmanian cancer registry were 
used to monitor the occurrence of HMs in the unaffected 
relatives that are part of this study. Population control DNA 
samples were also extracted from peripheral blood samples 
in the same laboratory, using the same methodology as the 
TFHMs samples. Genomic DNA was extracted from periph-
eral blood samples using the Nucleon BAcc 3 DNA extraction 
kit (Ge Healthcare).
Telomere length measurement. We investigated the mean 
relative telomere length in peripheral blood samples using a 
slightly amended protocol for a validated monochrome multi-
plex quantitative Pcr method outlined by cawthon (36). This 
method measures the relative telomere length by calculating the 
ratio, T/s, between telomere repeat copy number amplification 
(T) and the amplification of a single-copy gene, albumin (s). 
The average T/s ratio was obtained as the mean of the tripli-
cate measurements for each sample. individual measurements 
were excluded from the average T/s ratio calculation when the 
replicate failed or a large standard error was observed. The 
coefficient of variation calculated across all assay plates using 
repeated cross-plate samples was 3.4%.
Telomere length measurement was performed in 10 µl 
volumes using a lightcycler 480 in a 96-well plate format. 
each 96-well plate contained a six point standard curve 2, 5, 
15, 50, 100 and 150 ng, a unique sample common to each plate, 
a no template control and 24 unknown case/control samples 
all repeated in triplicate, with 1.6% sample replication across 
plates. The genomic DNA used for the standard curve was 
from a 27-year-old female control study participant.
Final reagent concentrations were 5 ng of genomic DNA, 
primer telg 200 nM (5'-AcAcTAAGGTTTGGGTTTGGGT 
TTGGGTTTGGGTTAGTGT-3'), primer telc 700 nM (5'-TG 
TTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAA 
cA-3'), primer albu 500 nM (5'-cGGcGGcGGGcGGcG 
cGGGcTGGGcGGAAATGcTGcAcAGAATccTTG-3'), 
primer albd 500 nM (5'-GcccGGcccGccGcGcccG 
TcccGccGGAAAAGcATGGTcGccTGTT-3'), AmpliTaq 
Gold (Applied Biosystems) 0.625 u, GeneAmp 10X PCR 
buffer (life Technologies) containing 50 mM kcl, 10 mM 
Tris-Hcl pH 8.3 and 1.5 mM Mgcl2, 1 mM DTT, 1 M Betaine 
(sigma-Aldrich), 0.0025 mM syto9 (life Technologies) and 
0.25 mM of each dNTP (Bioline). cycling conditions were as 
follows: 95˚c for 15 min, 2 cycles of 94˚c for 15 sec, 49˚c for 
60 sec; four cycles of 84˚c for 20 sec, 59˚c for 30 sec, then 40 
cycles of 94˚c for 15 sec, 59˚c for 30 sec with signal acquisi-
tion for telomere repeat copy number amplification, 84˚c for 
30 sec, then 85˚c for 20 sec with signal acquisition for albumin 
amplification. A melting curve was generated for each plate. ct 
values were calculated using linregPcr (37) and a standard 
Table i. summary of the TFHMs families used in this study.
   HM cases unaffected
  Generations with relatives
 known with telomere with telomere
 HM HM length length
Family cases cases measurement measurement
lk0001 14 4 1 16
lk0002 15 3 1 5
lk0004 7 2 1 11
lk0016 18 5 2 19
lk0024 3 2 1 0
lk0026 6 2 1 5
lk0040 7 4 2 2
lk0051 21 5 3 26
lk0054 9 3 0 2
lk0065 8 2 0 8
lk0124 24 5 2 34
lk0132 5 2 0 7
lk0139 7 2 1 2
lk0153 9 2 3 2
lk0511 2 2 1 0
lk0512 2 1 1 0
lk0537 2 1 2 0
lk0546 2 2 1 0
lk0560 2 2 1 0
lk0561 2 2 1 0
lk0600 5 3 2 0
lk0625 4 2 2 0
lk0647 2 2 1 0
lk0672 3 3 1 0
lk0836 6 3 2 5
lk1155 2 1 1 3
lk2042 32 5 6 40
lk2447 3 2 1 2
lk6000 6 2 1 0
lk7739 2 1 1 0
lk7740 2 2 2 0
lk7743 3 2 2 0
lk7744 2 2 0 1
lk7748 2 2 1 0
lk7749 3 2 1 0
lk7750 4 2 2 0
lk7751 9 3 1 0
lk7754 3 1 1 0
lk7755 2 2 1 0
lk7768 2 1 1 0
Non-familial - - 75 1
cases
HM, hematological malignancy; TFHM, Tasmanian Familial 
Hematological Malignancies study.
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curve was generated for both the telomere and albumin PCRs. 
A linear regression of the standard curve measurement values 
was used to correct for any variation in fluorescence levels 
derived from small fluctuations in DNA concentration. The 
equations from the linear regression of each standard curve 
were then used to calculate the log(DNA) value for the 
unknown case/control samples.
Statistical analysis. Average T/s ratios greater than 4 standard 
deviations from the control mean were excluded as outliers. 
Mean relative T/s ratios with 95% confidence intervals (ci) 
are reported in Table ii. For analysis mean relative T/s ratios 
were transformed to fit a normal distribution using the inverse-
normalization option in sOlAr (version 6.6.2) (38,39) to 
prevent non-normal distribution errors. in order to fully utilize 
the extended pedigree study design, correct for relatedness, 
and to maximize the information provided by telomere length 
as a quantitative trait we used variance components modeling 
in sOlAr (38,39) to determine the heritability of telomere 
length (adjusting for kinship and significant covariates) and to 
calculate the association between telomere length and disease. 
The primary benefit to using sOlAr is its ability to incor-
porate relatedness through the use of a kinship matrix and to 
fully utilize the quantitative trait data, which increases the 
power and accuracy of the trait heritability calculation.
Sex, age, age2 and their interactions were included as 
covariates in all relevant analyses. Potential batch effects were 
adjusted for by applying household modeling (38,39) by coding 
each assay plate as a separate household. sOlAr has been 
previously used in the analysis of telomere length in related 
Table ii. Mean age, sex distribution and relative telomere length in the sample groups.
sample group N Male sex, n (%) Mean age (range) Mean relative T/s ratioa (95% ci)
controls 758 578 (76.3) 67.51 (30.67-87.97) 0.64 (0.62-0.66)
unaffected relatives of HM cases 191 77 (40.3) 61.65 (27.26-92.95) 0.73 (0.69-0.76)
All HM cases 130 73 (56.2) 65.14 (13.24-95.53) 0.53 (0.50-0.56)
Familial HM cases 55 32 (58.2) 64.45 (13.24-87.45) 0.57 (0.52-0.63)
Non-familial HM cases 75 41 (54.7) 68.79 (22.42-95.53) 0.50 (0.46-0.53)
aMean relative T/s ratio is the ratio between telomere repeat copy number (T) and a single-copy gene, ALB, copy number (s), a measure of 
mean relative telomere length. ci, confidence interval; HM, hematological malignancy. Mean age (range) is expressed in years.
Table iii. Disease characteristics of study samples.
 HM familial cases, n (%) HM non-familial cases, n (%) All HM cases, n (%)
HM subtypes
  Acute lymphoblastic leukemia   2   (3.6)   0   2   (1.5)
  Acute myeloid leukemia   5   (9.1)   8 (10.7) 13 (10.0)
  chronic myeloid leukemia   0   3   (4.0)   3   (2.3)
  essential thrombocythemia   1   (1.8)   1   (1.3)   2   (1.5)
  Hodgkin lymphoma   5   (9.1)   4   (5.3)   9   (6.9)
  Myelodysplastic syndrome   2   (3.6)   0   2   (1.5)
  Myeloproliferative neoplasm   1   (1.8)   2   (2.7)   3   (2.3)
  T-cell non-Hodgkin lymphoma   1   (1.8)   2   (2.7)   3   (2.3)
Mature B cell neoplasms
  Non-Hodgkin lymphoma unclassified   2   (3.6) 10 (13.3) 12   (9.2)
  chronic lymphocytic leukemia 12 (21.8) 12 (16.0) 24 (18.5)
  Diffuse large B-cell lymphoma   4   (7.3) 10 (13.3) 14 (10.8)
  Follicular lymphoma   4   (7.3)   9 (12.0) 13 (10.0)
  Multiple myeloma   7 (12.7)   5   (6.7) 12   (9.2)
  Othera   9 (16.4)   9 (12.0) 18 (13.8)
  Total 55 75 130
aOther includes Burkitt lymphoma, hairy cell leukemia, lymphoma of mucosa-associated lymphoid tissue and Waldenström macroglobulin-
emia. HM, hematological malignancy.
ONCOLOGY REPORTS  33:  25-32,  2015 29
individuals (11,12,40). The algorithms utilized in sOlAr 
for the analysis of quantitative traits in related individuals 
are more appropriate to employ in the present study than a 
more traditional approach of analyzing quantitative traits 
using percentiles or quartiles. Nevertheless, we also present 
observations from a quartile analysis of inverse normalized 
relative T/s ratios adjusted for age, sex and batch effects in 
sOlAr with quartiles defined from the adjusted T/s ratios 
in the control population (Fig. 1). Bean plots in Fig. 1 were 
constructed using the r package ‘beanplot’ (41).
Results
Mean relative telomere length in familial and non-familial HM 
cases, unaffected relatives and control subjects was measured 
by monochrome multiplex quantitative Pcr. using sOlAr 
we found that the heritability of mean relative telomere length 
was 62.5% (P=4.7x10-5, se=0.14). The removal of HM cases 
(n=130) from analysis only marginally altered the heritability 
of mean relative telomere length (75.5%; P=1.2x10-5, se=0.15).
The use of variance components modeling in sOlAr 
permits appropriate statistical analyses inclusive of familial 
relationships. These analyses revealed that disease status was 
significantly associated with mean relative telomere length 
(Table iV, primary analysis model 1; P=2.9x10-6) with HM 
cases having shorter mean relative telomere length when 
compared with unaffected individuals. We conducted a sepa-
rate analysis distinguishing familial and non-familial cases. 
Familial cases and non-familial cases each had significantly 
shorter mean relative telomere length (Table iV; primary 
analysis model 2, P=2.2x10-4 and P=2.2x10-5, respectively).
The most frequent type of HM diagnosed in the present 
study was mature B cell neoplasms (MBcNs; Table iii). 
Analysis of MBcNs as one group and HMs other than MBcNs 
as a second group (combined due to the small numbers of 
other subtypes) showed that both groupings had shorter mean 
relative telomere length than unaffected individuals from both 
study families and population controls (Table iV; primary 
analysis model 3, P=3.5x10-5 and P=9.3x10-5, respectively). 
These groupings were then divided according to whether the 
HM case was familial or non-familial. Analysis showed that all 
HM case subgroupings maintained significantly shorter mean 
relative telomere length (Table iV; primary analysis model 4). 
An analysis using specific HM subtypes was not possible due 
to not having enough statistical power at this level of HM clas-
sification with small numbers of HM subtypes (Table iii). 
Variance components modeling also identified age and 
sex (Table iV; primary analysis model 1, P=4.8x10-8 and 
P=4.0x10-3, respectively) as significant covariates for mean 
relative telomere length variation across all models. Mean 
relative telomere length declined with age and males had 
shorter telomeres than females. Age2 was also a significant 
covariate, indicating that the decline in mean relative telomere 
length with age has a non-linear component (Table iii; primary 
analysis model 1, P=8.0x10-3).
Four sub-analyses of the primary data were also performed 
to determine whether particular features of the study popula-
tion were contributing to the disease associations found in the 
primary analysis models (Table iV). sub-analyses included 
exclusion of HM cases, controls and unaffected relatives 80 
years or older (n=126), exclusion of cll cases (n=24), exclusion 
of cases with samples collected within two years of diagnosis 
(n=24) as well as all three exclusions together (n=162, some 
individuals were in multiple exclusion categories). in each 
sub-analysis the principle findings from the primary analysis 
models were maintained.
Figure 1. Bean plot quartile analysis of adjusted inverse normalized relative telomere lengths. The adjusted inverse normalized relative telomere length for each 
group is displayed as a bean plot with individual sample measurements as lines within the bean and the overall distribution of all samples in each group shown. 
Horizontal bars for each bean indicate the mean of each group. The solid line and dashed lines show the mean and interquartile range of the control group.
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Categorization of cases into quartiles of mean relative telo-
mere length determined from the distribution of age, sex and 
batch effect adjusted mean relative telomere length in controls 
(Fig. 1) showed that 43.1% of HM cases were in the lowest 
quartile of mean relative telomere length (below the lower 
interquartile dashed line), with 36.4% of familial HM cases 
and 48% of non-familial HM cases in the lowest quartile, 
whilst only 13.1% of unaffected relatives were in the lowest 
quartile. similarly a low percentage of cases (5.4%) were in 
the longest quartile of mean relative telomere length (above the 
upper interquartile dashed line) whereas 28.3% of unaffected 
relatives were in the longest quartile. A clear trend for shorter 
mean relative telomere length in a higher percentage of HM 
cases was observed but this analysis did not permit familial 
relationships to be included in the analysis.
Discussion
These analyses determined that mean relative telomere length 
is highly heritable within the TFHMs families supporting 
previously reported heritability estimates in non-disease 
families (10-12). Our finding that mean relative telomere 
length was shorter in both familial and non-familial HM 
cases indicates that telomere length is likely to be important 
Table iV. Variance component modeling analysis of inverse normalized mean relative telomere length primary analysis and 
sub-analyses with exclusions.
    Possible
  ≥80 years old cll cases malignant samples All exclusions
 Primary excluded excluded excludeda applied
 analysis (n=126) (n=24) (n=24) (n=162)
Models and variables P-values P-values P-values P-values P-values
Model 1
  Age 4.8x10-8 7.5x10-5 1.6x10-8 6.9x10-8 3.4x10-5
  Age2 8.0x10-3 0.04 6.0x10-3 0.01 0.07
  Sex 4.0x10-3 0.01 7.0x10-3 2.0x10-3 0.01
  All HM cases 2.9x10-6 7.3x10-6 2.9x10-7 1.1x10-4 4.6x10-5
  % trait variance accounted for by model 10.07% 9.46% 10.38% 9.56% 9.38%
Model 2
  Age 4.3x10-8 5.1x10-5 1.6x10-8 7.4x10-8 3.7x10-5
  Age2 8.0x10-3 0.04 6.0x10-3 0.01 0.07
  Sex 3.0x10-3 0.01 6.0x10-3 2.0x10-3 9.0x10-3
  Familial HM cases 2.2x10-4 1.0x10-3 1.6x10-5 0.01 8.0x10-3
  Non-familial HM cases 2.2x10-5 6.9x10-6 7.1x10-5 3.3x10-5 2.7x10-5
  % trait variance accounted for by model 10.62% 10.29% 10.55% 10.48% 10.00%
Model 3
  Age 4.7x10-8 7.2x10-5 1.7x10-8 7.7x10-8 3.7x10-5
  Age2 8.0x10-3 0.04 6.0x10-3 0.01 0.07
  Sex 4.0x10-3 0.01 6.0x10-3 2.0x10-3 0.01
  MBcNs 3.5x10-5 7.8x10-5 5.5x10-6 5.7x10-4 3.8x10-4
  HMs other than MBcNs 9.3x10-5 1.5x10-4 3.4x10-5 1.0x10-3 5.8x10-4
  % trait variance accounted for by model 10.08% 9.50% 10.37% 9.56% 9.39%
Model 4
  Age 4.8x10-8 4.1x10-5 1.9x10-8 6.6x10-8 3.8x10-5
  Age2 9.0x10-3 0.05 7.0x10-3 0.02 0.08
  Sex 3.0x10-3 0.01 6.0x10-3 2.0x10-3 9.0x10-3
  Familial MBcNs 0.02 0.04 3.0x10-3 0.18 0.07
  Familial cases other than MBcNs 5.2x10-4 3.0x10-3 5.7x10-4 0.01 0.04
  Non-familial MBcNs 2.4x10-5 1.5x10-5 1.3x10-4 4.8x10-5 1.5x10-4
  Non-familial cases other than MBcNs 2.0x10-3 4.2x10-4 3.0x10-3 2.0x10-3 3.2x10-4
  % trait variance accounted for by model 10.87% 10.58% 10.57% 10.45% 10.05%
P-values for the significance of each trait or covariate were derived from variance component polygenic modeling in sOlAr. aHM case 
samples collected within ± 2 years of diagnosis were excluded. cll, chronic lymphocytic leukemia; HM, hematological malignancy; MBcNs, 
mature B-cell neoplasms.
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in the genetic etiology of HMs. A previous study of mean 
relative telomere length in familial myelodysplastic syndrome 
MDs-AMl has shown that affected individuals from four 
small families had shorter telomeres concurrent with muta-
tions in the telomerase gene TERT and its rNA component 
TERC (18). Of the five cases across the four families reported 
to have shorter telomeres, two had aplastic anemia, two had 
MDs and one had MDs-AMl. The present study extends 
the findings of kirwan and colleagues (18) to that of large 
families with multiple HM subtypes finding new evidence of 
the involvement of telomere length in both familial and non-
familial HMs.
Age, sex and age2 as covariates explained a proportion of 
the variation in mean relative telomere length in the present 
study. This is in keeping with telomere length declining with 
age and males having shorter telomeres than females (7). 
A significant age2 indicates a non-linear component in the 
age-related telomere length decline, a finding in line with a 
recent report showing a differential rate of decrease in telo-
mere length over different age ranges (42). Our population 
controls did have a higher percentage of males, which could 
be suggested to be driving the association with sex, however, 
SOLAR was used to correct the mean relative telomere length 
for sex effects.
An important caveat with our retrospective study is that the 
finding of shorter mean relative telomere lengths in HM cases 
could also be related to disease susceptibility, treatment or the 
disease process. The present study did not have the necessary 
clinical information to appropriately analyze these factors. 
Currently, the literature surrounding the role of chemothera-
peutic agents in telomere shortening remains controversial 
and inconclusive. several studies in both HMs and other 
cancers such as breast cancer have shown that telomere length 
is unaffected when comparing pre- and post-chemotherapy 
measurements, when comparing patients who receive chemo-
therapy to those that do not or when comparing telomere length 
between patients and population controls (25,28,43,44). Other 
studies show a heterogeneous effect of chemotherapy on telo-
mere length (45-47). it could be concluded from these reports 
and others that chemotherapy has no consistent influence on 
telomere length in blood cells particularly when examining 
multiple chemotherapeutic treatment regimens.
A second consideration is that shorter telomeres in HM 
cases could be the result of malignant cell DNA within the 
genomic DNA sample. We recognize that circulating malig-
nant cells can be present for many years in chronic HM 
subtypes such as cll. Based on the clinical diagnoses of HM 
cases in our study, we conducted two additional sub-analyses 
of the primary data. in the one analysis we removed all cll 
cases (n=24) on the basis that DNA obtained from blood of 
cases with this subtype of HM was likely to contain DNA 
from diseased cells (Table iV). in the second analysis we 
removed all cases for which blood samples were obtained for 
DNA within 2 years of diagnosis (n=24; Table iV). repeating 
the variance components modeling in these two analyses 
maintained the key significant associations with HM disease, 
suggesting that circulating disease did not contribute to the 
telomere length associations we have identified. in an addi-
tional sub-analysis we excluded all HM cases, controls and 
unaffected relatives (n=126) aged 80 years and above on the 
basis that the population HM risk increases with age. This 
did not change the principle findings of shorter telomeres in 
familial and non-familial HM cases nor did a final combined 
sub-analysis excluding individuals from all 3 sub-analyses. All 
cases, controls and unaffected relatives were included in the 
primary analysis models reported in Table iV.
in conclusion, our analyses showed for the first time that 
mean relative telomere length is heritable in large HM families 
with multiple generations affected by multiple subtypes of 
HMs, indicating a strong genetic effect driving trait variation. 
We also showed that both familial and non-familial HM cases 
from the same population had shorter mean relative telomere 
length. Taken together, the results from this retrospective study 
provide new evidence that mean relative telomere length is an 
important genetic factor in a wide range of HM subtypes and 
in individuals with and without a family history of disease. 
These findings contribute further support to the use of telo-
mere length as a prognostic risk factor for HMs
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Appendix 5.2 Table of telomere biology genes 
 
Gene Telomere 
Maintenance 
Regulation 
of TERT 
Extension of 
Telomeres 
Mirabello 
et al.318 
ABL1  ●   
ACD ● ●  ● 
AKT1  ●   
ATM  ●  ● 
BICD1    ● 
BLM  ●  ● 
CCND1  ●   
CDKN1B  ●   
CLPTM1L    ● 
DDX1    ● 
DDX11    ● 
DKC1 ● ● ●  
DNA2 ●  ●  
E2F1  ●   
E6  ●   
EGF  ●   
EGFR  ●   
ESR1  ●   
FEN1 ●  ●  
FOS  ●   
H2AFB1 ●    
H2AFX ●    
H2AFZ ●    
H2BFS ●    
HDAC1  ●   
HDAC2  ●   
HIST1H2AB ●    
HIST1H2AC ●    
HIST1H2AD ●    
HIST1H2AE ●    
HIST1H2AJ ●    
HIST1H2BA ●    
HIST1H2BB ●    
HIST1H2BC ●    
HIST1H2BD ●    
HIST1H2BE ●    
HIST1H2BF ●    
HIST1H2BG ●    
HIST1H2BH ●    
HIST1H2BI ●    
HIST1H2BJ ●    
HIST1H2BK ●    
HIST1H2BL ●    
HIST1H2BM ●    
HIST1H2BN ●    
HIST1H2BO ●    
HIST1H4A ●    
HIST1H4B ●    
HIST1H4C ●    
HIST1H4D ●    
HIST1H4E ●    
HIST1H4F ●    
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HIST1H4H ●    
HIST1H4I ●    
HIST1H4J ●    
HIST1H4K ●    
HIST1H4L ●    
HIST2H2AA
3 
●    
HIST2H2AA
4 
●    
HIST2H2AC ●    
HIST2H2BE ●    
HIST2H4A ●    
HIST2H4B ●    
HIST3H2BB ●    
HIST3H3 ●    
HIST4H4 ●    
HNRNPC  ●   
HSP90AA1  ●   
HUS1  ●   
IFNAR2  ●   
IFNG  ●   
IL2  ●   
IRF1  ●   
JUN  ●   
LIG1 ●  ●  
MAD1L1    ● 
MAPK1  ●   
MAPK3  ●   
MAX  ●   
MEN1    ● 
MRE11A  ●  ● 
MTOR  ●   
MXD1  ●   
MYC  ●  ● 
NBN  ●  ● 
NCL  ●   
NFKB1  ●   
NHP2 ●  ●  
NOLA1    ● 
NOLA2    ● 
NOLA3    ● 
NR2F2  ●   
PARP1    ● 
PARP2  ●  ● 
PCNA ●  ●  
PIF1    ● 
PINX1  ●  ● 
POLA1 ●  ●  
POLA2 ●  ●  
POLD1 ●  ●  
POLD2 ●  ●  
POLD3 ●  ●  
POLD4 ●  ●  
POLE ●  ●  
POLE2 ●  ●  
POT1 ● ●  ● 
PRIM1 ●  ●  
PRIM2 ●  ●  
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PRKDC    ● 
PTGES3  ●   
RAD1  ●   
RAD50  ●  ● 
RAD51AP1    ● 
RAD51C    ● 
RAD51L1    ● 
RAD51L3    ● 
RAD54L    ● 
RAD9A  ●   
RBBP4  ●   
RBBP7  ●   
RECQL    ● 
RECQL4    ● 
RECQL5    ● 
RFC1 ●  ●  
RFC2 ●  ●  
RFC3 ●  ●  
RFC4 ●  ●  
RFC5 ●  ●  
RPA1 ●  ●  
RPA2 ●  ●  
RPA3 ●  ●  
RPS6KB1  ●   
RTEL1    ● 
RUVBL1 ●  ●  
RUVBL2 ●  ●  
SAP18  ●   
SAP30  ●   
SIN3A  ●   
SIN3B  ●   
SIP1    ● 
SMAD3  ●   
SMG5  ●   
SMG6  ●   
SP1  ●   
SP3  ●   
TEP1    ● 
TERC ● ● ● ● 
TERF1 ● ●  ● 
TERF2 ● ●  ● 
TERF2IP ● ●  ● 
TERT ● ● ● ● 
TGFB1  ●   
TINF2 ● ●  ● 
TNKS  ●  ● 
TNKS2    ● 
UBE3A  ●   
WRAP53 ●  ●  
WRN  ●  ● 
WT1  ●   
XRCC5  ●   
XRCC6  ●  ● 
YWHAE  ●   
 
 
